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Abstract
In 2013, EFSA published a comprehensive systematic review of epidemiological studies published from
2006 to 2012 investigating the association between pesticide exposure and many health outcomes.
Despite the considerable amount of epidemiological information available, the quality of much of this
evidence was rather low and many limitations likely affect the results so ﬁrm conclusions cannot
be drawn. Studies that do not meet the ‘recognised standards’ mentioned in the Regulation (EU)
No 1107/2009 are thus not suited for risk assessment. In this Scientiﬁc Opinion, the EFSA Panel on Plant
Protection Products and their residues (PPR Panel) was requested to assess the methodological
limitations of pesticide epidemiology studies and found that poor exposure characterisation primarily
deﬁned the major limitation. Frequent use of case–control studies as opposed to prospective studies was
considered another limitation. Inadequate deﬁnition or deﬁciencies in health outcomes need to be
avoided and reporting of ﬁndings could be improved in some cases. The PPR Panel proposed
recommendations on how to improve the quality and reliability of pesticide epidemiology studies to
overcome these limitations and to facilitate an appropriate use for risk assessment. The
Panel recommended the conduct of systematic reviews and meta-analysis, where appropriate, of
pesticide observational studies as useful methodology to understand the potential hazards of pesticides,
exposure scenarios and methods for assessing exposure, exposure–response characterisation and risk
characterisation. Finally, the PPR Panel proposed a methodological approach to integrate and weight
multiple lines of evidence, including epidemiological data, for pesticide risk assessment. Biological
plausibility can contribute to establishing causation.
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Summary
The European Food Safety Authority (EFSA) asked the Panel on Plant Protection Products and their
Residues (PPR Panel) to develop a Scientiﬁc Opinion on the follow-up of the ﬁndings of the External
Scientiﬁc Report ‘Literature review of epidemiological studies linking exposure to pesticides and health
effects’ (Ntzani et al., 2013). This report was based on a systematic review and meta-analysis of
epidemiological studies published between 2006 and 2012 and summarised the associations found
between pesticide exposure and 23 major categories of human health outcomes. Most relevant
signiﬁcant associations were found for liver cancer, breast cancer, stomach cancer, amyotrophic lateral
sclerosis, asthma, type II diabetes, childhood leukaemia and Parkinson’s disease. While the inherent
weaknesses of the epidemiological studies assessed do not allow ﬁrm conclusions to be drawn on
causal relationships, the systematic review raised a concern about the suitability of regulatory studies
to inform on speciﬁc and complex human health outcomes.
The PPR Panel developed a Scientiﬁc Opinion to address the methodological limitations affecting
the quality of epidemiological studies on pesticides. This Scientiﬁc Opinion is intended only to assist the
peer review process during the renewal of pesticides under Regulation (EC) 1107/2009 where the
evaluation of epidemiological studies, along with clinical cases and poisoning incidents following any
kind of human exposure, if available, is a data requirement. Epidemiological data concerning exposures
to pesticides in Europe will not be available before ﬁrst approval of an active substance and so will not
be expected to contribute to a draft assessment report (DAR). However, there is the possibility that
earlier prior approval has been granted for use of an active substance in another jurisdiction and
epidemiological data from that area may be considered relevant. Regulation (EC) No 1107/2009
requires a search of the scientiﬁc peer-reviewed open literature, which includes existing
epidemiological studies. This type of data is more suited for the renewal process of active substances,
also in compliance with Regulation (EC) 1141/2010 which indicates that ‘The dossiers submitted for
renewal should include new data relevant to the active substance and new risk assessments’.
In this Opinion, the PPR Panel proposed a methodological approach speciﬁc for pesticide active
substances to make appropriate use of epidemiological data for risk assessment purposes, and
proposed recommendations on how to improve the quality and reliability of epidemiological studies on
pesticides. In addition, the PPR Panel discussed and proposed a methodology for the integration of
epidemiological evidence with data from experimental toxicology as both lines of evidence can
complement each other for an improved pesticide risk assessment process.
First, the opinion introduces the basic elements of observational epidemiological studies1 and
contrasts them with interventional studies which are considered to provide the most reliable evidence
in epidemiological research as the conditions for causal inference are usually met. The major
observational study designs are described together with the importance of a detailed description of
pesticide exposure, the use of validated health outcomes and appropriate statistical analysis to model
exposure–health relationships. The external and internal study validity is also addressed to account for
the role of chance in the results and to ascertain whether factors other than exposure can distort the
associations found. Several types of human data can contribute to the risk assessment process of
pesticides, particularly to support hazard identiﬁcation. Besides formal epidemiological studies, other
sources of human data such as case series, disease registries, poison control centre information,
occupational health surveillance data and post-marketing surveillance programmes, can provide useful
information for hazard identiﬁcation, particularly in the context of acute, speciﬁc health effects.
However, many of the existing epidemiological studies on pesticides exposure and health effects
suffer from a range of methodological limitations or deﬁciencies (Terms of Reference (ToR) 1). The
Panel notes that the complexity of studying associations between exposure to pesticides and health
outcomes in observational settings among humans is more challenging than in many other disciplines
of epidemiology. This complexity lies in some speciﬁc characteristics in the ﬁeld of pesticide
epidemiology such as the large number of active substances in the market (around 480 approved for
use in the European Union (EU)), the difﬁculties to measure exposure, and the frequent lack of
quantitative (and qualitative) data on exposure to individual pesticides. The systematic appraisal of
epidemiological evidence carried out in an EFSA external scientiﬁc report (Ntzani et al., 2013) identiﬁed
a number of methodological limitations. Poor exposure characterisation primarily deﬁnes the major
limitation of most existing studies because of the lack of direct and detailed exposure assessment to
speciﬁc pesticides (e.g. use of generic pesticide deﬁnitions). Frequent use of case–control studies as
1 This Opinion deals only with observational studies (also called epidemiological studies) and vigilance data. In contrast,
interventional studies (also called experimental studies, such as randomised clinical trials) are outside the scope of this Opinion.
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opposed to prospective studies is also a limitation. Inadequate deﬁnition or deﬁciencies in health
outcomes, deﬁciencies in statistical analysis and poor quality reporting of research ﬁndings were
identiﬁed as other limitations of some pesticide epidemiological studies. These limitations are to some
extent responsible for heterogeneity or inconsistency of data that challenge drawing robust conclusions
on causality. Given the small effect sizes for most of the outcomes addressed by Ntzani et al. (2013),
the contribution of bias in the study design can play a role.
The PPR Panel also provides a number of reﬁnements (ToR 2) and recommendations (ToR 3) to
improve future pesticide epidemiological studies that will beneﬁt the risk assessment. The quality and
relevance of epidemiological research can be enhanced by (a) an adequate assessment of exposure,
preferentially by using personal exposure monitoring or biomarker concentrations of speciﬁc pesticides
(or combination of pesticides) at an individual level, reported in a way that minimises misclassiﬁcation
of exposure and allows for dose–response assessment; (b) a sufﬁciently valid and reliable outcome
assessment (well deﬁned clinical entities or validated surrogates); (c) adequately accounting for
potentially confounding variables (including other known exposures affecting the outcomes); (d)
conducting and reporting subgroup analysis (e.g. stratiﬁcation by gender, age, etc.). A number of
reporting guidelines and checklists developed speciﬁcally for studies on environmental epidemiology
are of interest for epidemiological studies assessing pesticide exposures. This is the case for extensions
of the modiﬁed STROBE (STrengthening the Reporting of OBservational studies in Epidemiology)
criteria, among others, which includes recommendations on what should be included in an accurate
and complete report of an observational study.
Exposure assessment can be improved at the individual level (direct and detailed exposure
assessment to speciﬁc pesticides in order to provide a reliable dosimeter for the pesticide of concern
that can be supplemented with other direct measures such as biomonitoring). Besides, exposure can
be assessed at population level by using registered data that can then be linked to electronic health
records. This will provide studies with unprecedented sample size and information on exposure and
subsequent disease. Geographical information systems (GIS) and small area studies might also serve
as an additional way to provide estimates of residential exposures. These more generic exposure
assessments have the potential to identify general risk factors and may be important both informing
overall regulatory policies, and for identiﬁcation of matters for further epidemiological research. The
development of -omic technologies also presents intriguing possibilities for improving exposure
assessment through measurement of a wide range of molecules, from xenobiotics and metabolites in
biological matrices (metabolomics) to complexes with DNA and proteins (adductomics). Omics have
the potential to measure proﬁles or signatures of the biological response to the cumulative exposure to
complex chemical mixtures and allows a better understanding of biological pathways. Health outcomes
can be reﬁned by using validated biomarkers of effect, that is, a quantiﬁable biochemical, physiological
or any other change that, is related to level of exposure, is associated with a health impairment and
also helps to understand a mechanistic pathway of the development of a disease.
The incorporation of epidemiological studies into regulatory risk assessment (ToR 4) represents a
major challenge for scientists, risk assessors and risk managers. The ﬁndings of the different
epidemiological studies can be used to assess associations between potential health hazards and
adverse health effects, thus contributing to the risk assessment process. Nevertheless, and despite the
large amount of available data on associations between pesticide exposure and human health
outcomes, the impact of such studies in regulatory risk assessment is still limited. Human data can be
used for many stages of risk assessment; however, a single (not replicated) epidemiological study, in
the absence of other studies on the same pesticide active substance, should not be used for hazard
characterisation unless it is of high quality and meets the ‘recognised standards’ mentioned in the
Regulation (EU) No 1107/2009. As these ‘recognised standards’ are not detailed in the Regulation, a
number of recommendations should be considered for optimal design and reporting of epidemiological
studies to support regulatory assessment of pesticides. Although further speciﬁc guidance will be
helpful, this is beyond the ToR of this Opinion. Evidence synthesis techniques, such as systematic
reviews and meta-analysis (where appropriate) offer a useful approach. While these tools allow
generation of summary data, increased statistical power and precision of risk estimates by combining
the results of all individual studies meeting the selection criteria, they cannot overcome methodological
ﬂaws or bias of individual studies. Systematic reviews and meta-analysis of observational studies have
the capacity of large impact on risk assessment as these tools provide information that strengthens the
understanding of the potential hazards of pesticides, exposure scenarios and methods for assessing
exposure, exposure–response characterisation and risk characterisation. Although systematic reviews
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are also considered a potential tool for answering toxicological questions, their methodology would
need to be adapted to the different lines of evidence.
Study evaluation should be performed within a best evidence synthesis framework as it provides an
indication on the nature of the potential biases each speciﬁc study may have and an assessment of
overall conﬁdence in the epidemiological database. This Opinion reports the study quality parameters
to be evaluated in single epidemiological studies and the associated weight (low, medium and high) for
each parameter. Three basic categories are proposed as a ﬁrst tier to organise human data with
respect to risk of bias and quality: (a) low risk of bias and high/medium reliability; (b) medium risk of
bias and medium reliability; (c) high risk of bias and low reliability because of serious methodological
limitations or ﬂaws that reduce the validity of results or make them largely uninterpretable for a
potential causal association. These categories are intended to parallel the reliability and relevance
rating of each stream of evidence according to the EFSA peer review of active substances: acceptable,
supplementary and unacceptable. Risk assessment should not be based on results of epidemiological
studies that do not meet well-deﬁned data quality standards in order to meet the ‘recognised
standards’ mentioned in the Regulation (EU) No 1107/2009.
Epidemiological studies provide complementary data that can be integrated together with data from
in vivo laboratory animal studies, mechanistic in vitro models and ultimately in silico technology for
pesticide risk assessment (ToR 4). The combination of all these lines of evidence can contribute to a
Weight-of-Evidence (WoE) analysis in the characterisation of human health risks with the aim of
improving decision-making. Although the different sets of data can be complementary and
conﬁrmatory, and thus serve to strengthen the conﬁdence of one line of evidence on another, they
may individually be insufﬁcient and pose challenges for characterising properly human health risks.
Hence, all four lines of evidence (epidemiology, animal, in vitro, in silico) make a powerful combination,
particularly for chronic health effects of pesticides, which may take decades to be clinically manifested
in an exposed human population.
The ﬁrst consideration is how well the health outcome under consideration is covered by existing
toxicological and epidemiological studies on pesticides. When both types of studies are available for a
given outcome/endpoint, both should be assessed for strengths and weaknesses before being used for
risk assessment. Once the reliability of available human evidence (observational epidemiology and
vigilance data), experimental evidence (animal and in vitro data) and non-testing data (in silico
studies) has been evaluated, the next step involves weighting these sources of data. This opinion
proposed an integrated approach where all lines of evidence are considered in an overall WoE
framework to better support the risk assessment. This framework relies on a number of principles
highlighting when one line should take precedence over another. The concordance or discordance
between human and experimental data should be assessed in order to determine which data set
should be given precedence. Although the totality of evidence should be assessed, the more reliable
data should be given more weight, regardless of whether the data comes from human or experimental
studies. The more challenging situation is when study results are not concordant. In such cases, the
reasons for the difference should be considered and efforts should be made to develop a better
understanding of the biological basis for the contradiction.
Human data on pesticides can help verify the validity of estimations made based on extrapolation
from the full toxicological database regarding target organs, dose–response relationships and the
reversibility of toxic effects, and to provide reassurance on the extrapolation process without direct
effects on the deﬁnition of reference values. Thus, pesticide epidemiological data can form part of the
overall WoE of available data using modiﬁed Bradford Hill criteria as an organisational tool to increase
the likelihood of an underlying causal relationship.
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(10):5007
Table of contents
Abstract................................................................................................................................................... 1
Summary................................................................................................................................................. 3
1. Introduction................................................................................................................................... 8
1.1. Regulatory data requirements regarding human health in pesticide risk assessment ............................ 8
1.2. Background and Terms of Reference as provided by the requestor..................................................... 9
1.3. Interpretation of the Terms of Reference.......................................................................................... 10
1.4. Additional information..................................................................................................................... 11
2. General framework of epidemiological studies on pesticides............................................................... 11
2.1. Study design.................................................................................................................................. 11
2.2. Population and sample size ............................................................................................................. 13
2.3. Exposure ....................................................................................................................................... 13
2.4. Health outcomes ............................................................................................................................ 14
2.5. Statistical analysis and reporting...................................................................................................... 15
2.5.1. Descriptive statistics ....................................................................................................................... 15
2.5.2. Modelling exposure–health outcome relationship............................................................................... 15
2.6. Study validity ................................................................................................................................. 18
3. Key limitations of the available epidemiological studies on pesticides .................................................. 20
3.1. Limitations identiﬁed by the authors of the EFSA external scientiﬁc report .......................................... 20
3.2. Limitations in study designs ............................................................................................................ 21
3.3. Relevance of study populations ....................................................................................................... 21
3.4. Challenges in exposure assessment ................................................................................................. 22
3.5. Inappropriate or non-validated surrogates of health outcomes........................................................... 23
3.6. Statistical analyses and interpretation of results................................................................................ 23
4. Proposals for reﬁnement to future epidemiological studies for pesticide risk assessment ...................... 24
4.1. Assessing and reporting the quality of epidemiological studies ........................................................... 24
4.2. Study design.................................................................................................................................. 27
4.3. Study populations........................................................................................................................... 28
4.4. Improvement of exposure assessment ............................................................................................. 28
4.5. Health outcomes ............................................................................................................................ 32
5. Contribution of vigilance data to pesticides risk assessment ............................................................... 33
5.1. General framework of case incident studies ...................................................................................... 33
5.2. Key limitations of current framework of case incident reporting.......................................................... 33
5.3. Proposals for improvement of current framework of case incident reporting........................................ 36
6. Proposed use of epidemiological studies and vigilance data in support of the risk assessment of pesticides . 36
6.1. The risk assessment process ........................................................................................................... 36
6.2. Assessment of the reliability of individual epidemiological studies ....................................................... 37
6.3. Assessment of strength of evidence of epidemiological studies .......................................................... 39
6.3.1. Synthesis of epidemiological evidence .............................................................................................. 40
6.3.2. Meta-analysis as a tool to explore heterogeneity across studies ......................................................... 41
6.3.3. Usefulness of meta-analysis for hazard identiﬁcation ......................................................................... 43
6.3.4. Pooling data from similar epidemiological studies for potential dose–response modelling...................... 44
7. Integrating the diverse streams of evidence: human (epidemiology and vigilance data) and
experimental information ................................................................................................................ 45
7.1. Sources and nature of the different streams of evidence Comparison of experimental and
epidemiological approaches............................................................................................................. 46
7.2. Principles for weighting of human observational and laboratory animal experimental data ................... 48
7.3. Weighting all the different sources of evidence ................................................................................. 50
7.4. Biological mechanisms underlying the outcomes ............................................................................... 51
7.5. Adverse Outcome Pathways (AOPs) ................................................................................................. 52
7.6. Novel tools for identifying biological pathways and mechanisms underlying toxicity ............................. 53
7.7. New data opportunities in epidemiology........................................................................................... 53
8. Overall recommendations................................................................................................................ 54
8.1. Recommendations for single epidemiological studies ......................................................................... 54
8.2. Surveillance ................................................................................................................................... 57
8.3. Meta-analysis of multiple epidemiological studies .............................................................................. 57
8.4. Integration of epidemiological evidence with other sources of information .......................................... 58
9. Conclusions.................................................................................................................................... 58
References............................................................................................................................................... 60
Glossary and Abbreviations ....................................................................................................................... 65
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(10):5007
Annex A – Pesticide epidemiological studies reviewed in the EFSA External Scientiﬁc Report and other
reviews.................................................................................................................................................... 68
Annex B – Human biomonitoring project outsourced by EFSA ...................................................................... 81
Annex C – Experience of international regulatory agencies in regards to the integration of epidemiological
studies for hazard identiﬁcation ................................................................................................................. 83
Annex D – Effect size magniﬁcation/inﬂation............................................................................................... 92
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(10):5007
1. Introduction
1.1. Regulatory data requirements regarding human health in pesticide
risk assessment
Regulatory authorities in developed countries conduct a formal human risk assessment for each
registered pesticide based on mandated toxicological studies, done according to speciﬁc study
protocols, and estimates of likely human exposure.
In the European Union (EU), the procedure for the placing of plant protection products (PPP) on the
market is laid down by Commission Regulation No 1107/20092. Commission Regulations No 283/20133
and 284/20134 set the data requirements for the evaluation and re-evaluation of active substances and
their formulations.
The data requirements regarding mammalian toxicity of the active substance are described in part
A of Commission Regulation (EU) No 283/2013 for chemical active substances and in part B for
microorganisms including viruses. With regard to the requirements for pesticide active substances,
reference to the use of human data may be found in different chapters of Section 5 related to
different end-points. For instance, data on toxicokinetics and metabolism that include in vitro
metabolism studies on human material (microsomes or intact cell systems) belong to Chapter 5.1 that
deals with studies of absorption, distribution, metabolism and excretion in mammals; in vitro
genotoxicity studies performed on human material are described in Chapter 5.4 on genotoxicity testing
and speciﬁc studies such as acetylcholinesterase inhibition in human volunteers are found in Chapter
5.7 on neurotoxicity studies. Chapter 5.8 refers to supplementary studies on the active substance, and
some speciﬁc studies, such as pharmacological or immunological investigations.
Although the process of pesticide evaluation is mainly based on experimental studies, human data
could add relevant information to that process. The requirements relating to human data are mainly
found in Chapter 5.9 ‘Medical data’ of Regulation (EU) No 283/2013. It includes medical reports
following accidental, occupational exposure or incidents of intentional self-poisoning as well as
monitoring studies such as on surveillance of manufacturing plant personnel and others. The
information may be generated and reported through ofﬁcial reports from national poison control
centres as well as epidemiological studies published in the open literature. The Regulation requires that
‘relevant’ information on the effects of human exposure, where available, shall be used to conﬁrm the
validity of extrapolations regarding exposure and conclusions with respect to target organs, dose–
response relationships, and the reversibility of adverse effects.
Regulation (EU) No 1107/2009 equally states that, ‘where available, and supported with data on
levels and duration of exposure, and conducted in accordance with recognised standards, epidemiological
studies are of particular value and must be submitted’. However, it is clear that there is no obligation for
the petitioners to conduct epidemiological studies speciﬁc for the active substance undergoing the
approval or renewal process. Rather, according to Regulation (EC) No 1107/2009, applicants submitting
dossiers for approval of active substances shall provide ‘scientiﬁc peer-reviewed public available literature
[. . .]. This should be on the active substance and its relevant metabolites dealing with side-effects on
health [. . .] and published within the last ten years before the date of submission of the dossier’.
In particular, epidemiological studies on pesticides should be retrieved from the literature according
to the EFSA Guidance entitled ‘Submission of scientiﬁc-peer reviewed open literature for the approval
of pesticide active substances under Regulation (EC) No 1107/2009’ (EFSA, 2011a), which follows the
principles of the Guidance ‘Application of systematic review methodology to food and feed safety
assessments to support decision-making’ (EFSA, 2010a). As indicated in the EFSA Guidance, ‘the
process of identifying and selecting scientiﬁc peer-reviewed open literature for active substances, their
metabolites, or plant protection products’ is based on a literature review which is systematic in the
approach.
The submission of epidemiological studies and more generally of human data by the applicants in
Europe has especially previously sometimes been incomplete and/or has not been performed in
2 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant
protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309, 24.11.2009, p. 1–50.
3 Commission Regulation (EU) No 283/2013, of 1 March 2013, setting out the data requirements for active substances, in
accordance with Regulation (EC) No 1107/2009 of the European Parliament of the Council concerning the placing of plant
protection products on the market. OJ L 93, 3.4.2013, p. 1–84.
4 Commission Regulation (EU) No 284/2013 of 1 March 2013 setting out the data requirements for plant protection products, in
accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant
protection products on the market. OJ L 93, 3.4.2013, p. 85–152.
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compliance with current EFSA Guidance (EFSA, 2011a). This is probably owing to the fact that a
mandatory requirement to perform an (epidemiological) literature search according to speciﬁc EFSA
Guidance is relatively recent, e.g. introduced for AIR-3 substances (Regulation AIR-3: Reg. (EU)
No 844/2012; Guidance Document SANCO/2012/11251 – rev.4).
The integration of epidemiological data with toxicological ﬁndings in the peer review process of
pesticides in the EU should be encouraged but is still lacking. A recent and controversial example is the
one related to the evaluation of glyphosate in which signiﬁcant efforts were made to include
epidemiological studies in the risk assessment, but the conclusion was that these studies provided very
limited evidence of an association between glyphosate and health outcomes.
In the case of the peer review of 2,4-D, most of epidemiological data were not used in the risk
assessment because it was critical to know the impurity proﬁle of the active substance and this
information was not available in the publications (as happens frequently in epidemiological studies). In
conclusion, within the European regulatory system there is no example of a pesticide active substance
approval being inﬂuenced by epidemiological data.
Now that a literature search including epidemiological studies is mandatory and guidance is in place
(EFSA, 2011a), a more consistent approach can facilitate risk assessment. However, no framework has
been established on how to assess such epidemiological information in the regulatory process. In
particular, none of the classical criteria used for the evaluation of these studies is included in the
current regulatory framework (e.g. study design, use of odd ratios and relative risks, potential
confounders, multiple comparisons, assessment of causality). It follows that speciﬁc criteria or
guidance for the appropriate use of epidemiological ﬁndings in the process of writing and peer
reviewing Draft Assessment Reports (DARs) or Renewal Assessment Reports (RAR) is warranted. The
EFSA Stakeholder Workshop (EFSA, 2015a) anticipated that the availability of more robust and
methodologically sound studies presenting accurate information on exposure would bolster the
regulation of pesticides in the EU.
Another potential challenge is synchronisation between the process of renewal of active substances
and the output of epidemiological studies. Indeed, the planning, conduct, and analysis of
epidemiological studies often require a substantial amount of time, especially where interpretation of
data is complex.
1.2. Background and Terms of Reference as provided by the requestor
In 2013, the European Food Safety Authority (EFSA) published an External scientiﬁc report
‘Literature review on epidemiological studies linking exposure to pesticides and health effects’ carried
out by the University of Ioannina Medical School (Ntzani et al., 2013). The report is based on a
systematic review of epidemiological studies published between 2006 and 2012 and summarises the
association between pesticide exposure and any health outcome examined (23 major categories of
human health outcomes). In particular, a statistically signiﬁcant association was observed through ﬁxed
and random effect meta-analyses between pesticide exposure and the following health outcomes: liver
cancer, breast cancer, stomach cancer, amyotrophic lateral sclerosis, asthma, type II diabetes,
childhood leukaemia and Parkinson’s disease.
Despite the large number of research articles and analyses (> 6,000) available, the authors of the
report could not draw any ﬁrm conclusions for the majority of the health outcomes. This observation is
in line with previous studies assessing the association between the use of pesticides and the occurrence
of human health adverse effects which all acknowledge that such epidemiological studies suffer from a
number of limitations and large heterogeneity of data. The authors especially noted that broad
pesticides deﬁnitions in the epidemiological studies limited the value of the results of meta-analyses.
Also, the scope of the report did not allow the in-depth associations between pesticide exposure and
speciﬁc health outcomes. Nonetheless, the report highlights a number of health outcomes where
further research is needed to draw ﬁrmer conclusions regarding their possible association with pesticide
exposures.
Nevertheless, the outcomes of the External scientiﬁc report are in line with other similar studies
published in Europe,5,6 and raise a number of questions and concerns, with regard to pesticide
exposure and the associations with human health outcomes. Furthermore, the results of the report
5 France: INSERM report 2013: Pesticides – effets sur la sante.
6 UK: COT report 2011: Statement on a systematic review of the epidemiological literature on para-occupational exposure to
pesticides and health outcomes other than cancer, and COT report 2006: Joint Statement on Royal Commission on
Environmental Pollution report on crop spraying and the health of residents and bystanders.
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open the way for discussion on how to integrate results from epidemiological studies into pesticide risk
assessments. This is particularly important for the peer-review team at EFSA dealing with the
evaluation of approval of plant protection products for which the peer-review needs to evaluate
epidemiological ﬁndings according to EU Regulation No 283/2013. The regulation states that applicants
must submit ‘relevant’ epidemiological studies, where available.
For the Scientiﬁc Opinion, the PPR Panel will discuss the associations between pesticide exposure
and human health effects observed in the External scientiﬁc report (Ntzani et al., 2013) and how these
ﬁndings could be interpreted in a regulatory pesticide risk assessment context. Hence, the PPR
Panel will systematically assess the epidemiological studies collected in the report by addressing major
data gaps and limitations of the studies and provide related recommendations.
The PPR Panel will speciﬁcally:
1) collect and review all sources of gaps and limitations, based on (but not necessarily limited
to) those identiﬁed in the External scientiﬁc report in regard to the quality and relevance of
the available epidemiological studies.
2) based on the gaps and limitations identiﬁed in point 1, propose potential reﬁnements for
future epidemiological studies to increase the quality, relevance and reliability of the ﬁndings
and how they may impact pesticide risk assessment. This may include study design,
exposure assessment, data quality and access, diagnostic classiﬁcation of health outcomes,
and statistical analysis.
3) identify areas in which information and/or criteria are insufﬁcient or lacking and propose
recommendations for how to conduct pesticide epidemiological studies in order to improve
and optimise the application in risk assessment. These recommendations should include
harmonisation of exposure assessment (including use of biomonitoring data), vulnerable
population subgroups and/or health outcomes of interest (at biochemical, functional,
morphological and clinical level) based on the gaps and limitations identiﬁed in point 1.
4) discuss how to make appropriate use of epidemiological ﬁndings in risk assessment of
pesticides during the peer review process of draft assessment reports, e.g. weight-of-
evidence (WoE) as well as integrating the epidemiological information with data from
experimental toxicology, adverse outcome pathways (AOP), mechanism of actions, etc.
The PRAS Unit will consult the Scientiﬁc Committee on the consensual approach to EFSA’s
overarching scientiﬁc areas,7 including the integration of epidemiological studies in risk assessment.
1.3. Interpretation of the Terms of Reference
In the Terms of Reference (ToR), EFSA requested the PPR Panel to write a scientiﬁc Opinion on the
follow up of the results from the External Scientiﬁc Report on a systematic review of epidemiological
studies published between 2006 and 2012 linking exposure to pesticides and human health effects
(Ntzani et al., 2013). According to EU Regulation No 283/2013, the integration of epidemiological data
into pesticide risk assessment is important for the peer review process of DAR and RAR of active
substances for EU approval and their intended use as plant protection products.
In its interpretation of the terms of reference, the PPR Panel will then develop a Scientiﬁc Opinion to
address the methodological limitations identiﬁed in epidemiological studies on pesticides and to make
recommendations to the sponsors of such studies on how to improve them in order to facilitate their use
for regulatory pesticide risk assessment, particularly for substances in the post-approval period. The PPR
Panel notes that experimental toxicology studies also present limitations related to their methodology
and quality of reporting; however, the assessment of these limitations is beyond the ToR of this Opinion.
This Scientiﬁc Opinion is intended to assist the peer review process during the renewal of pesticides
under Regulation 1107/2009 where the evaluation of epidemiological studies, along with clinical cases
and poisoning incidents following any kind of human exposure, if available, represent a data
requirement. Epidemiological data concerning exposures to pesticides in Europe will not be available
before ﬁrst approval of an active substance (with the exception of incidents produced during the
manufacturing process, which are expected to be very unlikely) and so will not be expected to
contribute to a DAR. However, there is the possibility that earlier prior approval has been granted for
use of an active substance in another jurisdiction and epidemiological data from that area may be
considered relevant. Regulation (EC) No 1107/2009 requires a search of the scientiﬁc peer-reviewed
7 According to article 28 of Regulation (EC) No 178/2002.
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open literature, where it is expected to retrieve existing epidemiological studies. It is therefore
recognised that epidemiological studies are more suitable for the renewal process of active substances,
also in compliance with the provision of the EC regulation 1141/2010 indicating that ‘The dossiers
submitted for renewal should include new data relevant to the active substance and new risk
assessments to reﬂect any changes in data requirements and any changes in scientiﬁc or technical
knowledge since the active substance was ﬁrst included in Annex I to Directive 91/414/EEC’.
The PPR Panel will speciﬁcally address the following topics:
1) Review inherent weaknesses affecting the quality of epidemiological studies (including gaps
and limitations of the available pesticide epidemiological studies) and their relevance in the
context of regulatory pesticide risk assessment. How can these weaknesses be addressed?
2) What are potential contributions of epidemiological studies that complement classical
toxicological studies conducted in laboratory animal species in the area of pesticide risk
assessment?
3) Discuss and propose a methodological approach speciﬁc for pesticide active substances on
how to make appropriate use of epidemiological studies, focusing on how to improve the
gaps and limitations identiﬁed.
4) Propose reﬁnements to practice and recommendations for better use of the available
epidemiological evidence for risk assessment purposes. Discuss and propose a methodology
for the integration of epidemiological information with data from experimental toxicology.
This Scientiﬁc Opinion, particularly Section 2–4, is not intended to address the bases of
epidemiology as a science. Those readers willing to deepen into speciﬁc aspects of this science are
encouraged to read general textbook of epidemiology (e.g. Rothman et al., 2008).
It should be taken into account that this Opinion is focussed only on pesticide epidemiology studies
in the EU regulatory context and not from a general scientiﬁc perspective. Therefore, the actual
limitations and weaknesses of experimental toxicology studies will not be addressed herein.
1.4. Additional information
In order to fully address topics 1–4 above (Section 1.3), attention has been paid to a number of
relevant reviews of epidemiological studies and the experience of other National and International bodies
with knowledge of epidemiology in general and in applying epidemiology to pesticide risk assessment
speciﬁcally. Detailed attention has been given to these studies in Annex A and drawn from the experience
of the authors that have contributed constructively to understanding in this area. Also Annex A records
published information that has been criticised for its lack of rigour showing how unhelpful some
published studies may be. The lessons learned from such good (and less-good) practice have been
incorporated into the main text by cross-referring to Annex A. In this way, this Scientiﬁc Opinion has the
aim of clearly distilling and effectively communicating the arguments in the main text without
overwhelming the reader with all the supporting data which is nevertheless accessible.
In addition, Annex B contains a summary of the main ﬁndings of a project that EFSA outsourced in
2015 to further investigate the role of human biological monitoring (HBM) in occupational health and
safety strategies as a tool for reﬁned exposure assessment in epidemiological studies and to contribute
to the evaluation of potential health risks from occupational exposure to pesticides (Bevan et al., 2017).
2. General framework of epidemiological studies on pesticides
This section introduces the basic elements of epidemiological studies on pesticides and contrasts
them with other types of studies. For more details general textbook on epidemiology are
recommended (Rothman et al., 2008; Thomas, 2009).
2.1. Study design
Epidemiology studies the distribution and determinants of health outcomes in human or other
target species populations, to ascertain how, when and where diseases occur. This can be done
through observational studies and intervention studies (i.e. clinical trials),8 which compare study
8 In this opinion, ‘human data’ includes observational studies, also called epidemiological studies, where the researcher is
observing natural relationships between factors and health outcomes without acting upon study participants. Vigilance data
also fall under this concept. In contrast, intervention studies (also referred to as experimental studies) are outside the scope of
this Opinion, and their main feature is that the researcher intercedes as part of the study design.
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groups subject to differing exposure to a potential risk factor. Both types of studies are carried out in a
natural setting, which is a less controlled environment than laboratories.
Information on cases of disease occurring in a natural setting can also be systematically recorded in
the form of case reports or case series of exposed individuals only. Although case series/reports do not
compare study groups according to differing exposure, they may provide useful information,
particularly on acute effects following high exposures, which makes them potentially relevant for
hazard identiﬁcation.
In randomised clinical trials, the exposure of interest is randomly allocated to subjects and,
whenever possible, these subjects are blinded to their treatment, thereby eliminating potential bias
due to their knowledge about their exposure to a particular treatment. This is why they are called
intervention studies. Observational epidemiological studies differ from clinical intervention studies in
that the exposure of interest is not randomly assigned to the subjects enrolled and participants are
often not blinded to their exposure. This is why they are called observational. As a result, randomised
clinical trials rank higher in terms of design as they provide unbiased estimates of average treatment
effects.
The lack of random assignment of exposure in observational studies represents a key challenge, as
other risk factors that are associated with the occurrence of disease may be unevenly distributed
between those exposed and non-exposed. This means that known confounders need to be measured
and accounted for. However, there is always the possibility that unknown or unmeasured confounders
are left unaccounted for, although unknown confounders cannot be addressed. Furthermore, the fact
that study participants are often unaware of their current or past exposure or may not recall these
accurately in observational studies (e.g. second-hand smoke, dietary intake or occupational hazards)
may result in biased estimates of exposure if it is based on self-report. As an example, it is not unlikely
that when cancer cases and controls are asked whether they have previously been exposed to a
pesticide the cancer cases may report their exposure differently from controls, even in cases where the
past exposures did not differ between the two groups.
Traditionally, designs of observational epidemiological studies are classiﬁed as either ecological,
cross-sectional, case–control or cohort studies. This approach is based on the quality of exposure
assessment and the ability to assess directionality from exposure to outcome. These differences largely
determine the quality of the study (Rothman and Greenland, 1998; Pearce, 2012).
• Ecological studies are observational studies where either exposure, outcome or both are
measured on a group but not at individual level and the correlation between the two is then
examined. Most often, exposure is measured on a group level while the use of health registries
often allows for extraction of health outcomes on an individual level (cancer, mortality). These
studies are often used when direct exposure assessment is difﬁcult to achieve and in cases
where large contrast in exposures are needed (comparing levels between different countries or
occupations). Given the lack of exposure and/or outcome on an individual level, these studies
are useful for hypothesis generation but results generally need to be followed up using more
rigorous design in either humans or use of experimental animals.
• In cross-sectional studies, exposure and health status are assessed at the same time, and
prevalence rates (or incidence over a limited recent time) in groups varying in exposure are
compared. In such studies, the temporal relationship between exposure and disease cannot be
established since the current exposure may not be the relevant time window that leads to
development of the disease. The inclusion of prevalent cases is a major drawback of (most)
cross-sectional studies, particularly for chronic long-term diseases. Cross-sectional studies may
nevertheless be useful for risk assessment if exposure and effect occur more or less
simultaneously or if exposure does not change over time.
• Case–control studies examine the association between estimates of past exposures among
individuals that already have been diagnosed with the outcome of interest (e.g. cases) to a
control group of subjects from the same population without such outcome. In population-
based incident case–control studies, cases are obtained from a well-deﬁned population, with
controls selected from members of the population who are disease free at the time a case is
incident. The advantages of case–control studies are that they require less sample sizes, time
and resources compared to prospective studies and often they are the only viable option when
studying rare outcomes such as some types of cancer. In case–control studies, past exposure
is most often not assessed based on ‘direct’ measurement but rather through less certain
measurements such as a recall captured through interviewer or self-administered
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questionnaires or proxies such as job descriptions titles or task histories. Although case–control
studies may allow for proper exposure assessment, these studies are prone to recall-bias when
estimating exposure. Other challenges include the selection of appropriate controls; as well as
the need for appropriate confounder control.
• In cohort studies, the population under investigation consists of individuals who are at risk of
developing a speciﬁc disease or health outcome at some point in the future. At baseline and at
later follow-ups (prospective cohort studies) relevant exposures, confounding factors and
health outcomes are assessed. After an appropriate follow-up period, the frequency of
occurrence of the disease is compared among those differently exposed to the previously
assessed risk factor of interest. Cohort studies are therefore by design prospective as the
assessment of exposure to the risk factor and covariates of interest are measured before the
health outcome has occurred. Thus, they can provide better evidence for causal associations
compared to the other designs mentioned above. In some cases, cohort studies may be based
on estimates of past exposure. Such retrospective exposure assessment is less precise than
direct measure and prone to recall bias. As a result, the quality of evidence from cohort
studies varies according to the actual method used to assess exposure and the level of detail
by which information on covariates were collected. Cohort studies are particularly useful for
the study of relatively common outcomes. If sufﬁciently powered in terms of size, they can
also be used to appropriately address relatively rare exposures and health outcomes.
Prospective cohort studies are also essential to study different critical exposure windows. An
example of this is longitudinal birth cohorts that follow children at regular intervals until adult
age. Cohort studies may require a long observation period when outcomes have a long latency
prior to onset of disease. Thus, such studies are both complex and expensive to conduct and
are prone to loss of follow-up.
2.2. Population and sample size
A key strength of epidemiological studies is that they study diseases in the very population about
which conclusions are to be drawn, rather than a proxy species. However, only rarely will it be possible
to study the whole population. Instead, a sample will be drawn from the reference population for the
purpose of the study. As a result, the observed effect size in the study population may differ from that
in the population if the former does not accurately reﬂect the latter. However, observations made in a
non-representative sample may still be valid within that sample but care should then be made when
extrapolating ﬁndings to the general population.
Having decided how to select individuals for the study, it is also necessary to decide how many
participants should minimally be enrolled. The sample size of a study should be large enough to warrant
sufﬁcient statistical power. The standard power (also called sensitivity) is 80%, which means the ability of
a study to detect an effect of a given magnitude when that effect actually exists in the target population;
in other words, there is 80% probability of drawing the right conclusion from the results of the analyses
and a corresponding probability of 20% or drawing the wrong conclusion and missing a true effect.
Power analysis is often used to calculate the minimum sample size required to likely detect an effect of a
given size. Small samples are likely to constitute an unrepresentative sample. The statistical power is also
closely related to risk inﬂation, which needs to be given special attention when interpreting statistically
signiﬁcant results from small or underpowered studies (see Annex D).
Epidemiological studies, like toxicological studies in laboratory animals, are often designed to
examine multiple endpoints unlike clinical trials that are designed and conducted to test one single
hypothesis, e.g. efﬁcacy of a medical treatment. To put this in context, for laboratory animal toxicology
test protocols, OECD guidance for pesticides may prescribe a minimum number of animals to be
enrolled in each treatment group. This does not guarantee adequate power for any of the multitude of
other endpoints being tested in the same study. It is thus important to appropriately consider the
power of a study when conducting both epidemiology and laboratory studies.
2.3. Exposure
The quality of the exposure measurements inﬂuences the ability of a study to correctly ascertain
the causal relationship between the (dose of) exposure and a given adverse health outcome.
In toxicological studies in laboratory animals, the ‘treatment regime’ i.e. dose, frequency, duration
and route are well deﬁned beforehand and its implementation can be veriﬁed. This often allows
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2017;15(10):5007
expression of exposure in terms of external dose administered daily via oral route for example in a 90-
day study, by multiplying the amount of feed ingested every day by a study animal with the intended
(and veriﬁed) concentration of the chemical present in the feed. Also, in the future, the internal
exposure has to be determined in the pivotal studies.
In the case of pesticides, estimating exposure in a human observational setting is difﬁcult as the
dose, its frequency and duration over time and the route of exposure are not controlled and not even
well known.
Measuring the intensity, frequency and duration of exposure is often necessary for investigating
meaningful associations. Exposure may involve a high dose over a relatively short period of time, or a
low-level prolonged dose over a period from weeks to years. While the effects of acute, high-dose
pesticide exposure may appear within hours or days, the effects of chronic, low-dose exposures may
not appear until years later. Also, a disease may require a minimal level of exposure but increase in
probability with longer exposure.
There may be differences in absorption and metabolism via different routes (dermal, inhalation and
oral). While dermal or inhalation are often the routes exposure occurs in occupational settings,
ingestion (food, water) may be the major route of pesticide exposure for the general population.
Pharmacokinetic differences among individuals may result in differing systemic or tissue/organ doses
even where the absorbed external doses may appear similar.
2.4. Health outcomes
The term health outcome refers to a disease state, event, behaviour or condition associated with
health that is under investigation. Health outcomes are those clinical events (usually represented as
diagnosis codes, i.e. International Classiﬁcation of Diseases (ICD) 10) or outcomes (i.e. death) that are
the focus of the research. Use of health outcomes requires a well-deﬁned case deﬁnition, a system to
report and record the cases and a measure to express the frequency of these events.
A well-deﬁned case deﬁnition is necessary to ensure that cases are consistently diagnosed,
regardless of where, when and by whom they were identiﬁed and thus avoid misclassiﬁcation. A case
deﬁnition involves a standard set of criteria, which can be a combination of clinical symptoms/signs,
sometimes supplemented by conﬁrmatory diagnostic tests with their known sensitivity and speciﬁcity.
The sensitivity of the whole testing procedure (i.e. the probability that a person with an adverse health
condition is truly diagnosed) must be known to estimate the true prevalence or incidence.
The clinical criteria may also involve other characteristics (e.g. age, occupation) that are associated
with increased disease risk. At the same time, appropriately measured and deﬁned phenotypes or hard
clinical outcomes add validity to the results.
Disease registries contain clinical information of patients on diagnosis, treatment and outcome.
These registries periodically update patient information and can thus provide useful data for
epidemiological research. Mortality, cancer and other nation-wide health registries generally meet the
case-deﬁnition requirements and provide (almost) exhaustive data on the incident cases within a
population. These health outcomes are recorded and classiﬁed in national health statistics databases,
which depend on accepted diagnostic criteria that are evolving and differ from one authority to
another. This may confound attempts to pool data usefully for societal beneﬁt. Registry data present
many opportunities for meaningful analysis, but the degree of data completeness and validity may
challenge making appropriate inferences. Also, changes in coding conventions over the lifetime of the
database may have an impact on retrospective database research.
Although the disease status is typically expressed as a dichotomous variable, it may also be
measured as an ordinal variable (e.g. severe, moderate, mild or no disease) or as a quantitative
variable for example by measuring molecular biomarkers of toxic response in target organs or
physiological measures such as blood pressure or serum concentration of lipids or speciﬁc proteins.
The completeness of the data capture and its consistency are key contributors to the reliability of
the study. Harmonisation of diagnostic criteria, data storage and utility would bring beneﬁts to the
quality of epidemiological studies.
A surrogate endpoint is used as substitute for a well-deﬁned disease endpoint, an outcome measure,
commonly a laboratory measurement (biomarker of response). These measures are considered to be on
the causal pathway for the clinical outcome. In contrast to overt clinical disease, such biological markers
of health may allow to detect subtle, subclinical toxicodynamic processes. For such outcomes, detailed
analytical protocols for quantiﬁcation should be speciﬁed to enable comparison or replication across
laboratories. The use of AOPs can highlight differences in case deﬁnitions.
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Although surrogate outcomes may offer additional information, the suitability of the surrogate
outcome examined needs to be carefully assessed. In particular, the validity of surrogate outcomes
may represent a major limitation to their use (la Cour et al., 2010). Surrogate endpoints that have not
been validated should thus be avoided.
When the health status is captured in other ways, such as from self-completed questionnaires or
telephone interviews, from local records (medical or administrative databases) or through clinical
examination only, these should be validated to demonstrate that they reﬂect the underlying case
deﬁnition.
2.5. Statistical analysis and reporting
Reporting in detail materials, methods and results, and conducting appropriate statistical analyses
are key steps to ensure quality of epidemiological studies. Regarding statistical analysis, one can
distinguish between descriptive statistics and modelling of exposure–health outcome relationship.
2.5.1. Descriptive statistics
Descriptive statistics aim to summarise the important characteristics of the study groups, such as
exposure measures, health outcomes, possible confounding factors and other relevant factors. The
descriptive statistics often include frequency tables and measures of central tendency (e.g. means and
medians) and dispersion (e.g. variance and interquartile range) of the parameters or variables studied.
2.5.2. Modelling exposure–health outcome relationship
Modelling of the exposure–health relationship aims to assess the possible relationship between the
exposure and the health outcome under consideration. In particular, it can evaluate how this
relationship may depend on dose and mode of exposure and other possible intervening factors.
Statistical tests determine the probability that the observations found in scientiﬁc studies may have
occurred as a result of chance. This is done by summarising the results from individual observations
and evaluating whether these summary estimates differ signiﬁcantly between, e.g. exposed and
non-exposed groups, after taking into consideration random errors in the data.
For dichotomous outcomes, the statistical analysis compares study groups by assessing whether
there is a difference in disease frequency between the exposed and control populations. This is usually
done using a relative measure. The relative risk (RR) in cohort studies estimates the relative
magnitude of an association between exposure and disease comparing those that are exposed (or
those that have a higher exposure level) with those that are not exposed (or those that have a lower
exposure level). It indicates the likelihood of developing the disease in the exposed group relative to
those who are not (or less) exposed. An odds ratio (OR), generally an outcome measure in case–
control and cross-sectional studies, represents the ratio of the odds of exposure between cases and
controls (or diseased and non-diseased individuals in a cross-sectional study) and is often the relative
measure used in statistical testing. Different levels or doses of exposure can be compared in order to
see if there is a dose–response relationship. For continuous outcome measures, mean or median
change in the outcome are often examined across different level of exposure; either through analyses
of variance or through other parametric statistics.
While the statistical analysis will show that observed differences are signiﬁcantly different or not
signiﬁcantly different, both merit careful reﬂection (Greenland et al., 2016).
Interpretation of the absence of statistically signiﬁcant difference. Failure to reject the
null hypothesis does not necessarily mean that no association is present because the study may not
have sufﬁcient power to detect it. The power depends on the following factors:
• sample size: with small sample sizes, statistical signiﬁcance is more difﬁcult to detect, even if
true;
• variability in individual response or characteristics, either by chance or by non-random factors:
the larger the variability, the more difﬁcult to demonstrate statistical signiﬁcance;
• effect size or the magnitude of the observed difference between groups: the smaller the size
of the effect, the more difﬁcult to demonstrate statistical signiﬁcance.
Interpretation of statistically signiﬁcant difference. Statistical signiﬁcance means that the
observed difference is not likely due to chance alone. However, such a result still merits careful
consideration.
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• Biological relevance. Rejection of the null hypothesis does not necessarily mean that the
association is biologically meaningful, nor does it mean that the relationship is causal (Skelly,
2011). The key issue is whether the magnitude of the observed difference (or ‘effect size’) is
large enough to be considered biologically relevant. Thus, an association that is statistically
signiﬁcant may be or may be not biologically relevant and vice versa. While epidemiological
results that are statistically signiﬁcant may be dismissed as ‘not biologically relevant’,
non-statistically signiﬁcant results are seldom determined to be ‘biologically relevant’.
Increasingly, researchers and regulators are looking beyond statistical signiﬁcance for evidence
of a ‘minimal biologically important difference’ for commonly used outcomes measures.
Factoring biological signiﬁcance relevance into study design and power calculations, and
reporting results in terms of biological as well as statistical signiﬁcance will become increasingly
important for risk assessment (Skelly, 2011). This is the subject of an EFSA Scientiﬁc
Committee guidance document outlining generic issues and criteria to be taken into account
when considering biological relevance (EFSA Scientiﬁc Committee, 2017a); also a framework is
being developed to consider biological relevance at three main stages related to the process of
dealing with evidence (EFSA Scientiﬁc Committee, 2017b).
• Random error. Evaluation of statistical precision involves consideration of random error within
the study. Random error is the part of the study that cannot be predicted because that part is
attributable to chance. Statistical tests determine the probability that the observations found in
scientiﬁc studies have occurred as a result of chance. In general, as the number of study
participants increases, precision (often expressed as standard error) of the estimate of central
tendency (e.g. the mean) is increased and the ability to detect a statistically signiﬁcant
difference, if there is a real difference between study groups, i.e. the study’s power, is
enhanced. However, there is always a possibility, at least in theory, that the results observed
are due to chance only and that no true differences exist between the compared groups
(Skelly, 2011). Very often this value is set at 5% (signiﬁcance level).
• Multiple testing. As mentioned previously when discussing sample size, modelling of the
exposure–health relationship is in principle hypothesis-driven, i.e. it is to be stated beforehand
in the study objectives what will be tested. However, in reality, epidemiological studies (and
toxicological studies in laboratory animals) often explore a number of different health
outcomes in relation to the same exposure. If many statistical tests are conducted, some 5%
of them will be statistically signiﬁcant by chance. Such testing of multiple endpoints
(hypotheses) increases the risk of false positive results and this can be controlled for by use of
Bonferroni, Sidak or Benjamini–Hochberg corrections or other suitable methods. But this is
often omitted. Thus, when researchers carry out many statistical tests on the same set of
data, they can conclude that there are real differences where in fact there are none.
Therefore, it is important to consider large number of statistical results as preliminary
indications that require further validation. The EFSA opinion on statistical signiﬁcance and
biological signiﬁcance notes that the assumptions derived from a statistical analysis should be
related to the study design (EFSA, 2011b).
• Effect size magniﬁcation. An additional source of bias, albeit one that is lesser known, is that
which may result from small sample sizes and the consequent low statistical power. This lesser
known type of bias is ‘effect size magniﬁcation’ which can result from low powered studies.
While it is generally widely known that small, low-powered studies can result in false negatives
since the study power is inadequate to reliably detect a meaningful effect size, it is less well
known that these studies can result in inﬂation of effect sizes if those estimated effects pass a
statistical threshold (e.g. the common p < 0.05 threshold used to judge statistical
signiﬁcance). This effect –also known as effect size magniﬁcation – is a phenomenon by which
a ‘discovered’ association (i.e. one that has passed a given threshold of statistical signiﬁcance)
from a study with suboptimal power to make that discovery will produce an observed effect
size that is artiﬁcially – and systematically – inﬂated. This is because smaller, low-powered
studies are more likely to be affected by random variation among individuals than larger ones.
Mathematically, conditional on a result passing some predetermined threshold of statistical
signiﬁcance, the estimated effect size is a biased estimate of the true effect size, with the
magnitude of this bias inversely related to power of the study.
As an example, if a trial were run thousands of times, there will be a broad distribution of
observed effect sizes, with smaller trials systematically producing a wider variation in observed
effect sizes than larger trials, but the median of these estimated effect sizes is close to the true
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effect size. However, in a small and low powered study, only a small proportion of observed
effects will pass any given (high) statistical threshold of signiﬁcance and these will be only the
ones with the greatest of effect sizes. Thus, when these smaller, low powered studies with
greater random variation do indeed ﬁnd a signiﬁcance-triggered association as a result of
passing a given statistical threshold, they are more likely to overestimate the size of that
effect. What this means is that research ﬁndings of small and signiﬁcant studies are biased in
favour of ﬁnding inﬂated effects. In general, the lower the background (or control or natural)
rate, the lower the effect size of interest, and the lower the power of the study, the greater
the tendency towards and magnitude of inﬂated effect sizes.
It is important to note, however, that this phenomenon is only present when a ‘pre-screening’
for statistical signiﬁcance is done. The bottom line is that if it is desired to estimate a given
quantity such as an OR or RR, ‘pre-screening’ a series of effect sizes for statistical signiﬁcance
will result in an effect size that is systematically biased away from the null (larger than the true
effect size). To the extent that regulators, decision-makers, and others are acting in this way –
looking for statistically signiﬁcant results in what might be considered a sea of comparisons
and then using those that cross a given threshold of statistical signiﬁcance to evaluate and
judge the magnitude of the effect – will likely result in an exaggerated sense of the magnitude
of the hypothesised association. Additional details and several effect size simulations are
provided in Annex D of this document.
Confounding occurs when the relationship between the exposure and disease is to some extent
attributable to the effect of another risk factor, i.e. the confounder. There are several traditionally
recognised requirements for a risk factor to actually act as a confounder as described by McNamee
(2003) and illustrated below. The factor must:
• be a cause of the disease, or a surrogate measure of the cause, in unexposed people; factors
satisfying this condition are called ‘risk factors’;
• be correlated, positively or negatively, with exposure in the study populations independently
from the presence of the disease. If the study population is classiﬁed into exposed and
unexposed groups, this means that the factor has a different distribution (prevalence) in the
two groups;
• not be an intermediate step in the causal pathway between the exposure and the disease
Confounding can result in an over- or underestimation of the relationship between exposure and
disease and occurs because the effects of the two risk factors have not been separated or
‘disentangled’. In fact, if strong enough, confounding can also reverse an apparent association. For
instance, because agriculture exposures cover many different exposure categories, farmers are likely to
be more highly exposed than the general population to a wide array of risk factors, including biological
agents (soil organisms, livestock, farm animals), pollen, dust, sunlight and ozone amongst others,
which may act as potential confounding factors.
A number of procedures are available for controlling confounding, both in the design phase of the
study or in the analytical phase. For large studies, control in the design phase is often preferable. In
the design phase, the epidemiological researcher can limit the study population to individuals that
share a characteristic which the researcher wishes to control. This is known as ‘restriction’ and in fact
removes the potential effect of confounding caused by the characteristic which is now eliminated. A
second method in the design phase through which the researcher can control confounding is by
‘matching’. Here, the researcher matches individuals based on the confounding variable which ensures
that this is evenly distributed between the two comparison groups.
Beyond the design phase, at the analysis stage, control for confounding can be done by means of
either stratiﬁcation or statistical modelling. One means of control is by stratiﬁcation in which the
association is measured separately, under each of the confounding variables (e.g. males and females,
ethnicity or age group). The separate estimates can be ‘brought together’ statistically – when
appropriate – to produce a common OR, RR or other effect size measure by weighting the estimates
measured in each stratum (e.g. using Mantel–Haenszel approaches). This can be done at the cost of
reducing the sample size for the analysis. Although relatively easy to perform, there can be difﬁculties
associated with the inability of this stratiﬁcation to deal with multiple confounders simultaneously. For
these situations, control can be achieved through statistical modelling (e.g. multiple logistic
regression).
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Regardless of the approaches available for control of confounding in the design and analysis phases
of the study described above, it is important – prior to any epidemiological studies being initiated in
the ﬁeld – that careful consideration be given to confounders because researchers cannot control for a
variable which they have not considered in the design or for which they have not collected data.
Epidemiological studies – published or not – are often criticised for ignoring potential confounders
that may possibly either falsely implicate or inappropriately negate a given risk factor. Despite these
critiques, rarely is an argument presented on the likely size of the impact of the bias from such
possible confounding. It should be emphasised that a confounder must be a relatively strong risk
factor for the disease to be strongly associated with the exposure of interest to create a substantial
distortion in the risk estimate. It is not sufﬁcient to simply raise the possibility of confounding; one
should make a persuasive argument explaining why a risk factor is likely to be a confounder, what its
impact might be and how important that impact might be to the interpretation of ﬁndings. It is
important to consider the magnitude of the association as measured by the RR, OR, risk ratio,
regression coefﬁcient, etc. since strong relative risks are unlikely to be due to unmeasured
confounding, while weak associations may be due to residual confounding by variables that the
investigator did not measure or control in the analysis (US-EPA, 2010b).
Effect modiﬁcation. Effects of pesticides, and other chemicals, on human health can hardly be
expected to be identical across all individuals. For example, the effect that any given active substance
might have on adult healthy subjects may not be the same as that it may have on infants, elderly, or
pregnant women. Thus, some subsets of the population are more likely to develop a disease when
exposed to a chemical because of an increased sensitivity. For this, the term ‘vulnerable subpopulation’
has been used, which means children, pregnant women, the elderly, individuals with a history of
serious illness and other subpopulations identiﬁed as being subject to special health risks from
exposure to environmental chemicals (i.e. because of genetic polymorphisms of drug-metabolising
enzymes, transporters or biological targets). The average effect measures the effect of an exposure
averaged over all subpopulations. However, there may be heterogeneity in the strength of an
association between various subpopulations. For example, the magnitude of the association between
exposure to chemical A and health outcome B may be stronger in children than in healthy adults, and
absent in those wearing protective clothing at the time of exposure or in those of different genotype.
If heterogeneity is truly present, then any single summary measure of an overall association would be
deﬁcient and possibly misleading. The presence of heterogeneity is assessed by testing for the
presence of statistically signiﬁcant interaction between the factor and the effect in the various
subpopulations. But, in practice, this requires large sample size.
Investigating the effect in subpopulations deﬁned by relevant factors may advance knowledge on
the effect on human health of the risk factor of interest.
2.6. Study validity
When either a statistically signiﬁcant association or no such signiﬁcant association between, for
example, pesticide exposures and a health outcome is observed, there is a need to also evaluate the
validity of a research study, assessing factors that might distort the true association and/or inﬂuence
its interpretation. These imperfections relate to systematic sources of error that result in a
(systematically) incorrect estimate of the association between exposure and disease. In addition, the
results from a single study takes on increased validity when it is replicated in independent
investigations conducted on other populations of individuals at risk of developing the disease.
Temporal sequence. Any claim of causation must involve the cause preceding in time the
presumed effect. Rothman (2002) considered temporality as the only criterion that is truly causal, such
that lack of temporality rules out causality. While the temporal sequence of an epidemiological
association implies the necessity for the exposure to precede the outcome (effect) in time,
measurement of the exposure is not required to precede measurement of the outcome. This
requirement is easier met in prospective study designs (i.e. cohort studies), than when exposure is
assessed retrospectively (case–control studies) or assessed at the same time than the outcome (cross-
sectional studies). However, also in prospective studies, the time sequence for cause and effect and
the temporal direction might be difﬁcult to ascertain if a disease developed slowly and initial forms of
disease were difﬁcult to measure (H€oﬂer, 2005).
The generalisability of the result from the population under study to a broader population should
also be considered for study validity. While the random error discussed previously is considered a
precision problem and is affected by sampling variability, bias is considered a validity issue. More
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speciﬁcally, bias issues generally involve methodological imperfections in study design or study analysis
that affect whether the correct population parameter is being estimated. The main types of bias
include selection bias, information bias (including recall bias and interviewer/observer bias) and
confounding. An additional potential source of bias is effect size magniﬁcation, which has already been
mentioned.
Selection bias concerns a systematic error relating to validity that occurs as a result of the
procedures and methods used to select subjects into the study, the way that subjects are lost from the
study or otherwise inﬂuence continuing study participation.
Typically, such a bias occurs in a case–control study when inclusion (or exclusion) of study subjects
on the basis of disease is somehow related to the prior exposure status being studied. One example
might be the tendency for initial publicity or media attention to a suspected association between an
exposure and a health outcome to result in preferential diagnosis of those that had been exposed
compared to those that had not. Selection bias can also occur in cohort studies if the exposed and
unexposed groups are not truly comparable as when, for example, those that are lost from the study
(loss to follow-up, withdrawn or non-response) are different in status to those who remain. Selection
bias can also occur in cross-sectional studies due to selective survival: only those that have survived
are included in the study. These types of bias can generally be dealt with by careful design and
conduct of a study (see also Sections 4, 6 and 8).
The ‘healthy worker effect’ (HWE) is a commonly recognised selection bias that illustrates a speciﬁc
bias that can occur in occupational epidemiology studies: workers tend to be healthier than individuals
from the general population overall since they need to be employable in a workforce and can thus
often have a more favourable outcome status than a population-based sample obtained from the
general population. Such a HWE bias can result in observed associations that are masked or lessened
compared to the true effect and thus can lead to the appearance of lower mortality or morbidity rates
for workers exposed to chemicals or other deleterious substances.
Information bias concerns a systematic error when there are systematic differences in the way
information regarding exposure or the health outcome are obtained from the different study groups
that result in incorrect or otherwise erroneous information being obtained or measured with respect to
one or more covariates being measured in the study. Information bias results in misclassiﬁcation which
in turn leads to incorrect categorisation with respect to either exposure or disease status and thus the
potential for bias in any resulting epidemiological effect size measure such as an OR or RR.
Misclassiﬁcation of exposure status can result from imprecise, inadequate or incorrect
measurements; from a subject’s incorrect self-report; or from incorrect coding of exposure data.
Misclassiﬁcation of disease status can, for example, arise from laboratory error, from detection bias,
from incorrect or inconsistent coding of the disease status in the database, or from incorrect recall.
Recall bias is a type of information bias that concerns a systematic error when the reporting of disease
status is different, depending on the exposure status (or vice versa). Interviewer bias is another kind
of information bias that occurs where interviewers are aware of the exposure status of individuals and
may probe for answers on disease status differentially – whether intended or not – between exposure
groups. This can be a particularly pernicious form of misclassiﬁcation – at least for case–control studies
– since a diseased subject may be more likely to recall an exposure that occurred at an earlier time
period than a non-diseased subject. This will lead to a bias away from null value (of no relation
between exposure and disease) in any effect measure.
Importantly, such misclassiﬁcations as described above can be ‘differential’ or ‘non-differential’ and
these relate to (i) the degree to which a person that is truly exposed (or diseased) is correctly
classiﬁed as being truly exposed or diseased and (ii) the degree to which an individual who is truly not
exposed (or diseased) is correctly classiﬁed in that way. The former is known as ‘sensitivity’ while the
latter is referred to as ‘speciﬁcity’ and both of these play a role in determining the existence and
possible direction of bias. Differential misclassiﬁcation means that misclassiﬁcation has occurred in a
way that depends on the values of other variables, while non-differential misclassiﬁcation refers to
misclassiﬁcations that do not depend on the value of other variables.
What is important from an epidemiological perspective is that misclassiﬁcation biases – either
differential or non-differential – depend on the sensitivity and speciﬁcity of the study’s methods used
to categorise such exposures and can have a predictable effect on the direction of bias under certain
(limited) conditions: this ability to characterise the direction of the bias based on knowledge of the
study methods and analyses can be useful to the regulatory decision-maker since it allows the decision
maker to determine whether the epidemiological effect sizes being considered (e.g. OR, RR) are likely
underestimates or overestimates of the true effect size. While it is commonly assumed by some that
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non-differential misclassiﬁcation bias produces predictable biases towards the null (and thus
systematically under-predicts the effect size), this is not necessarily the case. Also, the sometimes
common assumption in epidemiology studies that misclassiﬁcation is non-differential (which is
sometimes also paired with the assumption that non-differential misclassiﬁcation bias is always
towards the null) is not always justiﬁed (e.g. see Jurek et al., 2005).
When unmeasured confounders are thought to affect the results, researchers should conduct
sensitivity analyses to estimate the range of impacts and the resulting range of adjusted effect
measures (US-EPA, 2010b). Quantitative sensitivity (or bias) analyses are, however, not typically
conducted in many epidemiological studies, with most researchers instead describing various potential
biases qualitatively in the form of a narrative in the discussion section of a paper.
It is often advisable that the epidemiological investigator performs sensitivity analysis to estimate
the impact of biases, such as exposure misclassiﬁcation or selection bias, by known but unmeasured
risk factors or to demonstrate the potential effects that a missing or unaccounted for confounder may
have on the observed effect sizes (see Lash et al., 2009; Gustafson and McCandless, 2010). Sensitivity
analyses should be incorporated in the list of criteria for reviewing epidemiological data for risk
assessment purposes.
3. Key limitations of the available epidemiological studies on
pesticides
3.1. Limitations identiﬁed by the authors of the EFSA external scientiﬁc
report
The EFSA External scientiﬁc report (Ntzani et al., 2013; summarised in Annex A) identiﬁed a
plethora of epidemiological studies which investigate diverse health outcomes. In an effort to
systematically appraise the epidemiological evidence, a number of methodological limitations were
highlighted. In the presence of these limitations, robust conclusions could not be drawn, but outcomes
for which supportive evidence from epidemiology existed were highlighted for future investigation. The
main limitations identiﬁed included (Ntzani et al., 2013):
• Lack of prospective studies and frequent use of study designs that are prone to bias (case–
control and cross-sectional studies). In addition, many of the studies assessed appeared to be
insufﬁciently powered.
• Lack of detailed exposure assessment, at least compared to many other ﬁelds within
epidemiology. The information on speciﬁc pesticide exposure and co-exposures was often
lacking, and appropriate biomarkers were seldom used. Instead, many studies relied on broad
deﬁnition of exposure assessed through questionnaires (often not validated).
• Deﬁciencies in outcome assessment (broad outcome deﬁnitions and use of self-reported
outcomes or surrogate outcomes).
• Deﬁciencies in reporting and analysis (interpretation of effect estimates, confounder control
and multiple testing).
• Selective reporting, publication bias and other biases (e.g. conﬂict of interest).
The observed heterogeneity in the results within each studied outcome was often large. However,
heterogeneity is not always a result of biases and may be genuine and consideration of a priori deﬁned
subgroup analysis and meta-regression should be part of evidence synthesis efforts. Occupational
studies, which are of particular importance to pesticide exposure, are also vulnerable to the healthy
worker effect, a bias resulting in lower morbidity and mortality rates within the workforce than in the
general population. The healthy worker effect tends to decline with increasing duration of employment
and length of follow-up.
Studies with sufﬁcient statistical power, detailed deﬁnition of pesticide exposure, data for many health
outcomes and transparent reporting are rare, apart from the Agricultural Health Study (AHS) and other
similarly designed studies. It is important to note that several of these methodological limitations have
not been limited to pesticide exposure studies and, most importantly, are not speciﬁc in epidemiology
and have been observed in other speciﬁc ﬁelds including in animal studies (Tsilidis et al., 2013).
Given the wide range of pesticides with various deﬁnitions found in the EFSA External scientiﬁc
report, it is difﬁcult to harmonise this information across studies. Although heterogeneity of ﬁndings
across studies can be as informative as homogeneity, information needs to be harmonised such that
replication can be assessed and summary effect sizes be calculated. This does not mean that if there is
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genuine heterogeneity the different studies cannot be pooled. Limited conclusions can be made from a
single study. Nonetheless, the report highlighted a number of associations between pesticides and
health effects that merit further consideration and investigation. Of interest is the fact that a
considerable proportion of the published literature focused on pesticides no longer approved for use in
the EU and in most developed countries e.g. studies focusing solely on DDT and its metabolites
constituted almost 10% of the eligible studies (Ntzani et al., 2013). These may still be appropriate
since they may persist as pesticide residues or because they continue to be used in developing
countries. Also, the report focused on epidemiological evidence in relation to any health outcome
across an approximately 5-year window. Although the report is valuable in describing the ﬁeld of
epidemiological assessment of pesticide–health associations, it is not able to answer speciﬁc disease-
pesticide questions thoroughly. A more in-depth analysis of speciﬁc disease endpoints associated with
pesticides exposure is needed, where this information is available, and studies published earlier than
the time window covered by the EFSA External scientiﬁc report should be also included.
3.2. Limitations in study designs
For ethical reasons, randomised controlled trials are not allowed to test the safety of low dose
pesticide exposure in the EU. Therefore, information on potential adverse health consequences in
humans has to be extracted using observational studies.
For diseases with long-latency periods, measurement of exposure at one time point may not
accurately reﬂect the long-term exposure which is needed to develop such diseases. This is particularly
important for non-persistent pesticides, whose levels in biological samples are not constant but vary
quite often. Thus, those studies that claim an association between a single measurement in urine
samples and a long latency outcome should be carefully interpreted.
Among the 795 studies reviewed in the Ntzani report, 38% were case–control studies and 32%
cross-sectional studies. As a result, evidence on potential adverse health consequences of pesticide
exposure is largely based on studies that lack prospective design at least for outcomes that have long
latency periods. For the cross-sectional studies, directionality cannot be assessed and observed
associations may often reﬂect reverse causation (is the disease caused by the exposure, or does the
disease inﬂuence the exposure?). Although reverse causation is a potential problem of cross-sectional
studies in many ﬁelds of epidemiology, in pesticide epidemiology, it is less of an issue, because in most
situations it is unlikely that a disease will cause exposure to pesticides.
Although case–control studies are frequently used for rare outcomes, such as several cancers, their
main limitation is that they are prone to recall bias and they have to rely on retrospective assessment
of exposure. However, they can still provide useful information, especially for rare outcomes. It is
important to examine whether results from case–control and prospective studies converge. This was,
for example, the case amongst studies that were conducted to examine associations between intake of
trans-fatty acids and cardiovascular disease (EFSA, 2004), where both case–control and prospective
studies consistently reported positive associations. The effect estimates between the two study designs
were systematically different with prospective studies reporting more modest effect sizes but both
study designs reached similar conclusions. As for pesticides, similar values have been observed for the
magnitude of association between Parkinson’s disease and pesticide exposure irrespective of the study
design (reviewed in Hernandez et al., 2016).
3.3. Relevance of study populations
Because the environmentally relevant doses of pesticides to which individuals are exposed are
lower than those required to induce observed toxicity in animal models, the associated toxic effects
need to be understood in the context of differences of susceptibility of subpopulations. Potentially
vulnerable groups are at an increased risk against exposure to low levels of pesticides than healthy
individuals, sometimes during sensitive windows of exposure. This is the case of genetic susceptibility,
which represents a critical factor for risk assessment that should be accounted for (Gomez-Martın
et al., 2015). Genetic susceptibility largely depends on functional genetic polymorphisms affecting
toxicokinetics (e.g. genes encoding xenobiotic metabolising enzymes and membrane transporters)
and/or toxicodynamics (e.g. different receptor gene polymorphisms). This genetic variability should be
considered on the basis of a plausible scientiﬁc hypothesis.
While different disorders, particularly neurodegenerative diseases (Parkinson’s disease, Alzheimer’s
disease, amyotrophic lateral sclerosis) have been linked to exposures to environmental factors (e.g.
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pesticides), in many instances the genetic architecture of the disorder has not been taken into
account. The prevalence of speciﬁc gene mutations may reach 5–10% and sometimes over 20% of
cases in certain populations (Gibson et al., 2017), so that the links of these diseases to pesticide
exposure may be heavily inﬂuenced by genetic structure within populations under study. Given the
small effect sizes for many of these disorders, the underlying effects of speciﬁc genes not accounted
for in the study design may modify the disease risk estimates. Hence, associations with pesticide
exposure may need to be evaluated in the light of common genetic inﬂuences known to be associated
with a spectrum of neurodegenerative diseases. However, genetic variation by itself does not
predispose people for an increased pesticide exposure.
A subgroup of population of special interest is represented by children, because their metabolism,
physiology, diet and exposure patterns to environmental chemicals differ from those of adults and can
make them more susceptible to their harmful effects. The window(s) of biologic susceptibility remain
unknown for the most part, and would be expected to vary by mechanism. Gender-based susceptibility
also merits consideration in case of pesticide-related reproductive toxicity and endocrine disruption.
Those subgroups are currently considered during the risk assessment process but may deserve more
attention to provide additional protection.
3.4. Challenges in exposure assessment
The main limitations of epidemiological studies conducted on pesticides derive from uncertainty in
exposure assessment. Limitations include the fact that most currently approved pesticides tend to have
short elimination half-lives and that their use involves application of various formulations depending on
the crop and season. As a result, accurate assessment needs to capture intermittent long-term exposure
of these non-persistent chemicals as well as being able to quantify exposure to individual pesticides.
Numerous studies have assessed internal exposure by measuring urinary non-active metabolites
common for a large group of pesticides (for example, dialkyl phosphates for organophosphates,
3-phenoxybenzoic acid for pyrethroids or 6-chloronicotinic acid for neonicotinoids). These data should
not be utilised to infer any risk because: (a) a fraction of these metabolites might reﬂect direct
exposure through ingestion of preformed metabolites from food and other sources, rather than
ingestion of the parent compound and (b) the potency of the different parent pesticides can vary by
orders of magnitude. Thereby, HBM data based on those urine metabolites can be unhelpful unless
they are paired with other data indicating the actual pesticide exposure.
Ideally exposure should be quantiﬁed on an individual level using biomarkers of internal dose. As
most available biomarkers reﬂect short term (few hours or days) exposure and given the cost and
difﬁculty of collecting multiple samples over time, many studies quantify exposure in terms of external
dose. Quantitative estimation of external dose needs to account for both frequency and duration of
exposure and should preferably be done on an individual but not group level. Often external exposure
is quantiﬁed using proxy measures such as:
• subject- or relative-reported jobs, job titles, tasks or other lifestyle habits which are being
associated with the potential exposure to or actual use of pesticides in general;
• handling of a speciﬁc product or set of products and potential exposure to these as
documented through existing pesticide records or diaries or estimated from crops grown;
• environmental data: environmental pesticide monitoring, e.g. in water, distance from and/or
duration of residence in a particular geographical area considered to be a site of exposure.
In many cases, these proxy measures are recorded with use of questionnaires, which can be either
interviewer-administered or based on self-report. However, questionnaire data often rely on individual
recall and knowledge and are thus potentially subject to both recall bias and bias introduced by the
interviewer or study subjects. These sources of bias can to some extent be quantiﬁed if the
questionnaires are validated against biomarkers (that is, to what extent do individual questions predict
biomarker concentrations in a sub-sample of participants). If the exposure is assessed retrospectively
the accuracy of the recall is for obvious reasons more likely to be compromised and impossible to
validate. When exposure is based on records, similar difﬁculties may occur due to, e.g. incomplete or
inaccurate records.
In many previous studies, duration of exposure is often used as a surrogate of cumulative
exposure, assuming that exposure is uniform and continuous over time (e.g. the employment period)
but this assumption must be challenged for pesticides. Although for some chemicals the exposure
patterns may be fairly constant, exposures for the large number of pesticides available in the market
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(10):5007
will vary with season, by personal protective equipment (PPE) and by work practices, and in many
cases, uses are not highly repetitive. At an individual level, exposures can vary on a daily and even
hourly basis, and often involve several pesticides. This temporal variability can result in particularly
high variation in systemic exposures for pesticides with short biological half-lives and considerable
uncertainty in extrapolating single or few measurements to individual exposures over a longer term.
Hence, many repeated measurements over time may be required to improve exposure estimates.
3.5. Inappropriate or non-validated surrogates of health outcomes
Self-reported health outcomes are frequently used in epidemiological research because of the
difﬁculty of verifying responses in studies with large samples and limited funds, among other reasons.
Although a number of studies have examined agreement between self-reported outcomes and medical
records, the lack of veriﬁcation of such metrics can lead to misclassiﬁcation, particularly in large
population-based studies, which may detract from reliability of the associations found.
Reliance on clinically manifested outcomes can increase the likelihood that individuals who have
progressed along the toxicodynamic continuum from exposure to disease but have not yet reached an
overt clinical disease state will be misclassiﬁed as not having the disease (Nachman et al., 2011).
Thereby, delay in onset of clinical symptoms following exposure may cause underreporting where
clinical assessment alone is used at an inappropriate point in time.
In the case of carcinogenesis, there are some examples where subclinical outcomes have been
assessed as preneoplastic lesions with potential to progress to neoplastic conditions. This is the case of
monoclonal gammopathy of undetermined signiﬁcance (MGUS), which has been associated with
pesticide exposure in the AHS (Landgren et al., 2009), as this condition has a 1% average annual risk
of progression to malignant multiple myeloma (Zingone and Kuehl, 2011). However, it is difﬁcult to
predict if and when an MGUS will progress to multiple myeloma. Since there are studies indicating that
pesticide exposure may be associated with the risk of precancerous lesions in animal research, a
combined epidemiological analysis of both preneoplastic and neoplastic outcomes may increase the
power of such an analysis.
Surrogate outcomes may seem an attractive alternative to clinically relevant outcomes since there
may be various surrogates for the same disease and they may occur sooner and/or be easier to
assess, thereby shortening the time to diagnosis. A valid surrogate endpoint must, however, be
predictive of the causal relationship and accurately predict the outcome of interest. In addition, these
surrogates should be relevant to the mode of action of a pesticide such that they should be anchored
to established toxicological endpoints to support their predictivity. Although surrogate markers may
correlate with an outcome, they may not capture the effect of a factor on the outcome. This may be
because the surrogate may not be causally or strongly related to the clinical outcome, but only a
concomitant factor, and thus may not be predictive of the clinical outcome. The validity of surrogate
outcomes may thus represent a major limitation to their use (la Cour et al., 2010).
However, concerns arise as to whether critical regulatory decisions can be made based on
epidemiological studies that did not directly measure the adverse health outcome but valid surrogates
instead. The use of surrogates as replacement endpoints should be considered only when there is
substantial evidence to establish their reliability in predicting clinical meaningful effects.
3.6. Statistical analyses and interpretation of results
The statistical analyses and the interpretation of scientiﬁc ﬁndings that appear in the epidemiological
literature on the relationship between pesticides and health outcomes do not substantially deviate
from those reported in other ﬁelds of epidemiological research. Therefore, the advantages and
limitations of epidemiological studies presented in Section 2.5 also apply to the epidemiological studies
on pesticides.
The few distinctive features of the epidemiological studies on pesticides include the following: (a)
sparse use of appropriate statistical analyses in the presence of measurement errors when assessing
exposure to pesticides and (b) paucity of information on other important factors that may affect the
exposure–health outcome relationship. These features are expanded on in the following paragraphs.
a) Statistical analyses in the presence of measurement errors
The difﬁculties inherent in correctly measuring exposure are frequent in many areas of
epidemiological research, such as nutritional epidemiology and environmental epidemiology. It is not
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easy to gauge the short- and long-term exposure outside controlled laboratory experimental settings.
In large populations, individuals are exposed to a variety of different agents in a variety of different
forms for varying durations and with varying intensities.
Unlike nutritional or environmental epidemiology, however, pesticide epidemiology has so far made
little use of statistical analyses that would appropriately incorporate measurement errors, despite their
wide availability and sizable literature on the topic. A direct consequence of this is that the inferential
conclusions may not have been as accurate and as precise as they could have been if these statistical
methods were utilised (Bengtson et al., 2016; Dionisio et al., 2016; Spiegelman, 2016).
b) Information on other important factors of interest
Identifying and measuring the other relevant factors that might affect an outcome of interest is a
recurrent and crucial issue in all ﬁelds of science. For example, knowing that a drug effectively cures a
disease on average may not sufﬁce if such drug is indeed harmful to children or pregnant women.
Whether or not age, pregnancy and other characteristics affect the efﬁcacy of a drug is an essential
piece of information to doctors, patients, drug manufacturers and drug-approval agencies alike.
Pesticide epidemiology provides an opportunity for careful identiﬁcation, accurate measuring and
thorough assessment of possible relevant factors and their role in the exposure–health outcome
relationship. Most often, relevant factors have been screened as potential confounders. When
confounding effects were detected, these needed to be adjusted for in the statistical analyses. This
has left room for further investigations that would shed light on this important issue by reconsidering
data that have already been collected and that may be collected in future studies. The statistical
methods in the pesticide literature have been mainly restricted to standard applications of basic
regression analyses, such as binary probability and hazard regression models. Potentially useful
analytical approaches, such as propensity score matching, mediation analyses, and causal inference,
would be helpful for pesticide epidemiology (Imbens and Rubin, 2015).
4. Proposals for reﬁnement to future epidemiological studies for
pesticide risk assessment
This section is aimed at addressing methods for assessment of available pesticide epidemiological
studies and proposals for improvement of such studies to be useful for regulatory purposes.
When considering the potential regulatory use of epidemiological data, many of the existing
epidemiological studies on pesticides exposure and health effects suffer from a range of
methodological limitations or deﬁciencies which limit their value in the assessment of individual active
substances. Epidemiological studies on pesticides exposure and health effects would ideally generate
semi-quantitative data or be able to have greater relevance to quantitative risk assessment with
respect to the output from prediction models. This would allow epidemiological results to be expressed
in terms more comparable to the quantitative risk assessments, which are more typically used in
evaluating the risks of pesticides. The question arises how such epidemiological data could be
considered for risk assessment when judged in comparison to the predictive models. A precisely
measured quantitative dose–response relationship is presently rarely attainable as a result of current
pesticide epidemiological studies.
The quality, reliability and relevance of the epidemiological evidence in relation to pesticide
exposure and health effects can be enhanced by improving (a) the quality of each individual study and
(b) the assessment of the combined evidence accrued from all available studies.
4.1. Assessing and reporting the quality of epidemiological studies
The quality and relevance of epidemiological research should be considered when selecting
epidemiological studies from the literature for use in risk assessment. The quality of this research can
be enhanced by (US-EPA, 2012; Hernandez et al., 2016):
a) an adequate assessment of exposure, preferentially biomarker concentrations at individual level
reported in a way which will allow for a dose–response assessment;
b) a reasonably valid and reliable outcome assessment (well-deﬁned clinical entities or validated
surrogates);
c) an adequate accounting for potentially confounding variables (including exposure to multiple
chemicals);
d) the conduct and reporting of subgroup analysis (e.g. stratiﬁcation by gender, age, ethnicity).
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It is widely accepted that biomedical research is subject to and suffers from diverse limitations. An
assessment of weaknesses in the design, conduct and analysis of epidemiology research studies on
pesticides is essential to identify potentially misleading results and identify reliable data.
Guidelines and checklists help individuals meet certain standards by providing sets of rules or
principles that guide towards the best behaviour in a particular area. Several tools and guidelines have
been developed to aid the assessment of epidemiological evidence; however, there is no speciﬁc tool
for assessing studies on pesticides. Although these studies have special considerations around exposure
assessment that require speciﬁc attention, standard epidemiological instruments for critical appraisal of
existing studies may apply. Existing reporting guidelines usually specify a minimum set of information
needed for a complete and clear account of what was done and what was found during a research
study focusing on aspects that might have introduced bias into the research (Simera et al., 2010).
A number of tools were speciﬁcally designed for quality appraisal of observational epidemiological
studies, such as the Newcastle–Ottawa scale (NOS) and the Research Triangle Institute (RTI) item
bank. The latter is a practical and validated tool which consists of a checklist of 29 questions for
evaluating the risk of bias and precision of epidemiological studies of chemical exposures. In addition,
the Biomonitoring, Environmental Epidemiology, and Short-Lived Chemicals (BEES-C) instrument was
developed to evaluate the quality of epidemiological research that use biomonitoring to assess short-
lived chemicals (LaKind et al., 2015), but it can also be used for persistent chemicals and
environmental measures as its main elements are cross-cutting and are more broadly applicable. Two
earlier efforts to develop evaluative schemes focused on epidemiology research on environmental
chemical exposures and neurodevelopment (Amler et al., 2006; Youngstrom et al., 2011).
Regarding quality of reporting, the Enhancing the QUAlity and Transparency Of health Research
(EQUATOR) Network, ofﬁcially launched in June 2008, is an international initiative that promotes
transparent and accurate reporting of health research studies. It currently lists over 90 reporting
guidelines with some of them being speciﬁc for observational epidemiological studies (e.g. Strengthening
the Reporting of OBservational studies in Epidemiology (STROBE)). The STROBE statement includes
recommendations on what should be included in an accurate and complete report of an observational
study including cross-sectional, case–control and cohort studies using a checklist of 22 items that relate
to the title, abstract, introduction, methods, results and discussion sections of articles (von Elm et al.,
2007). The STROBE statement has been endorsed by a growing number of biomedical journals which
refer to it in their instructions for authors. Table 1 presents a summary of the main features that STROBE
proposes to be taking into account when assessing the quality of reporting epidemiological studies.
Extensions to STROBE are available including the STROBE Extension to Genetic Association studies
(STREGA) initiative and the STROBE-ME statement for assessment of molecular epidemiology studies.
Since the STROBE checklist mentions only in a general way exposure and health outcomes, the PPR
Panel recommends that an extension of the STROBE statement be developed, for inclusion in the
EQUATOR network library, speciﬁcally relevant to the area of pesticide exposure and health outcomes.
This would greatly assist researchers and regulatory bodies in the critical evaluation of study quality.
Table 1: Main features of the STROBE tool to assess quality of reporting of epidemiological studies
STROBE Statement Items
Factor Item Recommendation
Title and Abstract
1 a) Indicate the study’s design with a commonly used term in the title of the
abstract
b) Provide in the abstract an informative and balanced summary of what was
done and what was found
Introduction
Background/rationale 2 Explain the scientiﬁc background and rationale for the investigation being
reported
Objectives 3 State speciﬁc objectives, including prespeciﬁed hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations and relevant dates, including periods of
recruitment, exposure, follow-up and data collection
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STROBE Statement Items
Factor Item Recommendation
Participants 6 a) Cohort study – Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up
Case–control study – Give the eligibility criteria, and the sources and
methods of case ascertainment and control selection. Give the rationale for
the choice of cases and controls
Cross-sectional study – Give eligibility criteria, and the sources and methods
of selection of participants
b) Cohort study – For matched studies, give matching criteria and the number
of exposed and unexposed
Case–control study – For matched studies, giving matching criteria and the
number of controls per case
Variables 7 Clearly deﬁne all outcomes, exposures, predictors, potential confounders and
effect modiﬁers. Give diagnostic criteria, if applicable
Data sources/
measurements
8* For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if
there is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why
Statistical methods 12 a) Describe all statistical methods, including those used to control for
confounding
b) Describe any methods used to examine subgroups and interactions
c) Explain how missing data were addressed
d) Cohort study – If applicable, explain how loss to follow-up was addressed
Case–control study – If applicable, explain how matching of cases and
controls was addressed
Cross-sectional study – If applicable, describe analytical methods taking
account of sampling strategy
e) Describe any sensitivity analyses
Results
Participants 13* a) Report numbers of individuals at each stage of study – e.g. numbers
potentially eligible, examined for eligibility, conﬁrmed eligible, included in the
study, completing follow-up and analysed
b) Give reasons for non-participation at each stage
c) Consider use of a ﬂow diagram
Descriptive data 14* a) Give characteristics of study participants (e.g. demographic, clinical, social)
and information on exposures and potential confounders
b) Indicate number of participants with missing data for each variable of
interest
c) Cohort study – Summarise follow-up time (e.g. average and total amount)
Outcome data 15* Cohort study – Report numbers of outcome events or summary measures over
time
Case–control study – Report numbers in each exposure category, or summary
measures of exposure
Cross-sectional study – Report numbers of outcome events or summary
measures
Main results 16 a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates
and their precision (e.g. 95% conﬁdence interval). Make clear which
confounders were adjusted for and why they were included
b) Report category boundaries when continuous variables were categorised
c) If relevant, consider translating estimates of relative risk into absolute risk
for a meaningful time period
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Selective reporting can occur because non-signiﬁcant results or unappealing signiﬁcant results may
not be published. Investigators should avoid the selective reporting of signiﬁcant results and high-risk
estimates. In this regard, standardisation of reporting of epidemiological studies could help to reduce
or avoid selective reporting. The STROBE statement and similar efforts are useful tools for this
purpose. Although some epidemiological research will remain exploratory and post hoc in nature, this
should be clariﬁed in the publications and selective reporting minimised, so that epidemiological
ﬁndings could be interpreted in the most appropriate perspective (Kavvoura et al., 2007).
Preregistration of studies and prepublication of protocols are the measures taken by some Journal
editors and Ethics Committees to reduce reporting bias and publication bias in clinical trials on
pharmaceuticals. Although a similar proposal has been suggested for observational epidemiological
studies in order to be conducted as transparently as possible to reduce reporting bias and publication
bias, there is no consensus among epidemiologists (Pearce, 2011; Rushton, 2011). In contrast, a
number of initiatives have been undertaken by professional societies to foster good epidemiological
practice. This is the case, for example, of the International Epidemiological Association (IEA, 2007) or
the Dutch Society for Epidemiology on responsible epidemiologic Research Practice (DSE, 2017).
Data quality assessment of formal epidemiological studies is based solely on the methodological
features of each individual study rather than on the results, regardless of whether they provide evidence
for or against an exposure/outcome association. However, for risk assessment, it is important to assess
not only the quality of study methods but also the quality of the information they provide. Indeed, good
studies may be dismissed during the formal quality assessment by the poor reporting of the information.
4.2. Study design
Well conducted prospective studies with appropriate exposure assessment provide the most reliable
information and are less prone to biases. When prospective studies are available, results from studies
of less robust design can give additional support. In the absence of prospective studies the results
from cross-sectional and case–control studies should be considered but interpreted with caution.
However, it is acknowledged that a well-designed case–control study may be superior to a less well
designed cohort study. Analytical approaches should be congruent with the study design, and
assumptions that the statistical methods required should be carefully evaluated.
Ideally observational studies for long-term diseases should be prospective and designed such that
the temporal separation between the exposure and the health outcome is appropriate with respect to
the time it takes to develop the disease. For outcomes such as cancer or cardiovascular diseases,
which often have a long latency period (> 10 years), exposure should be assessed more than once
prior to the outcome assessment. For other outcomes with a shorter latency period, such as immune
function disturbances, the appropriate temporal separation may be in the range of days or weeks and
a single exposure assessment may be adequate. In short, the ideal design of a study depends on the
latency period for the outcome under consideration. The expected latency period then determines both
the length of follow-up and the frequency for which the exposure has to be quantiﬁed.
STROBE Statement Items
Factor Item Recommendation
Other analyses 17 Report other analyses done – e.g. analyses of subgroups and interactions, and
sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or
imprecision. Discuss both direction and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives,
limitations, multiplicity of analyses, results from similar studies, and other
relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and,
if applicable, for the original study on which the present article is based
*: Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed
groups in cohort and cross-sectional studies.
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4.3. Study populations
The EU population, which exceeds 500 million people, can be assumed to be fairly heterogeneous
and so expected to include a number of more sensitive individuals that may be affected at lower doses
of pesticide exposure. To address this, in stratiﬁed sampling, the target population is divided into
subgroups following some key population characteristics (e.g. sex, age, geographic distribution,
ethnicity or genetic variation) and a random sample is taken within each subgroup. This allows
subpopulations to be represented in a balanced manner in the study population.
Vulnerable populations should then be examined in epidemiological studies either through subgroup
or sensitivity analysis. However, such analyses need to be deﬁned a priori. In case of ad hoc subgroup
sensitivity analysis, the statistical thresholds should be adjusted accordingly and the replication of
results should follow. Evidence of vulnerable subpopulations would ideally involve prospective studies
that include assessment of biomarkers of exposure, subclinical endpoints and disease incidence over
time.
It may be impossible to ﬁnd a threshold of a toxic-induced increase in disease in the population
because a large number of people are in a preclinical state and would be sensitive to the low end of
the dose–response curve. For that to be evident, the epidemiology data would need to characterise
the relationship between chemical exposure and risk of disease in a broad cross-section of the
population (or look at precursor lesions or key events) and allow a robust examination of a low-dose
slope.
On the basis of the degree of evidence relevant to a vulnerable subpopulation, consideration should
be given to whether dose–response assessment will focus on the population as a whole or will involve
separate assessments for the general population and susceptible subgroups. If it is the population as a
whole, the traditional approach is to address variability with uncertainty factors; it may also be possible
to analyse the effect of variability on risk by evaluating how the risk distribution of the disease shifts in
response to the toxicant. In essence, the risk distribution based on a subclinical biomarker is an
expression of toxicodynamic variability that can be captured in dose–response assessment.
The alternative approach is to address vulnerable subpopulations as separate from the general
population and assign them unique potencies via dose–response modelling speciﬁc to the groups that
might be based on actual dose–response data for the groups, on adjustments for speciﬁc toxicokinetic or
toxicodynamic factors, or on more generic adjustment or uncertainty factors. For a pesticide, if it is
known that a particular age group, disease (or disease-related end-point), genetic variant or co-exposure
creates unique vulnerability, efforts should be made to estimate the potency differences relative to the
general population and on that basis to consider developing separate potency values or basing a
single value on the most sensitive group or on the overall population with adjustments for vulnerable
groups.
4.4. Improvement of exposure assessment
The difﬁculties often associated with pesticide exposure assessment in epidemiological studies have
been highlighted above. The description of pesticide exposure (in particular quantitative information on
exposure to individual pesticides) is generally reported in insufﬁcient detail for regulatory purposes and
this limitation is difﬁcult to overcome, especially for diseases with a long latency period (e.g. many
cancers and neurodegenerative disorders).
It is noteworthy that the methods necessary to conduct exposure monitoring are to be submitted
by the applicant in the dossier. The regulation requirements do ask for validated methods that can be
used for determining exposure. The Commission Regulation (EU) No 283/2013, setting out the data
requirements for active substances, in accordance with Regulation (EC) No 1107/2009 of the European
Parliament and of the Council concerning the placing of PPP on the market, addresses information on
methods of analysis required to support both pre-approval studies and post-approval monitoring. In
this context, the post-approval requirements are the most relevant and the regulation literally states:
‘4.2. Methods for post-approval control and monitoring purposes – Methods, with a full description,
shall be submitted for:
a) the determination of all components included in the monitoring residue deﬁnition as submitted in
accordance with the provisions of point 6.7.1 in order to enable Member States to determine
compliance with established maximum residue levels (MRLs); they shall cover residues in or on
food and feed of plant and animal origin;
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b) the determination of all components included for monitoring purposes in the residue deﬁnitions
for soil and water as submitted in accordance with the provisions of point 7.4.2;
c) the analysis in air of the active substance and relevant breakdown products formed during or
after application, unless the applicant shows that exposure of operators, workers, residents or
bystanders is negligible;
d) the analysis in body ﬂuids and tissues for active substances and relevant metabolites.
As far as practicable these methods shall employ the simplest approach, involve the minimum cost,
and require commonly available equipment. The speciﬁcity of the methods shall be determined and
reported. It shall enable all components included in the monitoring residue deﬁnition to be determined.
Validated conﬁrmatory methods shall be submitted if appropriate. The linearity, recovery and precision
(repeatability) of methods shall be determined and reported.
Data shall be generated at the LOQ and either the likely residue levels or ten times the LOQ. The
LOQ shall be determined and reported for each component included in the monitoring residue
deﬁnition. For residues in or on food and feed of plant and animal origin and residues in drinking
water, the reproducibility of the method shall be determined by means of an independent laboratory
validation (ILV) and reported’.
From this, it can be concluded that the requirements exist, but are somewhat less stringent for
human biomonitoring than for monitoring of residues in food and feed.
Failure to use these existing methods restricts the potential for the use of epidemiological evidence
in the regulation of speciﬁc pesticides. It is therefore important that those contemplating future studies
carefully consider approaches to be used to avoid misclassiﬁcation of exposure, and to conduct
appropriate detailed exposure assessments for speciﬁc pesticides, which allow for sound dose–
response analyses, and demonstrate the validity of the methods used.
A given exposure may have a different health impact depending on the period in the lifespan when
exposure takes place. Greater attention needs to be paid to exposures occurring during periods of
potential susceptibility for disease development by ensuring that the exposure assessment adequately
addresses such critical times. This may be particularly relevant for studies involving neurodevelopment,
obesity or allergic responses, which are complex multistage developmental processes that occur either
prenatally or in the early post-natal life. For this reason, measurement of the exposure at one single
time period may not properly characterise relevant exposures for all health effects of the
environmental factors, and thus, the possibility arises of needing to measure the exposure at several
critical periods of biological vulnerability to environmental factors. It is particularly challenging to
construct an assessment of historical exposures which may deviate from current exposures, in both
the range of chemicals and intensity of exposure and also co-exposure to other substances which are
not included in the scope of study.
There are advantages and disadvantages to all methods of measuring pesticide exposure, and
speciﬁc study designs and aims should be carefully considered to inform a speciﬁc optimal approach.
Exposure assessment can be improved at the individual level in observational research by using:
a) Personal exposure monitoring: This can be used to document exposures as readings
measure pesticide concentration at the point of contact. Personal exposure monitors have been costly
and burdensome for study participants. However, technological advances have recently driven personal
exposure monitoring for airborne exposures to inexpensive, easy to use devices and these are suitable
for population research. Personal exposure monitors that are speciﬁc to pesticide exposure could
involve sensors to measure airborne concentrations, ‘skin’ patches to measure dermal concentrations,
indoor home monitors that capture dust to measure other means of exposure. These mobile
technology advances can be employed to provide observational studies with detailed and robust
exposure assessments. Such equipment is now increasingly being adapted to serve large-scale
population research and to capture data from large cohort studies. These coupled with other
technological advances, such as real time data transfers via mobile phones and mobile phone
applications to capture lifestyle and other habits, could bring next generation observational studies far
more detailed and robust exposure assessments compared to current evidence. However, the
generation of huge volumes of data can pose organisational, statistical and technical challenges,
particularly with extended follow-up times. Ethics and personal data protection issue should be taken
into account, and local regulations may prevent extensive use of such technologies. However, use of
such personal monitors only provides information for one of the different potential routes of exposure.
b) Biomarkers of exposure (human biomonitoring (HBM)). An alternative and/or complementary
approach is to ascertain the internal dose, which is the result of exposure via different routes (dermal,
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inhalation and dietary exposure). These biomarkers have the potential to play an important role in
assessing aggregate exposure to pesticides and informing cumulative risk assessment. Biomonitoring
requires measurements in biological samples of concentrations of chemical under consideration (parent
or metabolites) or markers of pathophysiologic effects thereof (such as adducts). However, challenges
may include uncertainties relating to extrapolation of measured concentrations in biological samples to
relevant doses.
Although biomonitoring has the potential to provide robust estimates of absorbed doses of
xenobiotics, modern pesticides and their metabolites are eliminated from the body relatively quickly, with
excretion half-lives typically measured in a few days (Oulhote and Bouchard, 2013). Consequently, use
of biomarkers is both resource intensive and intrusive. The process is even more intrusive when it has to
be conducted repeatedly on large numbers of individuals to monitor exposures over long durations.
Nevertheless, because of the potential to provide accurate integrated estimates of absorbed doses,
biological monitoring of pesticides and their metabolites can be usefully employed to calibrate other
approaches of exposure assessment. A good example of such an approach is that used by the Agricultural
Health Study (Thomas et al., 2010; Coble et al., 2011; Hines et al., 2011). Also, HBM methods can be
used with other forms of exposure assessment for the construction of long exposure histories.
Biomonitoring improves the precision in characterisation of exposure and allows the investigation of
changes in exposure that occur at environmentally relevant exposure concentrations. Data collected in
large-scale biomonitoring studies can be useful in setting reference ranges to assist in exposure
classiﬁcation in further epidemiological studies. Biomonitoring data also provide critical information for
conducting improved risk assessment and help to identify subpopulations at special risk for adverse
outcomes.
Biobanks, as repositories of biological samples, can be exploited to assess biomarkers of exposure
with the aim of investigating early exposure–late effect relationships. That is, whether exposures
occurring during early life are critical for disease development later in life (e.g. neurobehavioral
impairment, children tumours, immunotoxic disorders, etc.) and to retrospectively assess health risks
according to current health guidelines.
The results of measurements of metabolite levels in human matrices, e.g. urine, blood or hair do not
provide the complete story with respect to the actual received dose. Additional assessment, possibly
employing physiological-based toxicokinetic (PBTK) approaches, may be required to estimate the total
systemic or tissue/organ doses. A PBTK model is a physiologically based compartmental model used to
characterise toxicokinetic behaviour of a chemical, in particular for predicting the fate of chemicals in
humans. Data on blood ﬂow rates, metabolic and other processes that the chemical undergoes within
each compartment are used to construct a mass-balance framework for the PBTK model. PBTK models
cannot be used only to translate external exposures into an internal (target) dose in the body, but also
to infer external exposures from biomonitoring data. Furthermore, PBTK models need to be validated.
Toxicokinetic processes (ADME) determine the ‘internal concentration’ of an active substance
reaching the target and help to relate this concentration/dose to the observed toxicity effect. Studies
have been prescribed by the current regulations, but it would be beneﬁcial to survey all the evidence,
be it from in vitro, animal or human studies, about toxicokinetic behaviour of an active substance.
Further discussion on quality assurance issues and factors to consider in relation to HBM studies is
present in the report of the EFSA outsourced project (Bevan et al., 2017).
Exposure assessment can also be improved at the population level in observational research by using:
a) Larger epidemiological studies that make use of novel technologies and big data availability, such
as registry data or data derived from large databases (including administrative databases) on health
effects and pesticide usage, could provide more robust ﬁndings that might eventually be used for
informed decision-making and regulation. Much effort needs to concentrate around the use of
registered data which may contain records of pesticide use by different populations, such as farmers
or other professional users that are required to maintain.9 Such data could be further linked to
9 Regulation 1107/2009 Article 67 states: Record-keeping 1. Producers, suppliers, distributors, importers, and exporters of plant
protection products shall keep records of the plant protection products they produce, import, export, store or place on the
market for at least 5 years. Professional users of plant protection products shall, for at least 3 years, keep records of the plant
protection products they use, containing the name of the plant protection product, the time and the dose of application, the
area and the crop where the plant protection product was used. They shall make the relevant information contained in these
records available to the competent authority on request. Third parties such as the drinking water industry, retailers or
residents, may request access to this information by addressing the competent authority. The competent authorities shall
provide access to such information in accordance with applicable national or Community law.
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electronic health records (vide supra) and provide studies with unprecedented sample size and
information on exposure and subsequent disease and will eventually be able to answer robustly
previously unanswered questions. At the same time, information on active substances needs to be
better captured in these registries and large databases. Dietary pesticide residue exposure can be
estimated more accurately by using spraying journal data in combination with supervised residue trials.
This method has the advantage of including more comprehensive and robust source data, more
complete coverage of used pesticides and more reliable and precise estimates of residues below
standard limit of quantiﬁcation (LOQ) (Larsson et al., 2017).
b) Novel sophisticated approaches to geographical information systems (GIS) and small area
studies might also serve as an additional way to provide estimates of residential exposures. Exposure
indices based on GIS (i.e. residential proximity to agricultural ﬁelds and crop surface with inﬂuence
around houses), when validated, may represent a useful complementary tool to biomonitoring and
have been used to assess exposure to pesticides with short biological half-lives (Cornelis et al., 2009).
As some such exposures maybe inﬂuenced by wind direction, amongst other factors, this should be
taken into account through a special analysis of outcomes to make best of use of the approach. Also,
these indices could be more representative, albeit non-speciﬁc, measures of cumulative exposure to
non-persistent pesticides for long periods of time than biomonitoring data (Gonzalez-Alzaga et al.,
2015).
As already discussed, to be useful for the regulatory risk assessments of individual compounds
epidemiological exposure assessments should provide information on speciﬁc pesticides. However,
epidemiological studies which include more generic exposure assessments also have the potential to
identify general risk factors and suggest inferences of causal associations in relevant human
populations. Such observations may be important both informing overall regulatory policies, and for
identiﬁcation of matters for further epidemiological research.
Recent advances in modern technologies make it possible to estimate pesticide exposures to an
unprecedented extent using novel analytical strategies:
a) The development of the so called -omic techniques, such as metabolomics and adductomics,
also presents intriguing possibilities for improving exposure assessment through measurement of a
wide range of molecules, from xenobiotics and metabolites recorded over time in biological matrices
(blood, saliva, urine, hair, nails, etc.), to covalent complexes with DNA and proteins (adductomics) and
understanding biological pathways. These methodologies could be used in conjunction with other
tools. There is also both interest and the recognition that further work is required before such
techniques can be applied in regulatory toxicology. The use of the exposome (the totality of exposures
received by an individual during life) might be better deﬁned by using ‘omics’ technologies and
biomarkers appropriate for human biomonitoring. Nevertheless, important limitations have to be
acknowledged because of the lack of validation of these methodologies and their cost, which limits
their use at large scale.
b) Environmental exposures are traditionally assessed following ‘one-exposure-one-health-effect’
approach. In contrast, the exposome encompass the totality of human environmental exposures from
conception onward complementing the genetics knowledge to characterise better the environmental
components in disease aetiology. As such, the exposome includes not only any lifetime chemical
exposures but also other external and or internal environmental factors, such as infections, physical
activity, diet, stress and internal biological factors (metabolic factors, gut microﬂora, inﬂammation and
oxidative stress). A complete exposome would have to integrate many external and internal exposures
from different sources continuously over the life course. However, a truly complete exposome will likely
never be measured. Although all these domains of the exposome need to be captured by using
different approaches than the traditional ones, it is envisaged that no single tool will be enough to this
end.
The more holistic approach of exposure is not intended to replace the traditional ‘one-exposure-
one-health-effect’ approach of current epidemiological studies. However, it would improve our
understanding of the predictors, risk factors and protective factors of complex, multifactorial chronic
diseases. The exposome offers a framework that describes and integrates, holistically, the
environmental inﬂuences or exposures over a lifetime (Nieuwenhuijsen, 2015).
Collaborative research and integration of epidemiological or exploratory studies forming large
consortia are needed to validate these potential biomarkers and eventually lead to improved exposure
assessment. The incorporation of the exposome paradigm into traditional biomonitoring approaches
offers a means to improve exposure assessment. Exposome-wide association studies (EWAS) allow to
measurement of thousands of chemicals in blood from healthy and diseased people, test for disease
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 31 EFSA Journal 2017;15(10):5007
associations and identify useful biomarkers of exposure that can be targeted in subsequent
investigations to locate exposure sources, establish mechanisms of action and conﬁrm causality
(Rappaport, 2012). After identifying these key chemicals and verifying their disease associations in
independent samples of cases and controls, the chemicals can be used as biomarkers of exposures or
disease progression in targeted analyses of blood from large populations.
In relation to the exposome concept, the -omics technologies have the potential to measure
proﬁles or signatures of the biological response to the cumulative exposure to complex chemical
mixtures. An important advance would be to identify a unique biological matrix where the exposome
could be characterised without assessing each individual exposure separately in a given biological
sample. The untargeted nature of omics data will capture biological responses to exposure in a more
holistic way and will provide mechanistic information supporting exposure-related health effects.
Importantly, omics tools could shed light on how diverse exposures act on common pathways to cause
the same health outcomes.
While improved exposure assessment increases the power to detect associations, in any individual
study it is necessary to maximise the overall power of the study by optimising the balance between
the resource used for conducting an exposure assessment for each subject and the total number of
subjects.
4.5. Health outcomes
For pesticides, the health outcomes are broad as these chemicals have not shown a particular
effect in relation to just one single disease area. For each health outcome, multiple deﬁnitions may
exist in the literature with a varying degree of validation and unknown reproducibility across different
databases, which are limited by the lack of generalisability. A proper deﬁnition of a health outcome is
critical to the validity and reproducibility of observational epidemiological studies, and the consistency
and clarity of these deﬁnitions need to be considered across studies. While prospective observational
studies have explicit outcome deﬁnitions, inclusion and exclusion criteria and standardised data
collection, retrospective studies usually rely on identiﬁcation of health outcomes based largely on
coded data, and classiﬁcation and coding of diseases may change over time. Detailed description of
the actual codes used to deﬁne key health outcomes and the results of any validation efforts are
valuable to future research efforts (Stang et al., 2012; Reich et al., 2013). An example of coded
diseases is the ICD-10, which for instance can be used as a tool to standardise the broad spectrum of
malignant diseases.
In some surveillance studies, it is preferable to use broader deﬁnitions with a higher sensitivity to
identify all potential cases and then apply a narrower and more precise deﬁnition with a high positive
predictive value to reduce the number of false positives and resulting in more accurate cases. In
contrast, in formal epidemiological studies, a speciﬁc event deﬁnition is used and validated to
determine its precision; however, the ‘validation’ does not test alternative deﬁnitions, so it is not
possible to determine sensitivity or speciﬁcity.
Surrogate endpoints should be avoided unless they have been validated. Some criteria to assess
the validity of a surrogate outcome include:
• The surrogate has been shown to be in the causal pathway of the disease. This can be
supported by the following evidence: correlation of biomarker response to pathology and
improved performance relative to other biomarkers; biological understanding and relevance to
toxicity (mechanism of response); consistent response across mechanistically different
compounds and similar response across sex, strain and species; the presence of dose–
response and temporal relationship to the magnitude of response; speciﬁcity of response to
toxicity; that is, the biomarker should not reﬂect the response to toxicities in other tissues, or
to physiological effects without toxicity in the target organ.
• At least one well conducted trial using both the surrogate and true outcome (Grimes and
Schulz, 2005; la Cour et al., 2010). Several statistical methods are used to assess these criteria
and if they are fulﬁlled the validity of the surrogate is increased. However, many times some
uncertainty remains, making it difﬁcult to apply surrogates in epidemiological studies (la Cour
et al., 2010).
The data on health outcomes over the whole EU is potentially very extensive. If it can be managed
effectively, it will open the prospect of greater statistical power for epidemiological studies assessing
deleterious effects using very large sample sizes. Necessary prerequisites for these studies which may
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detect new subtle effects, chronic effects or effects on subpopulations when stratiﬁed are beyond the
remit of risk assessment. They include trans-national approaches to health informatics where
harmonised diagnostics, data storage and informatics coupled with legally approved access to
anonymised personal data for societal beneﬁt are established. Health records should include adequate
toxidrome classiﬁcation. The latter may in turn require improvements in medical and paramedical
training to ensure the quality of the input data.
Another opportunity for biological monitoring to be employed is where the investigation involves
the so-called biomarkers of effect. That is a quantiﬁable biochemical, physiological, or other change
that, depending on the magnitude, is associated with an established or possible health impairment or
disease. Biomarkers of effect should reﬂect early biochemical modiﬁcations that precede functional or
structural damage. Thus, knowledge of the mechanism ultimately leading to toxicity is necessary to
develop speciﬁc and useful biomarkers, and vice versa, an effect biomarker may help to explain a
mechanistic pathway of the development of a disease. Such biomarkers should identify early and
reversible events in biological systems that may be predictive of later responses, so that they are
considered to be preclinical in nature. Advances in experimental -omics technologies will show promise
and provide sound information for risk assessment strategies, i.e. on mode of action, response
biomarkers, estimation of internal dose and dose–response relationships (DeBord et al., 2015). These
technologies must be validated to assess their relevance and reliability. Once validated, they can be
made available for regulatory purposes.
5. Contribution of vigilance data to pesticides risk assessment
In addition to the formal epidemiological studies discussed in Sections 2–4, other human health
data can be generated from ad hoc reports or as a planned process, i.e. through monitoring systems
that have been implemented at the national level by public health authorities or authorisation holders.
Consistent with Sections 2–4, this section ﬁrst reviews how such a monitoring system should operate,
what the current situation is regarding the monitoring of pesticides and what recommendations for
improvement can be made.
5.1. General framework of case incident studies
A continuous process of collection, reporting and evaluation of adverse incidents has the potential
to improve the protection of health and safety of users and others by reducing the likelihood of the
occurrence of the same adverse incident in different places at later times, and also to alleviate
consequences of such incidents. This obviously also requires timely dissemination of the information
collected on such incidents. Such a process is referred to as vigilance.10
For example in the EU, the safety monitoring of medicines is known as pharmacovigilance; the
pharmacovigilance system operates between the regulatory authorities in Member States, the
European Commission and the European Medicines Agency (EMA). In some Member States, regional
centres are in place under the coordination of the national Competent Authorities. Manufacturers and
health care professionals report incidents to the Competent Authority at the national level, which
ensures that any information regarding adverse reactions is recorded and evaluated centrally and also
notiﬁes other authorities for subsequent actions. The records are then centralised by the EMA which
supports the coordination of the European pharmacovigilance system and provides advice on the safe
and effective use of medicines.
5.2. Key limitations of current framework of case incident reporting
Several EU regulations require the notiﬁcation and/or collection and/or reporting of adverse events
caused by pesticides in humans (occurring after acute or chronic exposure in the occupational setting,
accidental or deliberate poisoning, etc.). These include:
• Article 56 of EC Regulation 1107/2009 requires that ‘The holder of an authorisation for a plant
protection product shall immediately notify the Member States [. . .] In particular, potentially
10 The concept of survey refers to a single effort to measure and record something, and surveillance refers to repeated
standardized surveys to detect trends in populations in order to demonstrate the absence of disease or to identify its presence
or distribution to allow for timely dissemination of information. Monitoring implies the intermittent analysis of routine
measurements and observations to detect changes in the environment or health status of a population, but without eliciting a
response. Vigilance is distinct from surveillance and mere monitoring as it implies a process of paying close and continuous
attention, and in this context addresses speciﬁcally post marketing events related to the use of a chemical.
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harmful effects of that plant protection product, or of residues of an active substance, its
metabolites, a safener, synergist or co-formulant contained in it on human health [. . .] shall be
notiﬁed. To this end the authorisation holder shall record and report all suspected adverse
reactions in humans, in animals and the environment related to the use of the plant protection
product. The obligation to notify shall include relevant information on decisions or assessments
by international organisations or by public bodies which authorise plant protection products or
active substances in third countries’.
• Article 7 of EC Directive 128/2009 establishing a framework for Community action to achieve
the sustainable use of pesticides requires that: ‘2. Member States shall put in place systems for
gathering information on pesticide acute poisoning incidents, as well as chronic poisoning
developments where available, among groups that may be exposed regularly to pesticides such
as operators, agricultural workers or persons living close to pesticide application areas. 3. To
enhance the comparability of information, the Commission, in cooperation with the Member
States, shall develop by 14 December 2012 a strategic guidance document on monitoring and
surveying of impacts of pesticide use on human health and the environment’. However, at the
time of publishing this scientiﬁc opinion, this document has still not been released.
There are three additional regulations that apply, although indirectly, to pesticides and reporting:
• EC Regulation 1185/2009 concerning statistics on pesticides requires that Member States shall
collect data on pesticide sales and uses according to a harmonised format. The statistics on
the placing on the market shall be transmitted yearly to the Commission and the statistics on
agricultural use shall be transmitted every 5 year.
• Article 50 of Regulation (EC) 178/2002, laying down the general principles and requirements of
food law, set up an improved and broadened rapid alert system covering food and feed
(RASFF). The system is managed by the Commission and includes as members of the network
Member States, the Commission and the Authority. It reports on non-authorised occurrences of
pesticides residues and food poisoning cases.
• Article 45 (4) of EC Regulation 1272/2008 (CLP Regulation): importers and downstream users
placing hazardous chemical mixtures on the market of an EU Member State will have to submit a
notiﬁcation to the Appointed Body/Poison Centre of that Member State. The notiﬁcation needs to
contain certain information on the chemical mixture, such as the chemical composition and
toxicological information, as well as the product category to which the mixture belongs. The
inclusion of information on the product category in a notiﬁcation allows Appointed Bodies/Poison
Centres to carry out comparable statistical analysis (e.g. to deﬁne risk management measures),
to fulﬁl reporting obligations and to exchange information among MS. The product category is
therefore not used for the actual emergency health response as such, but allows the
identiﬁcation of exposure or poisoning trends and of possible measures to prevent future
poisoning cases. When formally adopted, the new Regulation will apply as of 1 January 2020.
While there are substantial legislative provisions, to this date a single uniﬁed EU
‘phytopharmacovigilance’11 system akin to the pharmacovigilance system does not exist for PPP.
Rather, a number of alerting systems have been developed within the EU to alert, notify, report and
share information on chemical hazards that may pose a risk to public health in Member States. These
systems cover different sectors including medicines, food stuffs, consumer products, industrial
accidents, notiﬁcations under International Health Regulations (IHR) and events detected by EU
Poisons Centres and Public Health Authorities. Each of these systems notify and distribute timely
warnings to competent authorities, public organisations, governments, regulatory authorities and
public health ofﬁcials to enable them to take effective action to minimise and manage the risk to public
health (Orford et al., 2014).
In the EU, information on acute pesticide exposure/incident originates mainly from data collected
and reported by Poison Control Centres (PCC’s). PCC’s collect both cases of acute and chronic
exposure/poisoning they are aware of, in the general population and in occupational settings. Cases
are usually well-documented and information includes circumstances of exposure/incident, description
of the suspected causal agent, level and duration of exposure, the clinical course and treatment and
an assessment of the causal relationship. In severe cases, the toxin and/or the metabolites are usually
11 ‘phytovigilance’ would refer to a vigilance system for plants; as pesticides are intended to be ‘medicines’ for crops, the term
‘phytopharmacovigilance’ is considered to be the more appropriate one here. Furthermore, it is a broad term used in France
covering soil, water, air, environment, animal data, etc.
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measured in blood or urine. However, follow-up of cases reported to the centres merits further
attention to identify potential long-term protracted effects.
There are two key obstacles to using Poison Centres data: ofﬁcial reports from national Poisons
Centres are not always publicly available and when they are, there is a large heterogeneity in the
format of data collections and coding, and assessment of the causal relationship. Indeed, each
Member State has developed its own tools for collection activities resulting in difﬁculties for comparing
and exchanging exposure data. In 2012, the European Commission funded a collaborative research
and development project to support the European response to emerging chemical events: the Alerting
and Reporting System for Chemical Health Threats, Phase III (ASHTIII) project. Among the various
tools and methodologies that were considered, methods to exchange and compare exposure data from
European PCC’s were developed. As a feasibility study, work-package 5 included the development of a
harmonised and robust coding system to enable Member States to compare pesticide exposure data.
However, results of a consultation with the PCC community showed that further coordination of data
coding and collection activities is supported. It was concluded that more support and coordination is
required at the EU and Member States level so that exposures data can be compared between
Member States (Orford et al., 2015).
In addition to data collected by PCC’s, several Member States have set up programmes dedicated
to occupational health surveillance.12 The purpose of these programmes is to identify the kinds of jobs,
types of circumstances and pesticides that cause health problems in workers in order to learn more
about occupational pesticide illnesses and injuries and how to prevent them. They are based on
voluntary event notiﬁcation by physicians (sometimes self-reporting by users) of any case of suspected
work-related pesticide injury or illness or poisoning. In addition to medical data, information gathered
includes data regarding type of crop, mode of application, temperature, wind speed, wearing of
personal protection equipment, etc. Once collected, these data are examined and a report is released
periodically; they provide a useful support to evaluate the safety of the products under re-registration.
These data also highlight emerging problems and allow deﬁnition of evidence-based preventive
measures for policy-makers. At EU level, the European Agency for Safety and Health at Work (EU-
OSHA)13 has very little in the way of monitoring of occupational pesticide-related illnesses data. In the
USA, a programme speciﬁcally dedicated to pesticides funded and administered by the National
Institute for Occupational Safety and Health (NIOSH) is in operation in a number of States.14
In summary, currently human data may be collected in the form of case reports or case series,
poison centres information, coroner’s court ﬁndings, occupational health surveillance programmes or
post-marketing surveillance programmes. However, not all this information is present in the medical
data submitted by applicants mainly because the different sources of information are diverse and
heterogeneous by nature, which makes some of them sometimes not accessible.
• Data collected through occupational health surveillance of the plant production workers or if
they do so, the medical data are quite limited being typically basic clinical blood measurements,
physical examinations, potentially with simple indications of how and where exposed took place,
and there usually is no long-term follow up. Furthermore, worker exposures in modern plants
(especially in the EU) are commonly very low, and often their potential exposure is to a variety
of pesticides (unless it is a facility dedicated to a speciﬁc chemical).
• Moreover, the reporting of data from occupational exposure to the active substances during
manufacture is often combined with results from observations arising from contact with the
formulated plant protection product as the latter information results from case reports on
poisoning incidents and epidemiological studies of those exposed as a result of PPP use.
Indeed, the presence of co-formulants in a plant protection product can modify the acute
toxicological proﬁle. Thus, to facilitate proper assessment, when reporting ﬁndings collected in
humans it should be clearly speciﬁed whether it refers to the active substance per se or a PPP.
With regard to the requirements of speciﬁc data on diagnoses of poisoning by the active substance
or formulated plant protection products and proposed treatments, which are also part of chapter 5.9
of the EC Regulation 283/2013, information is often missing or limited to those cases where the toxic
mode of action is known to occur in humans and a speciﬁc antidote has been identiﬁed.
12 For example: Phyt’attitude in France is a vigilance programme developed by the Mutualite Sociale Agricole: http://www.msa.
fr/lfr/sst/phyt-attitude
13 https://osha.europa.eu/en/about-eu-osha
14 SENSOR programme: https://www.cdc.gov/niosh/topics/pesticides/overview.html
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5.3. Proposals for improvement of current framework of case incident
reporting
In order to avoid duplication and waste of effort, a logical next step would be to now develop, with
all concerned public and private sector actors, an EU ‘phytopharmacovigilance’ system for chemicals
similar to the ones that have been put in place for medicines. This network could be based on
committed and speciﬁcally trained occupational health physicians and general practitioners in rural
areas, and resources should be allocated by Member States to establish and to successfully maintain
the system. Indeed such a network would be useful in detecting acute effects; it would also act as a
sentinel surveillance network for speciﬁc health effects (such as asthma, sensitisation, etc.) or for the
detection of emerging work-related disease. In fact, while much experience has already been gained
on how to gradually build such a system, it is nevertheless envisioned that this will take a number of
years to be put in place. Several difﬁculties will arise because of the nature of the data collected (the
sources of information are potentially diverse), the quality and completeness of the collected
information for every case (especially the circumstances), the grading of severity and accountability of
the observed effects (the link between the observed effect and the product). Rules should be deﬁned
so that they are identical from one ‘evaluator’ to another. The network should be stable over time (e.g.
continuity in national organisations involved, consistent methodology employed, etc.), to ensure that
the phytopharmacovigilance system fully complies with the objectives, i.e. monitoring changes over
time. The use of phytopharmacovigilance data is unlikely to be limited to risk assessment purposes
and may have an impact on risk management decisions (e.g. revisions in the terms and conditions of
product authorisations or ultimately product withdrawal); this should be clear to all stakeholders from
the outset.
Such a system may not merit being established solely for chemicals that are (predominantly) used
as pesticides. However, given the legislative provisions already in place for pesticides, its development
may need to be prioritised for pesticides.
In conclusion, the European Commission together with the Member States should initiate the
development of an EU-wide vigilance framework for pesticides. These should include:
• harmonisation of human incident data collection activities at the EU level;
• coordination of the compilation of EU-wide databases;
• improving the collaboration between Poison Centres and regulatory authorities at national level
in order to collect all the PPP poisonings produced in each Member State;
• guidance document on monitoring the impact of pesticide use on human health with
harmonisation of data assessment for causal relationships;
• regular EU-wide reports.
6. Proposed use of epidemiological studies and vigilance data in
support of the risk assessment of pesticides
This section brieﬂy reviews the risk assessment process (Section 6.1) based on experimental
studies and discusses what information epidemiological studies could add to that process. Next, the
assessment of the reliability of epidemiological studies is addressed in Section 6.2. In Section 6.3, the
relevance of one or more studies found to be reliable is assessed.
6.1. The risk assessment process
Risk assessment is the process of evaluating risks to humans and the environment from chemicals
or other contaminants and agents that can adversely affect health. For regulatory purposes, the
process used to inform risk managers consists of four steps (EFSA, 2012a). On the one hand,
information is gathered on the nature of toxic effects (hazard identiﬁcation) and the possible dose–
response relationships between the pesticide and the toxic effects (hazard characterisation). On the
other hand, information is sought about the potential exposure of humans (consumers, applicators,
workers, bystanders and residents) and of the environment (exposure assessment). These two
elements are weighed in the risk characterisation to estimate that populations be potentially exposed
to quantities exceeding the reference dose values, that is, to estimate the extra risk of impaired health
in the exposed populations. Classically, this is used to inform risk managers for regulatory purposes.
a) Step 1. Hazard identiﬁcation.
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Epidemiological studies and vigilance data are relevant for hazard identiﬁcation as they can point to
potential link between pesticide exposure and health. In this context, epidemiological data can provide
invaluable information in ‘scanning the horizon’ for effects not picked up in experimental models.
Importantly, these studies also provide information about potentially enhanced risks for vulnerable
population subgroups, sensitive parts of the lifespan, and gender selective effects.
b) Step 2. Hazard characterisation (dose–response assessment). As previously discussed a classic
dose–response framework is not normally considered when using epidemiological data as the exposure
dose is rarely assigned. The challenge presented when high quality epidemiological studies are
available is to see whether these can best be integrated into the scheme as numerical input. A dose–
response framework is rarely considered when using epidemiological data for risk assessment of
pesticides. However, previous scientiﬁc opinions of the EFSA CONTAM Panel have used epidemiology as
basis for setting reference values, particularly in the case of cadmium, lead, arsenic and mercury,
which are the most well-known and data rich (EFSA, 2009a,b, 2010b, 2012b). Even when they may
not form the basis of a dose–response assessment, vigilance and epidemiological data may provide
supportive evidence to validate or invalidate a dose–response study carried out in laboratory animals.
Characterisation of the relationships between varying doses of a chemical and incidences of adverse
effects in exposed populations requires characterisation of exposure or dose, assessment of response
and selection of a dose–response model to ﬁt the observed data in order to ﬁnd a no-effect level. This
raises two questions: can a dose–response be derived from epidemiological data to identify a no-effect
level. If not, can epidemiological information otherwise contribute to the hazard characterisation?
Understanding dose–response relationships could also be relevant where adverse health outcomes
are demonstrated to be associated with uses with higher exposures than EU good plant protection
practice would give rise to, but where no association is observed from uses with lower exposures. It is
clear that in this context the statistical summary of an epidemiological study deﬁning RR or OR is
potentially useful quantitative information to feed into the hazard characterisation process, when the
study design meets the necessary standards.
c) Step 3. Exposure assessment. Data concerning the assessment of exposure are often hard to
estimate in complex situations where a variety of uncontrolled ‘real-world’ factors confound the analysis.
As discussed previously, contemporary biological monitoring is rarely carried out in the general human
population for practical reasons including high cost, test availability and logistics. However, it is anticipated
that in the near future biomonitoring studies and data on quantitative exposure to pesticides will increase.
Step 4. Risk characterisation. In this ﬁnal step, data on exposure are compared with health-based
reference values to estimate the extra risk of impaired health in the exposed populations. Human data
can indeed help verify the validity of estimations made based on extrapolation from the full
toxicological database regarding target organs, dose–response relationships and the reversibility of
toxic effects, and to provide reassurance on the extrapolation process without direct effects on the
deﬁnition of reference values (London et al., 2010).
Epidemiological data might also be considered in the context of uncertainty factors (UFs). An UF of 10
is generally used on animal data to account for interspecies variability of effects and this is combined with
a further factor of 10 to account for variation in susceptibility of different parts of the human population.
However, there are cases where only human data are considered (when this is more critical than animals
data) and a single factor of 10 for intraspecies variability will apply. It is noted that at this moment
Regulation (EC) No 1107/2009 Article 4(6) stipulates that: ‘In relation to human health, no data collected
on humans shall be used to lower the safety margins resulting from tests on animals’. The implication of
this is that for risk assessment epidemiological data may only be used to increase the level of precaution
used in the risk assessment, and not to decrease UFs even where relevant human data are available.
6.2. Assessment of the reliability of individual epidemiological studies
Factors to be considered in determining how epidemiology should be considered for a WoE assessment
are described below and have been extensively outlined by available risk of bias tools for observational
epidemiological studies.15 The following examples represent factors to look for not an exhaustive list:
• Study design and conduct. Was the study design appropriate to account for the expected
distributions of the exposure and outcome, and population at risk? Was the study conducted
primarily in a hypothesis generating or a hypothesis-testing mode?
15 Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the
RTI Item Bank (https://www.ncbi.nlm.nih.gov/books/NBK154464/) and Cochrane handbook.
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• Population. Did the study sample the individuals of interest from a well-deﬁned population? Did
the study have adequate statistical power and precision to detect meaningful differences for
outcomes between exposed and unexposed groups?
• Exposure assessment. Were the methods used for assessing exposure valid, reliable and
adequate? Was a wide range of exposures examined? Was exposure assessed at quantitative
level or in a categorical or dichotomous (e.g. ever vs never) manner? Was exposure assessed
prospectively or retrospectively?
• Outcome assessment. Were the methods used for assessing outcomes valid, reliable and
adequate? Was a standardised procedure used for collecting data on health outcomes? Were
health outcomes ascertained independently from exposure status to avoid information bias?
• Confounder control: were potential confounding factors appropriately identiﬁed and
considered? How were they controlled for? Were the methods used to document these factors
valid, reliable and adequate?
• Statistical analysis. Did the study estimate quantitatively the independent effect of an exposure
on a health outcome of interest? Were confounding factors appropriately controlled in the
analyses of the data?
• Is the reporting of the study adequate and following the principles of transparency and the
guidelines of the STROBE statement (or similar tools)?
Study evaluation should provide an indication on the nature of the potential limitations each speciﬁc
study may have and an assessment of overall conﬁdence in the epidemiological database.
Furthermore, the nature and the speciﬁcity of the outcome with regards to other known risk factors
can inﬂuence the evaluation of human data for risk assessment purposes, particularly in case of
complex health endpoints such as chronic effects with long induction and latency periods.
Table 2 shows the main parameters to be evaluated in single epidemiological studies and the
associated weight (low, medium and high) for each parameter. Speciﬁc scientiﬁc considerations should
be applied on a case-by-case basis, but it would be unrealistic to implement these criteria in a rigid
and unambiguous manner.
Table 2: Study quality considerations for weighting epidemiological observational studies(a),(b)
Parameter High Moderate Low
Study design
and conduct
Prospective studies.
Prespeciﬁed hypothesis
(compound and outcome
speciﬁc)
Case–control studies.
Prospective studies not
adequately covering exposure
or outcome assessment
Cross-sectional, ecological
studies
Case–control studies not
adequately covering exposure
or outcome assessment
Population Random sampling. Sample size
large enough to warrant
sufﬁcient power
Population characteristics well
deﬁned (including vulnerable
subgroups)
Questionable study power, not
justiﬁed in detail
Non-representative sample of
the target population
Population characteristics not
sufﬁciently deﬁned
No detailed information on how
the study population was
selected
Population characteristics poorly
deﬁned
Exposure
assessment
Accurate and precise
quantitative exposure
assessment (human
biomonitoring or external
exposure) using validated
methods
Validated questionnaire and/or
interview for chemical-speciﬁc
exposure answered by subjects
Non-valid surrogate or
biomarker in a speciﬁed matrix
and external exposure
Questionnaire and/or interview
for chemical-speciﬁc exposure
answered by subjects or proxy
individuals
Poor surrogate
Low-quality questionnaire
and/or interview; information
collected for groups of
chemicals
No chemical-speciﬁc exposure
information collected;
ever/never use of pesticides in
general evaluated
Outcome
Assessment
Valid and reliable outcome
assessment. Standardised and
validated in study population
Medical record or diagnosis
conﬁrmed
Standardised outcome, not
validated in population, or
screening tool; or, medical
record non-conﬁrmed
Non-standardised and
non-validated health outcome
Inappropriate or self-reported
outcomes.
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If the above assessment is part of the evidence synthesis exercise, where epidemiological research
is being assessed and quantitatively summarised, it permits more accurate estimation of absolute risk
related to pesticide exposure and further quantitative risk assessment.
In the particular case of pesticide epidemiology data, three basic categories are proposed as a ﬁrst tier
to organise human data with respect to risk of bias and reliability16: (a) low risk of bias and high reliability
(all or most of the above quality factors have been addressed with minor methodological limitations); (b)
medium risk of bias and medium reliability (many of the above quality factors have been addressed with
moderate methodological limitations); (c) high risk of bias and low reliability, because of serious
methodological limitations or ﬂaws that reduce the validity of results or make them largely
uninterpretable for a potential causal association. The latter studies are considered unacceptable for risk
assessment mainly because of poor exposure assessment, misclassiﬁcation of exposure and/or health
outcome, or lack of statistical adjustment for relevant confounders. Risk assessment should not be based
on results of epidemiological studies that do not meet well-deﬁned data quality standards. Furthermore,
results of exploratory research will need to be conﬁrmed in future research before they can be used for
risk assessment.
6.3. Assessment of strength of evidence of epidemiological studies
This section brieﬂy discusses some important issues speciﬁcally related to combining and
summarising results from different epidemiological studies on the association between pesticides and
human health.
The approach for weighting epidemiological studies is mainly based on the modiﬁed Bradford Hill
criteria, which are a group of conditions that provide evidence bearing on a potentially causal
relationship between an incidence and a possible consequence (strength, consistency, speciﬁcity,
temporality, biological gradient, plausibility, coherence, experiment and analogy) (Table 3). Clearly, the
Parameter High Moderate Low
Confounder
control
Adequate control for important
confounders relevant to
scientiﬁc question, and
standard confounders
Careful consideration is given
to clearly indicated confounders
Confounders are partially
controlled for
Moderately control of
confounders and standard
variables
Not all variables relevant for
scientiﬁc question are
considered
No control of potential
confounders and effect
modiﬁers in the design and
analysis phases of the study
Statistical
Analysis
Appropriate to study design,
supported by adequate sample
size, maximising use of data,
reported well (not selective)
Statistical methods to control
for confounding are used and
adjusted and unadjusted
estimates are presented.
Subgroups and interaction
analysis are conducted
Acceptable methods, analytic
choices that lose information,
not reported clearly
Post hoc analysis conducted
but clearly indicated
Only descriptive statistics or
questionable bivariate analysis
is made
Comparisons not performed or
described clearly
Deﬁciencies in analysis (e.g.
multiple testing)
Reporting Key elements of the Material
and Methods, and results are
reported with sufﬁcient detail
Numbers of individuals at each
stage of study is reported
A plausible mechanism for the
association under investigation
is provided
Some elements of the Material
and Methods or results are
not reported with sufﬁcient
detail
Interpretation of results
moderately addressed
Deﬁciencies in reporting
(interpretation of effect
estimates, confounder control)
Selective reporting
Paucity of information on
relevant factors that may affect
the exposure–health
relationship. Misplaced focus of
the inferential objectives
Not justiﬁed conclusions
(a): Overall study quality ranking based on comprehensive assessment across the parameters.
(b): Adapted from US-EPA (2016), based in turn on Mu~noz-Quezada et al. (2013) and LaKind et al. (2014).
16 These categories are in accordance with those currently used by EFSA for the peer review of pesticide active substances:
acceptable, supplementary and unacceptable.
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more of these criteria that are met the stronger the basis for invoking the association as evidence for a
meaningful association. However, Bradford Hill was unwilling to deﬁne what causality was and never
saw the criteria as sufﬁcient or even absolutely necessary but simply of importance to consider in a
common-sense evaluation.
For predictive causality, care must be taken to avoid the logical fallacy post hoc ergo propter hoc
that states ‘Since event Y followed event X, event Y must have been caused by event X’. H€oﬂer (2005)
quotes a more accurate ‘counterfactual’ deﬁnition as follows ‘but for E, D will not occur or would not
have occurred, but given E it will/would have occurred’. Yet, more detailed descriptions using symbolic
logic are also available (Maldonado and Greenland, 2002). Rothman and Greenland (2008) stated that
‘the only sine qua non for a counterfactual effect is the condition that the cause must precede the
effect. If the event proposed as a result or “effect” precedes its cause, there may be an association
between the events but certainly no causal relationship’.
6.3.1. Synthesis of epidemiological evidence
Systematic reviews and meta-analysis of observational studies can provide information that
strengthens the understanding of the potential hazards of pesticides, exposure–response
characterisation, exposure scenarios and methods for assessing exposure, and ultimately risk
characterisation (van den Brandt, 2002). Systematic reviews entail a detailed and comprehensive plan
Table 3: Considerations for WoE analysis based on the modiﬁed Bradford Hill criteria for evidence
integration
Category Considerations
Strength of
Association
The assessment of the strength of association (not only the magnitude of association but
also statistical signiﬁcance) requires examination of underlying methods, comparison to the
WoE in the literature and consideration of other contextual factors including the other
criteria discussed herein
Consistency of
Association
Associations should be consistent across multiple independent studies, particularly those
conducted with different designs and in different populations under different
circumstances. This criterion also applies to ﬁndings consistent across all lines of evidence
(epidemiology, animal testing, in vitro systems, etc.) in light of modern data integration
Speciﬁcity The original criteria of evidence linking a speciﬁc outcome to an exposure can provide a
strong argument for causation has evolved and may have new and interesting implications
within the context of data integration. Data integration may elucidate some mechanistic
speciﬁcity among the varied outcomes associated with complex exposures. The lack of
speciﬁcity can help to narrow down speciﬁc agents associated with disease
Temporality Evidence of a temporal sequence between exposure to an agent and appearance of the
effect within an appropriate time frame constitutes one of the best arguments in favour of
causality. Thus, study designs that ensure a temporal progression between the two
measures are more persuasive in causal inference
Biological Gradient
(Dose–response)
Increased effects associated with greater exposures, or duration of exposures, strongly
suggest a causal relationship. However, its absence does not preclude a causal association
Biological Plausibility Data explained and supported by biologically plausible mechanisms based on experimental
evidence strengthen the likelihood that an association is causal. However, lack of
mechanistic data should not be taken as evidence against causality
Coherence The interpretation of evidence should make sense and not to conﬂict with what is known
about the biology of the outcome in question under the exposure-to-disease paradigm. If
it does, the species closest to humans should be considered to have more relevance to
humans
Experimental
Evidence
Results from randomised experiments provide stronger evidence for a causal association
than results based on other study designs. Alternatively, an association from a non-
experimental study may be considered as causal if a randomised prevention derived from
the association conﬁrms the ﬁnding
Sequence of Key
events
Provide a clear description of each of the key events (i.e. measurable parameters from a
combination of in vitro, in vivo or human data sources) that underlie the established
MoA/AOP for a particular health outcome. A fully elucidated MoA/AOP is a not requirement
for using epidemiology studies in human health risk assessment
Adapted from H€oﬂer (2005), Fedak et al. (2015) and US-EPA (2016).
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and search strategy deﬁned a priori aimed at reducing bias by identifying, appraising and synthesising
all relevant studies on a particular topic. The major steps of a systematic review are as follows:
formulation of the research question; deﬁnition of inclusion and exclusion criteria; search strategy for
studies across different databases; selection of studies according to predeﬁned strategy; data
extraction and creation of evidence tables; assessment of methodological quality of the selected
studies; including the risk of bias; synthesis of data (a meta-analysis can be performed if studies
allow); and interpretation of results and drawing of conclusions (EFSA, 2010a). Evidence synthesis is,
however, challenging in the ﬁeld of pesticide epidemiology as standardisation and harmonisation is
difﬁcult. Nonetheless, evidence synthesis should play a pivotal role in assessing the robustness and
relevance of epidemiological studies.
Statistical tools have been developed that can help assess this evidence. When multiple studies on
nearly identical sets of exposures and outcomes are available, these can provide important scientiﬁc
evidence. Where exposure and outcomes are quantiﬁed and harmonised across studies, data from
individual epidemiological studies with similar designs can be combined to gain enough power to
obtain more precise risk estimates and to facilitate assessment of heterogeneity. Appropriate
systematic reviews and quantitative synthesis of the evidence needs to be performed regularly (e.g.
see World Cancer Research Fund approach to continuous update of meta-analysis for cancer risk
factor17). Studies should be evaluated according to previously published criteria for observational
research and carefully examine possible selection bias, measurement error, sampling error,
heterogeneity, study design, and reporting and presentation of results.
Meta-analysis is the term generally used to indicate the collection of statistical methods for
combining and contrasting the results reported by different studies (Greenland and O’Rourke, 2008).
Meta-analysis techniques could be used to examine the presence of diverse biases in the ﬁeld such as
small study effects and excess signiﬁcance bias. Meta-analyses, however, do not overcome the
underlying biases that may be associated with each study design (i.e. confounding, recall bias or other
sources of bias are not eliminated). The extent to which a systematic review or meta-analysis can
draw conclusions about the effects of a pesticide depends strongly on whether the data and results
from the included studies are valid, that is, on the quality of the studies considered. In particular,
consistent ﬁndings among original studies resulting from a consistent bias will produce a biased
conclusion in the systematic review. Likewise, a meta-analysis of invalid studies may produce a
misleading result, yielding a narrow conﬁdence interval around the wrong effect estimate.
In addition to summarising the basic study characteristics of the literature reviewed, a typical meta-
analysis should include the following components: (a) the average effect size and effect size
distribution for each outcome of interest and an examination of the heterogeneity in the effect size
distributions; (b) subgroup analysis in which the variability present in the effect size distribution is
systematically analysed to identify study characteristics that are associated with larger or smaller effect
sizes; (c) publication bias analysis and other sensitivity analyses to assess the validity of conclusions
drawn (Wilson and Tanner-Smith, 2014).
In a meta-analysis, it is important to specify a model that adequately describes the effect size
distribution of the underlying population of studies. Meta-analysis using meaningful effect size
distributions will help to integrate quantitative risk into risk assessment models. The conventional
normal ﬁxed- and random-effects models assume a normal effect size population distribution,
conditionally on parameters and covariates. Such models may be adequate for estimating the overall
effect size, but surely not for prediction if the effect size distribution exhibits a non-normal shape
(Karabatsos et al., 2015).
6.3.2. Meta-analysis as a tool to explore heterogeneity across studies
When evaluating the ﬁndings of different studies, many aspects should be carefully evaluated.
Researchers conducting meta-analyses may tend to limit the scope of their investigation to the
determination of the size of association averaged over the considered studies. The motivation often is
that aggregating the results yields greater statistical power and precision for the effect of interest.
Because individual estimates of effect vary by chance, some variation is expected. However, estimates
must be summarised only when meaningful. An important aspect that is often overlooked is
heterogeneity of the strength of associations across subgroups of individuals. Heterogeneity between
17 World Cancer Research Fund International. Continuous Update Project (CUP) http://www.wcrf.org/int/research-we-fund/
continuous-update-project-cup
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studies needs to be assessed and quantiﬁed when present (Higgins, 2008). In meta-analysis,
heterogeneity among results from different studies may indeed be as informative as homogeneity.
Exploring the reasons underlying any observed inconsistencies of ﬁndings is generally conducive of
great understanding.
Figure 1 shows three forest plots from a ﬁctitious example in which each of three pesticides (A, B
and C) is evaluated in meta-analysis of two studies. It is assumed that both studies for each pesticide
are of the highest quality and scientiﬁc rigor. No biases are suspected.
The following text contains short comments on the interpretation of the results in Figure 1, one
pesticide at a time.
• Exposure to pesticide A seems to double the risk of the disease. The results are consistent
between the two studies and the conﬁdence intervals do not contain the null value, one. These
results, however, do not imply that (a) the risk ratio would be about 2 in any other study that
was conducted on the same exposure and disease; or that (b) the risk ratio is two in any
group of individuals (e.g. males or females, young or old).
• Exposure to pesticide B seems to halve the risk of the disease. The results are consistent
between the two studies and the conﬁdence intervals do not contain the null value, one. These
results, however, do not imply that (a) the risk ratio would be about a half in any other study
that was conducted on the same exposure and disease; or that (b) the risk ratio is about a
half in any group of individuals (e.g. males or females, young or old).
• Exposure to pesticide C seems to double the risk of the disease in one study and to halve the
risk in the other. The results are inconsistent between the two studies and the conﬁdence
intervals do not contain the null value, one. These results, however, do not imply that (a) the
risk ratio would be about one in any other study that was conducted on the same exposure
and disease; or that (b) the risk ratio is about one in any group of individuals (e.g. males or
females, young or old).
What evidence can the results shown in Figure 1 provide?
The risk ratio reported by any study can be generalised to other populations only if all the relevant
factors have been controlled for (Bottai, 2014; Santacatterina and Bottai, 2015). In this context, relevant
factors are variables that are stochastically dependent with the health outcome of interest. For example,
cardiovascular diseases are more prevalent among older subjects than among younger individuals. Age is
therefore a relevant factor for cardiovascular diseases. The evidence provided by the results shown in
Figure 1 are potentially valid only if this step was taken in each of the studies considered. If that was the
case for the studies, then, there is evidence that exposure to pesticide A doubles the risk in the speciﬁc
group of individuals considered by each of the two studies. If the risk ratios are summary measures over
the respective study populations, then none of the ﬁndings should be generalised. However, if the risk
ratios for pesticide A were not adjusted for any factor, and the underlying populations were very different
0 1 2 3
Pesticide A
0 1 2 3
Pesticide B
0 1 2 3
Pesticide C
Figure 1: Forest plots from a ﬁctitious example in which each of three pesticides (A, B and C) is
evaluated in a meta-analysis of two studies. The x-axis in each plot represents the
estimated risk ratio of the disease of interest comparing exposed and unexposed
individuals. The squares denote the estimated risk ratio in each study and the grey
diamonds the summarised risk ratio. The horizontal lines indicate 95% conﬁdence intervals
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across the two studies, then there would still be evidence that there may be no relevant factors and
pesticide A doubles the risk in any subgroup of individuals. Pesticide B appears to halve the risk, and the
estimated conﬁdence intervals are narrower for pesticide B than for pesticide A. Generalisability of the
ﬁndings, however, holds for pesticide B under the conditions stated above for pesticide A. As for pesticide
C, the forest plot provides evidence that exposure to this pesticide raises the risk of the disease in the
group of individuals in one of the studies and decreases it in the group considered in the other study.
Again, if the risk ratios are summary measures over the respective study populations, then none of the
ﬁndings should be generalised. Investigating the reasons behind the inconsistency between the two
studies on pesticide C can provide as much scientiﬁc insight as investigating the reasons behind the
similarity between the studies on pesticide A or pesticide B.
In general, the overall summary measures provided by forest plots, such as the silver diamonds in
each of the three panels of Figure 1, are of little scientiﬁc interest. When evaluating the ﬁndings of
different studies, many aspects should be carefully evaluated. An important aspect that is often
overlooked is heterogeneity of the strength of associations across subgroups of individuals. When
information about subgroup analysis is provided in the publications that describe a study, this should
be carefully evaluated. Sensitivity analyses should complement the results provided by different
studies. These should aim to evaluate heterogeneity and the possible impact of uncontrolled for
relevant factors along with information and sampling error. A synoptic diagram is displayed in Figure 2.
6.3.3. Usefulness of meta-analysis for hazard identiﬁcation
Human data can be used for many stages of risk assessment. Single epidemiological studies, if
further studies on the same pesticide are not available, should not be used as a sole source for hazard
identiﬁcation, unless they are high quality studies (according to criteria shown in Table 2). Evidence
synthesis techniques which bring together many studies, such as systematic reviews and meta-analysis
(where appropriate) should be utilised instead. Although many meta-analyses have been carried out
for the quantitative synthesis of data related to chronic diseases, their application for risk assessment
modelling is still limited.
Importantly, evidence synthesis will provide a methodological assessment and a risk of bias
assessment of the current evidence highlighting areas of uncertainties and identifying associations with
robust and credible evidence.
Figure 3 shows a simple methodology proposed for the application of epidemiological studies into
risk assessment. The ﬁrst consideration is the need of combining different epidemiological studies
• Information error, such as measurement error, effect size magnification
Bias
• Which were considered and which were not considered
• How were they distributed in each study
• What population is the resulting inference on
Relevant Factors
• Standard errors, not p-values, of the estimates of the parameters of interest 
Sampling Error
• Range of the parameters of interest that are consistent with observed data
Sensitivity Analyses
Figure 2: Items to consider when evaluating and comparing multiple studies
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addressing the same outcome. This can be made following criteria proposed by EFSA guidance for
systematic reviews (EFSA, 2010a). Then, the risk of bias is assessed based on the factors described in
Section 6.2 for a WoE assessment, namely: study design and conduct, population, exposure
assessment, outcome assessment, confounder control, statistical analysis and reporting of results.
Those studies categorised as of low reliability will be considered unacceptable for risk assessment. The
remaining studies will be weighted and used for hazard identiﬁcation.
If quantitative data are available, a meta-analysis can be conducted to create summary data and to
improve the statistical power and precision of risk estimates (OR, RR) by combining the results of all
individual studies available or meeting the selection criteria. As meta-analyses determine the size of
association averaged over the considered studies, they provide a stronger basis for hazard
identiﬁcation. Moreover, under certain circumstances, there is the possibility to move towards risk
characterisation metrics because these measured differences in health outcomes (OR, RR) can be
converted to dose–response relationships (Nachman et al., 2011). Although quite unusual in practice,
this would allow for the identiﬁcation of critical effects in humans and/or setting reference values
without the need of using animal extrapolation.
Since heterogeneity is common in meta-analyses, there is a need to assess which studies could be
combined quantitatively. Heterogeneity can be genuine, representing diverse effects in different
subgroups, or might represent the presence of bias. If heterogeneity is high (I2 greater than 50%),
individual studies should not be combined to obtain a summary measure because of the high risk of
aggregating bias from different sources. Sources of heterogeneity should be explored through
sensitivity analysis and/or meta-regression. Furthermore, the presence of diverse biases in the meta-
analysis should be examined, such as small study effects, publication bias and excess signiﬁcance bias.
It is important to ﬁnd models that adequately describe the effect size distribution of the underlying
studied populations.
6.3.4. Pooling data from similar epidemiological studies for potential dose–response
modelling
As in other ﬁelds of research, ﬁndings from a single epidemiological study merit veriﬁcation through
replication. When the number of replications is abundant, it may be worthwhile to assess the entire set
of replicate epidemiological studies through a meta-analysis and ascertain whether, for key outcomes,
ﬁndings are consistent across studies. Such an approach will provide more robust conclusions about
the existence of cause-effect relationships.
Figure 3: Methodology for utilisation of epidemiological studies for risk assessment
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Once a hazard has been identiﬁed, the next step in risk assessment is to conduct a dose–response
assessment to estimate the risk of the adverse effect at different levels of exposure and/or the
concentration level below which no appreciable adverse health effect can be assumed for a given
population. However, this step requires fully quantitative (or at least semi-quantitative) exposure data
at an individual level. Summary estimates resulting from quantitative synthesis would be more
informative for risk assessment if they present an OR for a given change in the continuous variable of
exposure (or per a given percentile change in exposure) as this allows for relative comparisons across
studies and could be of help to derive health-based reference values. Only within such a framework
can data from human studies with similar designs be merged to gain enough power to model proper
dose–response curves (Greenland and Longnecker, 1992; Orsini et al., 2012).
Conversely, meta-analytical approaches may be of limited value if a combined OR is calculated
based on meta-analyses interpreting exposure as a ‘yes’ or a ‘no’ (ever vs never) because exposures
are not necessarily to active ingredients in the same proportion in all studies included. Even though in
these cases, meta-analyses may consistently ﬁnd an increased risk associated with pesticide exposure,
for risk assessment the exposure needs to characterise the effect of speciﬁc pesticide classes or even
better individual pesticides as their potency may differ within the same class (Hernandez et al., 2016).
This approach would allow points of departure to be identiﬁed (e.g. benchmark doses (BMD)) and
would be relevant for the integration of epidemiological studies into quantitative risk assessment.
Although BMD modelling is currently used for analysing dose–response data from experimental studies,
it is possible to apply the same approach to data from observational epidemiological studies (Budtz-
Jørgenson et al., 2004). The EFSA Scientiﬁc Committee conﬁrmed that the BMD approach is a
scientiﬁcally more advanced method compared to the no observed-adverse-effect level (NOAEL)
approach for deriving a Reference Point, since it makes extended use of the dose–response data from
experimental and epidemiological studies to better characterise and quantify potential risks. This
approach, in principle, can be applicable to human data (EFSA Scientiﬁc Committee, 2017b), although
the corresponding guidelines are yet to be developed.
Dose–response data from observational epidemiological studies may differ from typical animal toxicity
data in several respects and these differences are relevant to BMD calculations. Exposure data often do
not fall into a small number of well-deﬁned dosage groups. Unlike most experimental studies,
observational studies may not include a fully unexposed control group, because all individuals may be
exposed to some extent to a chemical contaminant. In this case, the BMD approach still applies since
ﬁtting a dose–response curve does not necessarily require observations at zero exposure. However, the
response at zero exposure would then need to be estimated by low-dose extrapolation. Hence, the BMD
derived from epidemiological data can be strongly model-dependent (Budtz-Jørgensen et al., 2001).
Epidemiology data need to be of sufﬁcient quality to allow the application of the BMD approach,
especially in terms of assigning an effect to a speciﬁc pesticide and its exposure. Clear rules and
guidance, and deﬁnition of model parameters need to be considered for such a BMD approach, which
might differ from BMD approaches from controlled experimental environments. Although the BMD
modelling approach has been applied to epidemiological data on heavy metals and alcohol
(Lachenmeier et al., 2011), currently, few individual studies on pesticides are suitable for use in dose–
response modelling, much less in combination with other studies. However, future studies should be
conducted and similarly reported so that they could be pooled together for a more robust assessment.
7. Integrating the diverse streams of evidence: human (epidemiology
and vigilance data) and experimental information
This section ﬁrst considers in Section 7.1 the different nature of the main streams of evidence, i.e.
originating either from experimental studies or from epidemiological studies. The approach used is that
recommended by the EFSA Scientiﬁc Committee Guidance on WoE (EFSA Scientiﬁc Committee, 2017b),
which distinguishes three successive phases to assess and integrate these different streams of
information: reliability, relevance and consistency. The ﬁrst step, consists in the assessment of the
reliability of individual studies be they epidemiological (addressed in Section 6) or experimental
(beyond the scope of this Scientiﬁc Opinion). Then, the relevance (strength of evidence) of one or
more studies found to be reliable is assessed using principles of epidemiology (addressed in Section 6)
and toxicology. Next, Section 7.2 considers how to bring together different streams of relevant
information from epidemiological and experimental studies, which is considered in a WoE approach, to
assess consistency and biological plausibility for humans.
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7.1. Sources and nature of the different streams of evidence
Comparison of experimental and epidemiological approaches
In the regulatory risk assessment of pesticides, the information on the toxic effects is based on the
results of a full set of experiments as required by Regulation (EC) 283/2013 and 284/2013, and
conducted according to OECD guidelines. They are carried out in vivo or in vitro, so there will always
be some high-quality experimental data available for pesticides as required to be provided by
applicants under Regulation (EC) 1107/2009. A number of categories are established for rating the
reliability of each stream of evidence according to the EFSA peer review of active substances:
acceptable, supplementary and unacceptable. The data quality and reliability of in vivo or in vitro
toxicity studies should be assessed using evaluation methods that better provide more structured
support for determining a study’s adequacy for hazard and risk assessments. Criteria have been
proposed for conducting and reporting experimental studies to enable their use in health risk
assessment for pesticides (Kaltenh€auser et al., 2017).
Animal (in vivo) studies on pesticide active substances conducted according to standardised test
guidelines and good laboratory practices (GLP, e.g. OECD test guidelines) are usually attributed higher
reliability than other research studies. Notwithstanding, since there is no evidence that studies
conducted under such framework have a lower risk of bias (Vandenberg et al., 2016), evidence from
all relevant studies, both GLP and non-GLP, should also be considered and weighted. Thus, data from
peer-reviewed scientiﬁc literature should be taken into account for regulatory risk assessment of
pesticide active substances, provide they are of sufﬁcient quality after being assessed for
methodological reliability. Their contribution to the overall WoE is inﬂuenced by factors including test
organism, study design and statistical methods, as well as test item identiﬁcation, documentation and
reporting of results (Kaltenh€auser et al., 2017).
The internal validity of in vitro toxicity studies should be evaluated as well to provide a better
support for determining a study’s adequacy for hazard and risk assessments. In silico modelling can be
used to derive structure–activity relationships (SAR) and to complement current toxicity tests for the
identiﬁcation and characterisation of the mode or mechanisms of action of the active substance in
humans. These alternative toxicity testing (and non-testing) approaches could be helpful in the
absence of animal data, e.g. to screen for potential neurodevelopmental or endocrine disruption
effects of pesticides, and to increase conﬁdence in animal testing. Considering the demand for
minimising the number of animal studies for regulatory purposes, non-animal testing information can
provide relevant stand-alone evidence that can be used in the WoE assessment.
A number of toxicological issues are amenable for systematic review, from the impact of chemicals
on human health to risks associated with a speciﬁc exposure, the toxicity of chemical mixtures, the
relevance of biomarkers of toxic response or the assessment of new toxicological test methods
(Hoffmann et al., 2017). For instance, in a previous Scientiﬁc Opinion EFSA used a systematic review
for the determination of toxicological mechanisms in the frame of AOP approach (Choi et al., 2016;
EFSA Scientiﬁc Committee, 2017c).
Besides toxicity data on the active substance, such data may also be required on metabolites or
residues if human exposure occur through the diet or drinking water. Results from these studies are
then considered in relation to expected human exposures estimated through food consumption and
other sources of exposure. The strength of this approach is that in vivo studies account for potential
toxic metabolites, though not always animal metabolic pathways parallels the ones of humans.
Experimental studies in laboratory animals are controlled studies where confounding is eliminated
by design, which is not always the case with epidemiological studies. Animals used in regulatory
studies are, however, typically inbred, genetically homogeneous and due to the controlled environment
they lack the full range of quantitative and qualitative chemical susceptibility proﬁles. Nevertheless,
animal surrogates of human diseases are being challenged by their scientiﬁc validity and translatability
to humans, and the lack of correlation often found between animal data and human outcomes can be
attributed to the substantial interspecies differences in disease pathways and disease-induced changes
in gene expression proﬁles (Esch et al., 2015). Thereby, many experimental models do not capture
complex multifactorial diseases making animal-to-human extrapolation subject to considerable
uncertainty. Current risk assessment is therefore by its nature predictive and may be insufﬁcient
because it is chemical-speciﬁc and humans are exposed to a large number of chemicals from
environmental, dietary and occupational sources or because of different toxicokinetic differences. In
recognition of the uncertain nature of animal-to-human extrapolation, the regulatory risk assessment
advice does not just consider the relevant point(s) of departure (NOAEL, LOAEL or BMDL) that have
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been identiﬁed as safe but lowers these values using uncertainty factors (UFs) to propose safe
reference dose values, either for acute or chronic toxicity.
Given the limitations of studies in laboratory animals, epidemiological studies in the ‘real world’ are
needed, even if they have limitations of their own. Epidemiological studies incorporate the true (or
estimated) range of population exposures, which usually are intermittent and at inconsistent doses
instead of occurring at a consistent rate and dose magnitude (Nachman et al., 2011). Since
epidemiological studies are based on real-world exposures, they provide insight into actual human
exposures that can then be linked to diseases, avoiding the uncertainty associated with extrapolation
across species. Hence, it can be said that they address the requirements of Regulation 1107/2009
Article 4, which stipulates that the risk assessment should be based on good plant protection practice
and realistic use conditions. Thus, epidemiological studies assist problem formulation and hazard/risk
characterisation whilst avoiding the need for high dose extrapolation (US-EPA, 2010).
Epidemiological studies therefore provide the opportunity to (a) identify links with speciﬁc human
health outcomes that are difﬁcult to detect in animal models; (b) afﬁrmation of the human relevance
of effects identiﬁed in animal models; (c) ability to evaluate health effects for which animal models are
unavailable or limited (Raffaele et al., 2011). Epidemiological evidence will be considered over
experimental animal evidence only when sufﬁciently robust pesticide epidemiological studies are
available. However, in epidemiological studies, there are always a variety of factors that may affect the
health outcome and confound the results. For example, when epidemiological data suggest that
exposures to pesticide formulations are harmful they usually cannot identify what component may be
responsible due to the complexity of accurately assessing human exposures to pesticides. While some
co-formulants are not intrinsically toxic, they can be toxicologically relevant if they change the
toxicokinetics of the active substance. In addition, confounding by unmeasured factor(s) associated
with the exposure can never be fully excluded; however, a hypothetical confounder (yet unrecognised)
may not be an actual confounder and has to be strongly associated with disease and exposure in order
to have a meaningful effect on the risk (or effect size) estimate, which is not always the case.
Many diseases are known to be associated with multiple risk factors; however, a hazard-by-hazard
approach is usually considered for evaluating the consequences of individual pesticide hazards on
vulnerable systems (Figure 4A). Speciﬁcally, single-risk analysis allows a determination of the individual
risk arising from one particular hazard and process occurring under speciﬁc conditions, while it does
not provide an integrated assessment of multiple risks triggered by different environmental stressors
(either natural or anthropogenic) (Figure 4B). Risk assessment would beneﬁt by developing procedures
for evaluating evidence for co-occurrence of multiple adverse outcomes (Nachman et al., 2011), which
is more in line with what happens in human setting. For these reasons, if appropriately conducted,
epidemiological studies can be highly relevant for the risk assessment process.
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In parallel with epidemiological data, vigilance data can provide an additional stream of evidence,
especially for acute toxicity. Cases are usually well-documented and information can be used at
different steps of the risk assessment; these include: level and duration of exposure, clinical course
and assessment of the causal relationship. In severe cases, the toxin and/or the metabolites are
usually measured in blood or urine which allows for comparison with animal data and in some cases
for setting toxicological values.
In summary, experimental studies or epidemiological studies and vigilance data represent two
different approaches to collect and assess evidence i.e. one emanating from controlled exposures
(usually to a single substance) using experimental study design and a relatively homogeneous
surrogate population, the other reﬂecting the changes observed in a heterogeneous target population
from mixed (and varying) exposure conditions using non-experimental study design (ECETOC, 2009).
Epidemiology and toxicology each bring important and different contributions to the identiﬁcation of
human hazards. This makes both streams of evidence complementary, and their combination
represents a powerful approach. Animal studies should always inform the interpretation of
epidemiological studies and vice versa; hence, they should not be studied and interpreted
independently.
7.2. Principles for weighting of human observational and laboratory
animal experimental data
Following the identiﬁcation of reliable human (epidemiological or vigilance) studies and the
assessment of the relevance of the pooled human studies, the separate lines of evidence that were
found to be relevant need to be integrated with other lines of evidence that were equally found to be
relevant.
The ﬁrst consideration is thus how well the health outcome under consideration is covered by
toxicological and epidemiological studies. When both animal and human studies are considered to be
available for a given outcome/endpoint, this means that individual studies will ﬁrst have been assessed
for reliability and strength of evidence (Sections 6.2 and 6.3, respectively, for epidemiological studies)
Figure 4: Role of epidemiological studies when compared to classical toxicological studies
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prior to the weighting of the various sources of evidence. Although the different sets of data can be
complementary and conﬁrmatory, individually they may be insufﬁcient and pose challenges for
characterising properly human health risks. Where good observational data are lacking, experimental
data have to be used. Conversely, when no experimental data is available, or the existing experimental
data were found not to be relevant to humans, the risk assessment may have to rely on the available
and adequate observational studies.
A framework is proposed for a systematic integration of data from multiple lines of evidence (in
particular, human and experimental studies) for risk assessment (Figure 5). Such integration is based
on a WoE analysis accounting for relevance, consistency and biological plausibility using modiﬁed
Bradford Hill criteria (Table 3). For a comparative interpretation of human and animal data, this
framework should rely on the following principles (adapted from ECETOC, 2009; Lavelle et al., 2012):
• Although the totality of evidence should be assessed, only the studies that are found to be
reliable (those categorised as acceptable or supplementary evidence) are considered further. If
the data from the human or the experimental studies is considered to be of low reliability
(categorised as unacceptable), no risk assessment can be conducted.
• A WoE approach should be followed where several lines of evidence are found to be relevant.
For pesticide active substances, experimental studies following OECD test guidelines are
deemed high reliability unless there is evidence to the contrary. The strength of evidence from
animal studies can be upgraded if there is high conﬁdence in alternative pesticide toxicity
testing or non-testing methods (e.g. in vitro and in silico studies, respectively). As for
epidemiological evidence, the conduct of meta-analysis provides a more precise estimate of the
magnitude of the effect than individual studies and also allows for examining variability across
studies (see Section 6.3).
• Next, the studies that are found to be more relevant for the stage being assessed are to be
given more weight, regardless of whether the data comes from human or animal studies.
Where human data are of highest relevance, and supported by a mechanistic scientiﬁc
foundation, they should take precedence for each stage of the risk assessment. When human
and experimental data are of equal or similar relevance, it is important to assess their
concordance (consistency across the lines of evidence) in order to determine whether and
which data set may be given precedence.
– In case of concordance between human and experimental data, the risk assessment should
use all the data as both yield similar results in either hazard identiﬁcation (e.g. both
indicate the same hazard) or hazard characterisation (e.g. both suggest similar safe dose
levels). Thus, both can reinforce each other and similar mechanisms may be assumed in
both cases.
– In case of non-concordance, the framework needs to account for this uncertainty. For
hazard identiﬁcation, the data suggesting the presence of a hazard should generally take
precedence. For dose–response, the data resulting in the lower acceptable level should
take precedence. In every situation of discordance, the reasons for this difference should
be considered. If the reason is related to the underlying biological mechanisms, or
toxicokinetic differences between humans and animal models, then conﬁdence in the risk
assessment will increase. Conversely, if the reason cannot be understood or explained,
then the risk assessment may be less certain. In such cases, efforts should be made to
develop a better understanding of the biological basis for the contradiction.
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Epidemiological studies provide complementary data to analyse risk and should be contextualised in
conjunction with well-designed toxicological in vivo studies and mechanistic studies. The overall
strength of the evidence achieved from integrating multiple lines of evidence will be at least as high as
the highest evidence obtained for any single line. This integrated approach provides explicit guidance
on how to weight and integrate toxicological and epidemiological evidence. This is a complex task that
becomes even more difﬁcult when epidemiological data deal with multifactorial, multihit, chronic
diseases for which toxicological models, or disease-speciﬁc animal models, are limited.
7.3. Weighting all the different sources of evidence
The WHO/IPCS deﬁnes the WoE approach as a process in which all of the evidence considered
relevant for risk assessment is evaluated and weighted (WHO/IPCS, 2009). The WoE approach, taking
the risk assessment of chemical substances as an example, requires the evaluation of distinct lines of
evidence (in vivo, in vitro, in silico, population studies, modelled and measured exposure data, etc.).
The challenge is to weight these types of evidence in a systematic, consistent and transparent way
(SCENIHR, 2012). The weighting may be formally quantitative or rely on categorisation according to
criterion referencing of risk.
An EFSA Working Group was established to provide transparent criteria for the use of the WoE
approach for the evaluation of scientiﬁc data by EFSA’s Panels and Scientiﬁc Committee (EFSA, 2015b).
The aim of this Working Group was to provide support to stakeholders on how individual studies
should be selected and weighted, how the ﬁndings integrated to reach the ﬁnal conclusions and to
identify uncertainties regarding the conclusions.
The WoE approach is not consistently considered in the risk assessment of pesticides in the peer
review process of DAR or RAR. Expert judgement alone, without a structured WoE approach, has been
more commonly used. A few examples can be found, such as the peer review of glyphosate (EFSA,
2015c), where the rapporteur Member State (RMS) considered all the data either from industry or
Figure 5: Methodology for the integration of human and animal data for risk assessment
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from public literature, including epidemiological data, and took a speciﬁc WoE approach with
established ad hoc criteria and considering all data available for proposing an ‘overall’ NOAEL for each
endpoint of toxicity explored.
The US-EPA has recently applied speciﬁc criteria for the WoE approach to the peer review of the
pesticide chlorpyrifos by following the ‘Framework for incorporating human epidemiologic & incident
data in health risk assessment’. In this speciﬁc case, a WoE analysis has been conducted to integrate
quantitative and qualitative ﬁndings across many lines of evidence including experimental toxicology
studies, epidemiological studies and physiologically based pharmacokinetic and pharmacodynamic
(PBPK-PD) modelling. Chlorpyrifos was also used as an example for the EFSA Guidance on literature
search under Regulation (EC) No 1107/2009. In addition, an EFSA conclusion (EFSA, 2014a) took into
consideration the US-EPA review (2011) to revise its ﬁrst conclusion produced in 2011.
In sum, a broader WoE approach can be applied to evaluate the available scientiﬁc data using
modiﬁed Bradford Hill criteria as an organisational tool to increase the likelihood of an underlying
causal relationship (Table 3). Although epidemiology increasingly contributes to establishing causation,
an important step to this end is the establishment of biological plausibility (US-EPA, 2010; Adami et al.,
2011; Buonsante et al., 2014).
7.4. Biological mechanisms underlying the outcomes
A biological mechanism describes the major steps leading to a health effect following interaction of
a pesticide with its biological targets. The mechanism of toxicity is described as the major steps
leading to an adverse health effect. An understanding of all steps leading to an effect is not necessary,
but identiﬁcation of the key events following chemical interaction is required to describe a mechanism
(of toxicity in the case of an adverse health effect). While many epidemiological studies have shown
associations between pesticide exposures and chronic diseases, complementary experimental research
is needed to provide mechanistic support and biological plausibility to the human epidemiological
observations. Experimental exposures should be relevant to the human population provided that the
biologic mechanisms in laboratory animals occur in humans.
Establishing biological plausibility as part of the interpretation of epidemiological studies is relevant
and should take advantage of modern technologies and approaches (Section 7.6). In this context, the
AOP framework can be used as a tool for systematically organising and integrating complex information
from different sources to investigate the biological mechanisms underlying toxic outcomes and to inform
the causal nature of links observed in both experimental and observational studies (Section 7.5).
The use of data to inform speciﬁc underlying biological mechanisms or pathways of the potential toxic
action of pesticides is limited since only selected pesticide chemicals have been investigated for biological
function in relation to a speciﬁc health outcome. It may be possible to formulate a mode of action (MoA)
hypothesis, particularly where there is concordance between results of comparable animal studies or
when different chemicals show the same pattern of toxicity. It is essential to identify the toxicant and the
target organ as well as the dose–response curve of the considered effect and its temporal relationship. If
the different key events leading to toxicity and a MoA hypothesis can be identiﬁed, it is sometimes
possible to evaluate the plausibility of these events to humans (ECETOC, 2009).
Sulfoxaﬂor is an example where MoA has been extensively studied and has been also widely used
as an example during the ECHA/EFSA MOA/HRF workshop held in November 2014. Sulfoxaﬂor induced
hepatic carcinogenicity in both rats and mice. Studies to determine the MoA for these liver tumours
were performed in an integrated and prospective manner as part of the standard battery of toxicology
studies such that the MoA data were available prior to, or by the time of, the completion of the
carcinogenicity studies. The MoA data evaluated in a WoE approach indicated that the identiﬁed rodent
liver tumour MoA for sulfoxaﬂor would not occur in humans. For this reason, sulfoxaﬂor is considered
not to be a potential human liver carcinogen.
Furthermore, sometimes MoA data may indicate a lack of possible effects. If there are biological data
that indicate an adverse effect is not likely to occur in humans, this should inform the interpretation of
epidemiological studies. Nevertheless, while primary target site selectivity between pests and humans
plays an important role in pesticides safety, secondary targets in mammals must also be considered.
In the case of exposure to multiple pesticides, the decision to combine risks can be taken if the
pesticides share a common mechanism of toxicity (act on the same molecular target at the same target
tissue, act by the same biochemical mechanism of action, and share a common toxic intermediate)
which may cause the same critical effect or just based on the observation that they share the same
target organ (EFSA 2013a,b). However, cumulative risk assessment is beyond the scope of this Opinion.
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7.5. Adverse Outcome Pathways (AOPs)
The AOP methodology provides a framework to collect and evaluate relevant chemical, biological
and toxicological information in such a way that is useful for risk assessment (OECD, 2013). An AOP
may be deﬁned as the sequence of key events following the interaction of a chemical with a biological
target (molecular initiating event (MIE)) to the in vivo adverse outcome relevant to human health. All
these key events are necessary elements of the MoA and should be empirically observable or
constitute biologically based markers for such an event. An AOP is therefore a linear pathway from one
MIE to one adverse outcome at a level of biological organisation relevant to risk assessment. The goal
of an AOP is to provide a ﬂexible framework to describe the cascade of key events that lead from a
MIE to an adverse outcome in a causal linkage (EFSA PPR Panel, 2017). The ‘key events’ must be
experimentally measurable and the ﬁnal adverse effect is usually associated with an in vivo OECD Test
Guideline. However, in some cases the adverse outcome may be at a level of biological organisation
below that of the apical endpoint described in a test guideline (OECD, 2013).
A particular MIE may lead to several ﬁnal adverse effects and, conversely, several MIEs may
converge in the same ﬁnal adverse effect. However, each AOP will have only one MIE and one ﬁnal
adverse effect, but may involve an unlimited number of intermediate steps (Vinken, 2013). It should
be noted that key events at different levels of biological organisation provide a greater WoE than
multiple events at the same level of organisation (OECD, 2013).
The essential biochemical steps involved in a toxic response are identiﬁed and retrieved from an in-
depth survey of relevant scientiﬁc literature or from experimental studies. Any type of information can
be incorporated into an AOP, including structural data, ‘omics-based’ data and in vitro, in vivo or in
silico data. However, in vivo data are preferred over in vitro data and endpoints of interest are
preferred to surrogate endpoints (Vinken, 2013). The AOPs identiﬁed must not be incompatible with
normal biological processes, since they need to be biologically plausible.
Qualitative AOPs (intended as an AOP including the assembly and evaluation of the supporting WoE
following the OECD guidance for AOP development) should be the starting and standard approach in
the process of integration of epidemiology studies into risk assessment by supporting (or identifying
the lack of support for) the biological plausibility of the link between exposure to pesticides affecting
the pathway and the adverse outcome. Accordingly, qualitative AOPs may be developed solely for the
purpose of hazard identiﬁcation, to support biological plausibility of epidemiological studies based on
mechanistic knowledge (EFSA PPR Panel, 2017).
The AOP framework is a ﬂexible and transparent tool for the review, organisation and interpretation
of complex information gathered from different sources. This approach has the additional advantage of
qualitatively characterising the uncertainty associated with any inference of causality and identifying
whether additional mechanistic studies or epidemiological research would be more effective in reducing
uncertainty. The AOP framework is therefore a useful tool for risk assessment to explore whether an
adverse outcome is biologically plausible or not. For the purpose of analysing the biological plausibility,
AOPs can serve as an important tool, particularly when the regulatory animal toxicological studies are
negative but the evaluation of the apical endpoint (or relevant biomarkers) observed in epidemiological
studies is considered inadequate based on the AOP. By means of mechanistically describing apical
endpoints, the AOP contributes to the hazard identiﬁcation and characterisation steps in risk
assessment. As the AOP framework is chemically agnostic, if complemented by the MoA and/or
Integrated Approach on Testing and Assessment (IATA) framework, it will support the chemical speciﬁc
risk assessment (EFSA PPR Panel, 2017).
AOP and MoA data can be used to assess the ﬁndings of epidemiological studies to weight their
conclusions. Whether those ﬁndings are inconsistent with deep understanding of biological
mechanisms, or simply empirical, they should be given less weight than other ﬁndings that are
consistent with AOP or MoA frameworks once established. However, there are relatively few examples
of well-documented AOPs and a full AOP/MoA framework is not a requirement for using
epidemiological studies in risk assessment.
AOPs are thus a critical element to facilitate moving towards a mechanistic-based risk assessment
instead of the current testing paradigm relying heavily on apical effects observed in animal studies.
Shifting the risk assessment paradigm towards mechanistic understanding would reduce limitations of
the animal data in predicting human health effects for a single pesticide, and also support the
current efforts being made on cumulative risk assessment of pesticide exposure (EFSA PPR Panel,
2017).
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7.6. Novel tools for identifying biological pathways and mechanisms
underlying toxicity
The elucidation of toxicity pathways brings the opportunity of identifying novel biomarkers of early
biological perturbations in the toxicodynamic progression towards overt disease, particularly from
advances in biomonitoring, in -omics technologies and systems biology (toxicology). The revolution of
omics in epidemiology holds the promise of novel biomarkers of early effect and offers an opportunity
to investigate mechanisms, biochemical pathways and causality of associations.
The growing recognition of the value of biomonitoring data in epidemiological investigations may
help to reduce misclassiﬁcation by providing objective measures of exposure and outcome. As long as
biomarker data for exposure, outcome and susceptibility are increasingly generated, epidemiology will
have a greater impact in the understanding of toxicodynamic progression as a function of pesticide
exposure and eventually in risk assessment. A challenge for risk assessors will be to acknowledge
where subtle and early changes along the toxicodynamic pathway are indicative of increased potential
for downstream effects (Nachman et al., 2011). Omics data can be used for gaining insight to the MoA
by identifying pathways affected by pesticides and as such can assist hazard identiﬁcation, the ﬁrst
step in risk assessment.
Transcriptomic, metabolomic, epigenomic and proteomic proﬁles of biological samples provide a
detailed picture, sometimes at individual molecule resolution, of the evolving state of cells under the
inﬂuence of environmental chemicals, thus revealing early mechanistic links with potential health
effects. Nowadays, the challenges and beneﬁts that advances in -omics techniques can bring to
regulatory toxicology are still being explored (Marx-Stoelting et al., 2015). Clear rules for assessing the
speciﬁcity of these biomarkers are necessary.
Those -omic applications most relevant and advanced in the context of toxicology are analysis of
MoA and the derivations of AOP, and biomarker identiﬁcation, all of which potentially assist
epidemiology too. For example, (a) transcriptomics: comparing gene expression (mRNA) proﬁles can
be used for biomarker discovery, grouping expressed genes into functional groups (Gene Ontology
categories) or for Gene Set Analysis. Such techniques may provide varying information regarding
biological mechanisms. (b) Proteomics: studying the protein proﬁle of samples, with sophisticated
analysis of protein quantity and post-translational modiﬁcations which may be associated with changes
in biological pathways following exposure and possible disease development, utilising informatics and
protein databases for identiﬁcation and quantiﬁcation. (c) Metabolomics uses nuclear magnetic
resonance spectroscopy or mass-spectrometry based techniques to produce data which are analysed
via software, and databases, to identify markers (molecular signatures and pathways) that correlate
with exposure or disease. (d) The use of the exposome (the totality of exposures received by an
individual during life) might be better deﬁned by using -omics technologies and biomarkers appropriate
for human biomonitoring. Nevertheless, important limitations stemming from the lack of validation of
these methodologies and their cost limit their use at large scale.
The application of -omics technologies to environmental health research requires special
consideration to study design, validation, replications, temporal variance and meta-data analysis
(Vlaanderen et al., 2010). For larger studies, intra-individual variability in the molecular proﬁles
measured in biological samples should show less variability than the interindividual variation in proﬁles
of gene expression, protein levels or metabolites, which are highly variable over time. It is important
that these inter-individual variations should not be larger than variation related to exposure changes,
but it is not certain if this will be true.
The biologically meaningful omics signatures identiﬁed by performing omics-exposure and omics-
health association studies provide useful data for advanced risk assessment. This approach supports
moving away from apical toxicity endpoints towards earlier key events in the toxicity pathway resulting
from chemical-induced perturbation of molecular/cellular responses (NRC, 2007).
7.7. New data opportunities in epidemiology
The current technological landscape permits the digitisation and storage of unprecedented amount
of data from many sources, including smart phones, text messages, credit card purchases, online
activity, electronic medical records, global positioning system (GPS) and supermarket purchasing data.
While some of these data sources may provide valuable information for risk assessment, many of them
contain personal information that can outpace legal frameworks and arise questions about the ethics
of its use for scientiﬁc or regulatory purposes. A speciﬁc example is constituted by data containing
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personal information related to health, which are considered sensitive or especially protected, such as
electronic medical records, information from occupational or environmental questionnaires, geographic
location, health or social security number, etc. These various forms of health information are being
easily created, stored and accessed. Big data provide researchers with the ability to match or link
records across a number of data sources. Linking of big data sources of health and heritable
information offers great promise for understanding disease predictors (Salerno et al., 2017); however,
there are challenges in using current methods to process, analyse and interpret the data systematically
and efﬁciently or to ﬁnd relevant signals in potential oceans of noise, as noted by the Board on
Environmental Studies and Toxicology of the National Academies of Sciences, Engineering, and
Medicine in its 2017 report.18
In addition, medico-administrative data, such as drug reimbursements drawn from National Health
Insurance or hospital discharge databases, can be cross-linked with data on agricultural activities
drawn from agricultural census or geographical mapping. It is acknowledged that in several instances
this information can be obtained at group level only, and an important challenge will be to obtain data
at individual level and/or on individual habits.
Biobanks also constitute new data sources from healthy or diseased populations. They consist of an
organised collection of human biological specimens and associated information stored for diverse
research purposes. These biosamples are available for application of novel technologies with potential
for generating data valuable for exposure assessment or exposure reconstruction. If studies’ design
and conduct are harmonised, data and samples can be shared between biobanks to promote powerful
pooled analyses and replications studies (Burton et al., 2010).
Large scale epidemiological studies with deep phenotyping provide also unprecedented opportunities
to link well phenotyped study participants with the aforementioned data. For example, UK Biobank, has
recruited over 500,000 individuals with questionnaire, medical history and physical measurements data
as well as stored blood and urine samples with available genome wide association data for all 500,000
participants, and linkage to Hospital Episode Statistics, national registry data and primary care records.
To gain information on air pollution and noise levels, the postcode of participants has been linked to air
pollution or noise estimates. In addition, piloting of personal exposure monitoring will take place in order
to collect individual level data on these exposures. These approaches could be extended to gain
information on pesticide exposure, either through geographical linkage, linkage with purchasing and
occupational registries, and personal exposure monitoring. Similar biobanks exist in many other EU
countries (http://www.bbmri-eric.eu/BBMRI-ERIC has collected most EU studies).
8. Overall recommendations
8.1. Recommendations for single epidemiological studies:
The following recommendations for improving epidemiological studies are aimed to conform to the
‘recognised standards’ mentioned in Regulation (EU) No 1107/2009 to make them of particular value
to risk assessment of pesticides (‘where available, and supported with data on levels and duration of
exposure, and conducted in accordance with recognised standards, epidemiological studies are of
particular value and must be submitted’). Accordingly, these recommendations can indeed not be
considered as a practical guidance for researchers on how to conduct such studies, but for those who
are planning to conduct a study for further use in pesticide risk assessment.
a) Study design (including confounding)
1) Since prospective epidemiological designs provide stronger evidence for causal
inference, these studies are encouraged over the other designs for pesticide risk
assessment.
2) Future epidemiological studies should be conducted using the appropriate sample size in
order to properly answer the question under investigation. A power analysis should thus
be performed at the study design stage.
3) Future studies should take into consideration heterogeneity, subpopulations, exposure
windows and susceptibility periods and conditions (pregnancy, development, diseases,
etc.).
18 National Academies of Sciences, Engineering, and Medicine; Division on Earth and Life Studies; Board on Environmental
Studies and Toxicology; Committee on Incorporating 21st Century Science into Risk-Based Evaluations. Washington (DC):
National Academies Press (US); 2017 Jan.
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4) A wide range of potential confounding variables (including co-exposure to other
chemicals, lifestyle, socioeconomic factors, etc.) should be measured or accounted for
during the design stage (e.g. matching) of the study.
5) Consideration of host factors that may inﬂuence toxicity and act as effect modiﬁers.
These will include genetic polymorphisms data (e.g. paraoxonase-1 genotype) or
nutritional factors (e.g. iodine status) among others.
6) Collaboration between researchers is encouraged to build-up consortia that enhance the
effectiveness of individual cohorts.
Collection and appropriately storage of relevant biological material should be undertaken for future
exposure assessment, including the use of novel technologies.
b) Exposure (measurement, data transformation for reporting and statistical analysis):
1) Collection of speciﬁc information on exposure should avoid as far as possible broad
deﬁnitions of exposure, non-speciﬁc pesticide descriptions and broad exposures
classiﬁcations such as ‘never’ vs. ‘ever’ categories. Nevertheless, these categories may
be valuable under certain circumstances, e.g. to anticipate a class effect.
2) Studies which only look at broad classes of pesticides (generic groups of unrelated
substances), or ‘insecticides’, ‘herbicides’, etc. or even just ‘pesticides’ in general are of
much less use (if any) for risk assessment. Studies that investigate speciﬁc named
pesticides and co-formulants are more useful for risk assessment.
3) Pesticides belonging to the same chemical class or eliciting the same mode of toxic
action or toxicological effects might be grouped in the same category. Further
reﬁnement with information on frequency, duration and intensity of exposure might help
in estimating exposure patterns.
4) In occupational epidemiology studies, operator and worker behaviour and proper use of
PPE should be adequately reported as these exposure modiﬁers may signiﬁcantly change
exposures and thereby potential associations.
5) Improving the accuracy of exposure measurement is increasingly important, particularly
for cohort studies. Long-term cohort studies which cover the etiologically relevant time
period should improve the accuracy of measures of exposures by use of repeated
biologic measures or repeated updates of self-reported exposures.
6) Indirect measures of environmental exposure for wider populations, including records on
pesticide use, registry data, GIS, geographical mapping, etc., as well as data derived
from large databases (including administrative databases) may be valuable for
exploratory studies. If these data are not available, records/registries should be initiated.
Likewise, estimation of dietary exposure to pesticide from food consumption databases
and levels of pesticide residues from monitoring programmes can be used as well. As
with direct exposure assessment, each method of indirect measurement should be
reviewed for risk of bias and misclassiﬁcation and weighted appropriately.
7) Whenever possible, exposure assessment should use direct measurements of exposure
to named pesticides in order to establish different levels of exposure (e.g. personal
exposure metering/biological monitoring), possibly in conjunction with other methods of
exposure assessment which are more practicable or even necessary for large studies
and historical exposures. New studies should explore novel ways of personal exposure
monitoring. Results should be expressed using standardised units to normalise exposure
across populations
8) The characterisation of exposure assessment over time can beneﬁt by undertaken a more
comprehensive exposure monitoring strategy coupled with information on exposure
determinants over a longer time period collected from questionnaires or job-exposure
matrices supported by biomonitoring data. Exposure assessment models can be
comprehensively supported by HBM studies, which would allow identiﬁcation of the critical
exposure parameters. If such case, adjustments can then be made to the parameter
assumptions within the models, leading to more realistic evaluations of exposure.
9) The use of the exposome concept and metabolomics in particular hold great promise for
next-generation epidemiological studies both for better exposure measurement
(biomarkers of exposure), for identiﬁcation of vulnerable subpopulations and for
biological interpretation of toxicity pathways (biomarkers of disease).
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 55 EFSA Journal 2017;15(10):5007
10) Improved knowledge on exposure (and toxicity) to pesticide mixtures will be beneﬁcial
for comprehensive risk assessment. Consideration of the joint action of combined
exposures to multiple pesticides acting on common targets, or eliciting similar adverse
effects, is relevant for cumulative risk assessment. This requires all the components of
the mixture to be known as well as an understanding of the MoA, dose–response
characteristics and potential interactions between components. Characterisation of the
exposure is a key element for combined exposure to multiple pesticides where the
pattern and magnitude of exposure changes over time.
c) Adverse Outcomes (measurement, data transformation for reporting and statistical analysis):
1) Self-reported health outcomes should be avoided or conﬁrmed by independent, blinded
assessment of disease status by a medical expert assigned to the study.
2) Outcomes under study should be well deﬁned and surrogate endpoints should be avoided
unless they have been validated. Care must be taken when deﬁnitions of diseases and
subclasses of diseases change over time (cancer, neurodegenerative disorders, etc.).
3) Use should be made of biological markers of early biological effect to improve the
understanding of the pathogenesis of diseases. These quantitative biological parameters
from mechanistic toxicology will enhance the usefulness of epidemiology because they
improve the study sensitivity, reduce misclassiﬁcation and enhance human relevance as
compared to ﬁndings from studies in experimental animals. Since these reﬁned
endpoints are early events in the toxicodynamic pathway and often measured on a
continuous scale, they might be preferable to more overt and traditional outcomes.
4) The use of biomarkers of effect may be helpful in assessing aggregate exposure to
pesticides and informing cumulative risk assessment.
5) Developing read across methods allowing health outcomes to be identiﬁed using
epidemiological studies and to link acute and chronic incidents records with experimental
ﬁndings.
d) Statistical (descriptive statistics, modelling of exposure–effect relationship):
1) Statistical analysis should be based on a priori deﬁned analytical (statistical) protocols, to
avoid post hoc analyses for exploratory studies and report all the results, regardless of
whether they are statistically signiﬁcant or not.
2) Data should be reported in such a way that permit, where appropriate, mathematical
modelling to estimate individual/population exposures and dose–response assessment
irrespective of whether direct or indirect measures are used.
3) Reports should include both unadjusted and adjusted proportions and rates of outcome
of interest across studies that are based on underlying populations with different
structure of relevant factors and exposures.
4) Possible relevant factors, and their role in the exposure–health outcome relationship,
should be carefully identiﬁed, accurately measured and thoroughly assessed. Most often,
relevant factors have been screened as potential confounders. When confounding effects
were detected, these needed to be adjusted for using appropriate statistical methods
that include sensitivity analysis.
5) Potentially useful analytical approaches, such as propensity score matching, mediation
analyses, and causal inference are encouraged to be applied in pesticide epidemiology.
6) When the association between a given pesticide exposure and a disease is found to
be statistically signiﬁcant, particularly in (presumed) low powered studies, it would be
general good practice to perform a power analysis/design calculation to determine the
degree to which the statistically signiﬁcant effect size estimate (e.g. OR or RR) may be
artiﬁcially inﬂated or magniﬁed.19
19 Additional information on power and sample size recommendations and related issues including effect size magniﬁcation and
design calculations are provided in Annex D to this report. Speciﬁcally, a power calculation requires 3 values to be clearly
reported by epidemiological studies: (i) the number of subjects in the non-exposed group (including individuals with and
without the disease of interest); (ii) the number of subjects in the exposed group (also including individuals with and without
the disease of interest); (iii) the number of diseased subjects in the non-exposed group.
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e) Reporting of results:
1) These should follow practices of good reporting of epidemiological research outlined in the
STROBE statement and in the EFSA guideline on statistical reporting (EFSA, 2014b) and
include the further suggestions identiﬁed in this Opinion including effect size inﬂation
estimates.
2) Although some epidemiological research will remain exploratory and post hoc in nature,
this should be acknowledged and supported by appropriate statistical analysis.
3) Epidemiological studies are encouraged to provide access to raw data for further
investigations and to deposit their full results and scripts or software packages used for
analyses.
4) Report, or deposit using online sources, all results along with scripts and statistical tools
used to allow the reproducibility of results to be tested.
5) Report all sources of funding and adequately report ﬁnancial and other potential
conﬂicts of interest.
As a general recommendation, the PPR Panel encourages development of guidance for
epidemiological research in order to increase its value, transparency and accountability for risk
assessment.20 An increased quality of epidemiological studies, together with responsible research
conduct and scientiﬁc integrity, will beneﬁt the incorporation of these studies into risk assessment.
8.2. Surveillance
1) Increase the reporting of acute and chronic incidents by setting up post-marketing
surveillance programmes (occupational and general population) as required by article 7 of
EU directive 2009/128; this should be fulﬁlled by developing surveillance networks with
occupational health physicians and by boosting the collaboration between national
authorities dealing with PPP and poison control information centres.
2) Develop a valid method for assessing the weight/strength of the causal relationship
(‘imputability’) for acute and chronic incidents, and develop glossaries and a thesaurus to
support harmonised reporting between EU member states.
3) Harmonised data from member states should be gathered at the EU level and examined
periodically by the Commission/EFSA and a report should be released focussing on the most
relevant ﬁndings.
4) Develop an EU-wide vigilance framework for pesticides.
5) There is scope for training improvements regarding pesticide toxidromes in toxicology courses for
medical and paramedical staff responsible for diagnostic decisions, data entry and management.
8.3. Meta-analysis of multiple epidemiological studies
1) Evidence from epidemiological studies might be pooled by taking into account a thorough
evaluation of the methods and biases of individual studies, an assessment of the degree of
heterogeneity among studies, development of explanations underlying any heterogeneity
and a quantitative summary of the evidence (provided that it is consistent).
2) For every evidence synthesis effort, studies should be reviewed using relevant risk of bias
tools. Studies with different designs, or with different design features, may require (some)
different questions for risk of bias assessments.
3) Evidence syntheses should not be restricted to speciﬁc time frames; they should include the
totality of evidence. These efforts are more relevant if focused on speciﬁc health outcome or
disease categories.
4) In evidence synthesis efforts, beyond the quantitative synthesis of the effect sizes, there
should be consideration on the calculated predictive intervals, small study effects and
asymmetry bias, conﬂicts of interest, confounding, excess signiﬁcance bias,21 and
heterogeneity estimates.
20 An example is the guideline developed by the Dutch Society for Epidemiology on responsible epidemiologic Research Practice
(2017).
21 Excess signiﬁcance bias refers to the situation in which there are too many studies with statistically signiﬁcant results in the
published literature on a particular outcome. This pattern suggests strong biases in the literature, with publication bias,
selective outcome reporting, selective analyses reporting, or fabricated data being possible explanations (Ioannidis and
Trikalinos, 2007).
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5) In the presence of heterogeneity, studies with highly selected populations, albeit
unrepresentative of their respective populations, may prove valuable and deserve
consideration as they may represent genuine and not statistical heterogeneity.
6) A more consistent reporting such as for age, race and gender across studies would enhance
the meta-analyses.
7) Where quantitative data of individual pesticides are available from epidemiological studies,
they can be combined or pooled for dose–response modelling, which could enable
development of quantitative risk estimates and points of departure (BMDL, NOAEL).
8) International consortium of cohort studies should be encouraged to support data pooling to
study disease–exposure associations that individual cohorts do not have sufﬁcient statistical
power to study (e.g. AGRICOH).
8.4. Integration of epidemiological evidence with other sources of
information
1) All lines of evidence (epidemiology, animal, in vitro data) should be equally scrutinised for
biases.
2) Validated and harmonised methods should be developed to combine observational studies,
animal/basic science studies and other sources of evidence for risk assessment.
3) Experimental and human data should both contribute to hazard identiﬁcation and to dose–
response assessment.
4) A systematic integration of data from multiple lines of evidence should be based on a WoE
analysis accounting for relevance, consistency and biological plausibility using modiﬁed
Bradford Hill criteria. The principles underlying this framework are described in Section 7.2
and summarised in Figure 5.
5) Epidemiological ﬁndings should be integrated with other sources of information (data from
experimental toxicology, mechanism of action/AOP) by using a WoE approach. An integrated
and harmonised approach should be developed by bringing together animal, mechanistic
and human data in an overall WoE framework in a systematic and consistent manner.
6) The AOP framework offers a structured platform for the integration of various kinds of
research results.
7) Animal, in vitro data and human data should be assessed as a whole for each endpoint. A
conclusion can be drawn as to whether the results from the experiments are conﬁrmed by
human data for each endpoint and this could be included in the RARs.
9. Conclusions
This Scientiﬁc Opinion is intended to help the peer review process during the renewal of pesticides
authorisation (and, where possible, during the approval process) under Regulation 1107/2009 which
requires a search of the scientiﬁc peer-reviewed open literature, including existing epidemiological
studies. These are more suitable for the renewal process of active substances, also in compliance with
Regulation 1141/2010, which indicates that the dossiers submitted for renewal should include new
data relevant to the active substance.
The four key elements of the terms of reference are repeated below and the parts of the text
addressing the individual terms are identiﬁed in order. As they follow from the text passages grouped
with each of the ToRs the recommendations relevant to each of the ToRs are also indicated as follows.
‘The PPR Panel will discuss the associations between pesticide exposure and human health effects
observed in the External scientiﬁc report (Ntzani et al., 2013) and how these ﬁndings could be
interpreted in a regulatory pesticide risk assessment context. Hence, the PPR Panel will systematically
assess the epidemiological studies collected in the report by addressing major data gaps and
limitations of the studies and provide recommendations thereof’.
‘The PPR Panel will speciﬁcally’:
1) Collect and review all sources of gaps and limitations, based on (but not necessarily limited to)
those identiﬁed in the External Scientiﬁc report in regard to the quality and relevance of the
available epidemiological studies. Responses in Section 3 pp. 20–24, Section 5.2 pp. 33–35:
no Recommendations appropriate.
2) Based on the gaps and limitations identiﬁed in point 1, propose potential reﬁnements for
future epidemiological studies to increase the quality, relevance and reliability of the ﬁndings
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and how they may impact pesticide risk assessment. This may include study design,
exposure assessment, data quality and access, diagnostic classiﬁcation of health outcomes,
and statistical analysis. Responses in Section 4 pp 24–33: recommendations in Sections 8.1,
8.2 and 8.3 pp. 54–58.
3) Identify areas in which information and/or criteria are insufﬁcient or lacking and propose
recommendations for how to conduct pesticide epidemiological studies in order to improve
and optimise the application in risk assessment. These recommendations should include
harmonisation of exposure assessment (including use of biomonitoring data), vulnerable
population sub-groups and/or health outcomes of interest (at biochemical, functional,
morphological and clinical level) based on the gaps and limitations identiﬁed in point 1.
Responses in Sections 4.2–4.5 pp. 27–33, Section 5.3 pp. 36: recommendations in
Section 8.1 c) 1–4, pp. 56.
4) Discuss how to make appropriate use of epidemiological ﬁndings in risk assessment of
pesticides during the peer review process of draft assessment reports, e.g. WoE as well as
integrating the epidemiological information with data from experimental toxicology, AOPs,
mechanism of actions, etc. Responses in Sections 6.2 and 6.3 pp. 37–45 and 7 pp. 45–54:
Responses in Section 8.4 pp. 58.
As explained above, appropriate epidemiological data and post-approval surveillance may usefully
contribute to the risk assessment framework by hazard identiﬁcation, and – with methodological
improvements – hazard characterisation. It can be improved by contributions from WoE analysis,
Uncertainty analysis, and identiﬁcation and estimation of biases. It is the responsibility of applicants to
collect the available relevant literature, to consider its relevance and quality using relevant EFSA
criteria including those for systematic review and to introduce discussion of the outcomes within the
DAR, RAR and post-approval frameworks that are prescribed under EU law.
The deﬁnition of appropriate quality will require analysis of sample size, statistical procedures,
estimates of effect size inﬂation, assessment of biases and their contribution to the conclusions drawn.
The nature of the studies will require consideration at all relevant points in the risk assessment
process so that for example epidemiological data on reproductive topics will be considered alongside
laboratory animal studies designed to reveal reproductive effects and in the context of
recommendation for labelling for reproductive toxicity (for ECHA).
Unless there is history of use in countries outside the EU, the relevant epidemiological studies will
be restricted in their effect on the DAR but the RAR and Surveillance framework is potentially able to
beneﬁt from epidemiology progressively as time after ﬁrst approval passes and from prior use of Active
Ingredients in other jurisdictions. It is recommended that RAR and surveillance protocols should reﬂect
this difference.
The speciﬁc recommendations listed above follow from detailed arguments based on an analysis of
present and foreseen strengths weaknesses opportunities and threats related to the use of
epidemiological data in risk assessment. Broadly these are as follows:
Strengths. Include:
• The fact that the evidence concerns human speciﬁc risks.
• That health outcomes are integrated measures of the effects of all exposure to toxins.
• The ability to elicit subjective experience from potentially affected people.
Weaknesses. Include:
• The exposures to pesticides are usually complex; contribution of a speciﬁc active ingredient is
not easily deciphered.
• The exposures occur in various settings where precisely controlled conditions are lacking.
• Most data reﬂect the responses of mixed populations.
• Many data show low level associations that are inconsistently repeatable and require
sophisticated analysis.
Opportunities. Despite the range of limitations described in this Opinion, which apply to many
available published epidemiological studies, there are opportunities to beneﬁt risk assessment of
pesticides. These include:
• The access to very large numbers of potentially exposed individuals for studies that may reveal
subtle health effects and reveal the experience of sensitive sub-groups.
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• The prospect of improving exposure estimation using biomonitoring and new molecular
approaches to establish tissue burdens of potential toxins and their residues.
• The possibility of fully integrating human data into the conventional risk assessment based on
responses in laboratory animals.
• Utilising WoE, AOP, Expert judgement, Expert Knowledge Elicitation (EKE) and Uncertainty
Analysis to evaluate differences in the quality of potentially relevant data.
• The opportunity to engage professional epidemiologists and statisticians to reﬁne interpretation
of epidemiological ﬁndings and to recommend improved designs to tackle difﬁcult areas such
as chronic and combined exposure risks and dose–response data.
• A major information technology opportunity exists in pooling data from a variety of national
sources. Once the relevant legal, methodological and ethical issues are overcome much more
valuable data can be collected. When this data is made available, in a form that can be used in
a ‘big data’ setting for societal beneﬁt there will be potential for signiﬁcant improvements in
epidemiological studies. First, however, it will be necessary to preserve individual privacy and
essential commercial conﬁdentiality. Once these obstacles are overcome the statistical power of
epidemiological studies can be improved and applied to identify and possibly characterise
hazards better. These aims can be realised effectively by agreed actions at a high EU level.
Interstate approval for providing data and interactive platforms will need to be backed by
harmonisation of population health information, food consumption data, active substance and
co-formulant spatial and temporal application data. Such rich data can be expected to assist in
increasing consistency, a criterion that strengthens evidence of causality and reliability. It
promises larger sample sizes for epidemiological studies that will be better able to identify
vulnerable groups that may require special protection from pesticide toxicity.
Threats. Include:
• Widespread perception of risk levels to the human population or to wildlife and the
environment that are unrealistic and that cause negative consequences in societies.
• Poor experimental design yielding false positive or false negative conclusions that undermine
data from other valid sources.
• Failure to respond to emerging risks as a result of ineffective surveillance or unwillingness to
make appropriate anonymised data available for societal beneﬁt.
• Waste of data through failure to collect appropriate information regarding exposure
(speciﬁcally occupational exposure) by registries (cancer or congenital anomalies) or
surveillance programmes which hinders linking health outcomes to exposure.
• Waste of data through failure to harmonise diagnostic criteria, failure to record data in a
sufﬁciently detailed combinable form for integrated analysis, poor training of medical and
paramedical staff in relevant toxidromes that will allow optimum quality of data entered into
Health Statistics Databases.
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Glossary and Abbreviations
ADI Acceptable daily intake. A measure of the amount of a pesticide in food or
drinking water that can be ingested (orally) on a daily basis over a lifetime
without an appreciable health risk.
ADME Abbreviation used in pharmacology (and toxicology) for absorption, distribution,
metabolism, and excretion of a chemical o pharmaceutical compound and
describes its disposition within an organism.
AOP Adverse Outcome Pathway. A structured representation of biological events
leading to adverse effects relevant to risk assessment.
ARfD Acute Reference Dose. An estimate of the amount a pesticide in food or drinking
water (normally expressed on a body weight basis) that can be ingested in a
period of 24 hours or less without appreciable health risks to the consumer on
the basis of all known facts at the time of the evaluation.
Biomarker Also known as ‘biological marker’. A characteristic that is objectively measured
and evaluated as an indication of normal biologic processes, pathogenic
processes or pharmacologic responses to a therapeutic intervention
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BMD Benchmark Dose. A threshold dose or concentration that produces a
predetermined change in response rate of an adverse effect (the benchmark
response or BMR) compared to background. The lower 95% conﬁdence limit is
calculated (BMDL) to be further used as a point of departure to derive health-
based reference values.
HBM Human biomonitoring. The measurement of a chemical and/or its metabolites in
human biological ﬂuids or tissues. Also referred as to the internal dose of a
chemical resulting from integrated exposures from all exposure routes.
Human data They include observational studies (also called epidemiological studies) where the
researcher is observing natural relationships between factors and health
outcomes without acting upon study participants. Vigilance data also fall under
this concept. In contrast, interventional studies (also called experimental studies
or randomised clinical trials), where the researcher intercedes as part of the study
design, are outside the scope of this opinion.
IARC International Agency for Research on Cancer. An agency of the World Health
Organization whose role is to conduct and coordinate research into the causes
and occurrence of cancer worldwide.
LOAEL Lowest-observed-adverse-effect level. The lowest concentration or amount of a
chemical stressor evaluated in a toxicity test that shows harmful effects (e.g. an
adverse alteration of morphology, biochemistry, function, or lifespan of a target
organism).
NOAEL No observed-adverse-effect level. Highest dose at which there was not an
observed toxic or adverse effect.
OR Odds ratio. A measure of association between an exposure and an outcome. The
OR represents the odds that an outcome will occur given a particular exposure,
compared to the odds of the outcome occurring in the absence of that exposure.
PBTK-TD Physiologically based toxicokinetic/toxicodynamic modelling is a mathematical
modelling approach aimed at integrating a priori knowledge of physiological
processes with other known/observed information to mimic the fates and effects
of compounds in the bodies of humans, preclinical species and/or other
organisms.
PPP Plant Protection Product. The term ‘pesticide’ is often used interchangeably with
‘plant protection product’, however, pesticide is a broader term that also covers
non plant/crop uses, for example biocides.
RR Relative risk. Ratio of the probability of an event (e.g. developing a disease)
occurring in an exposed group to the probability of the event occurring in a
comparison, non-exposed group.
RMS Rapporteur member state. The member state of the European Union initially in
charge of assessing and evaluating a dossier on a pesticide active substance
toxicological assessment.
Sensitivity The ability of a test to correctly classify an individual as 0diseased0. Probability of
being test positive when disease present.
Speciﬁcity The ability of a test to correctly classify an individual as disease-free. Probability
of being test negative when disease absent.
Surrogate endpoint A biomarker intended to substitute for a clinical endpoint
AHS Agricultural Health Study
ASHTIII Alerting and Reporting System for Chemical Health Threats, Phase III
BEES-C Biomonitoring, Environmental Epidemiology, and Short-Lived Chemicals
DAR draft assessment report
DDE dichlorodiphenyldichloroethylene
DDT dichlorodiphenyltrichloroethane
EMA European Medicines Agency
EPA US Environmental Protection Agency
EQUATOR Enhancing the QUAlity and Transparency Of health Research
EU-OSHA European Agency for Safety and Health at Work
EWAS Exposome-wide association studies
GIS Geographical information systems
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GLP good laboratory practice
GPS global positioning system
HWE healthy worker effect
IATA Integrated Approach on Testing and Assessment
ICD International Classiﬁcation of Diseases
IHR International Health Regulations
INSERM French National Institute of Health and Medical Research
LOQ limit of quantiﬁcation
MGUS monoclonal gammopathy of undetermined signiﬁcance
MIE molecular initiating event
MoA mode of action
NHL non-Hodgkin’s lymphoma
NIOSH National Institute for Occupational Safety and Health
NOS Newcastle-Ottawa scale
OECD Organisation for Economic Co-operation and Development
OPP Ofﬁce of Pesticide Programs
PCC Poison Control Centre
PPE personal protective equipment
RAR Renewal Assessment Report
RASFF rapid alert system covering food and feed
RTI Research Triangle Institute
SAR structure–activity relationship
STREGA STROBE Extension to Genetic Association studies
STROBE STrengthening the Reporting of OBservational studies in Epidemiology
ToR Term of Reference
UF uncertainty factor
WHO World Health Organization
WoE Weight-of-Evidence
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Annex A – Pesticide epidemiological studies reviewed in the EFSA External
Scientiﬁc Report and other reviews
The extensive evidence gathered by the EFSA External Scientiﬁc Report (Ntzani et al., 2013)
highlights that there is a considerable amount of information available on pesticide exposure and
health outcomes from epidemiological studies. Nonetheless, the quality of this evidence is usually low
and many biases are likely to affect the results to an extent that ﬁrm conclusions cannot be made. In
particular, exposure epidemiology has long suffered from poor measurement and deﬁnition and in
particular for pesticides this has always been exceptionally difﬁcult to assess and deﬁne.
A.1. The EFSA External scientiﬁc report
A.1.1. Methodological quality assessment
The External Scientiﬁc Report consists of a comprehensive systematic review of all the
epidemiological studies published between 1 January 2006 and 30 September 2012, investigating the
association between pesticide exposure and the occurrence of any human health-related outcomes.
The methodological assessment of eligible studies (to evaluate risk of bias associated with each
study) was focused on: study design, study population, level of details in exposure deﬁnition and the
methods of exposure measurement and the speciﬁcity of the measurement. Efforts undertaken to
account for confounders through matching or multivariable models, blinded exposure assessment and
well-deﬁned and valid outcome assessment were considered.
The elements of the methodological appraisal were considered from the Research Triangle Institute
(RTI; Research Triangle Park, NC, USA) item bank, a practical and validated tool for evaluating the risk
of bias and precision of observational studies. Those elements are described below (Table A.1).
Quantitative synthesis of the results was attempted when there were 5 or more eligible studies per
examined outcome and when there was no substantial heterogeneity among the published evidence.
Publication bias was assessed using funnel plots which allowed to visually inspect asymmetry when
more than 10 studies were included in the meta-analysis.
Toxicological data was not reviewed or discussed in the External Scientiﬁc Report.
A.1.2. Inclusion/exclusion criteria
All types of pesticides, including those banned in the EU, were considered to enhance the totality of
the epidemiological evidence available at the time of the review.
Table A.1: Elements from the Research Triangle Institute (RTI; Research Triangle Park, NC, USA)
item bank for methodological appraisal of epidemiological studies
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Exclusion criteria:
• Studies without control populations (case reports, case series) and ecological studies
• Pesticide poisoning or accidental high dose exposure
• Studies with no quantitative information on effect estimates
• Studies with different follow-up periods and examining the same outcome, only the one with
the longest follow-up was retained to avoid data duplication.
• Studies referred to the adverse effects of substances used as therapy for various medical
conditions (e.g. warfarin-based anticoagulants)
• Studies on solvents and other non-active ingredients (e.g. co-formulants) in pesticides
• Studies examining the association between exposure and biomarkers of exposure were not
considered eligible as they do not examine health outcomes
• Studies/analyses investigating exposure to pesticides: arsenic, hexachlorocyclohexane (HCH) a
or b, lead, dioxins and dioxin-like compounds including polychlorinated biphenyls (PCBs) were
not considered
• Narrative reviews were excluded but not systematic reviews or meta-analyses.
Publications reporting series of acute poisonings or clinical cases, biomonitoring studies unrelated to
health effects, or studies conducted on animals or human cell systems were not included; only
epidemiological studies addressing human health effects were selected. Publications that lacked
quantitative data for measuring associations were also excluded.
Cohort studies, case–control studies and cross-sectional studies were included. Each study
underwent an assessment of its eligibility based on a method including 12 criteria such as study
design, precise description of the inclusion/exclusion criteria, level of detail in describing exposure,
robustness in the measurement of exposure, adjustment for potential confounding factors, method of
assessment of the health outcome, sample size, etc. Among these 12 criteria, three were related to
the degree of precision in the description/measurement of exposure, which may explain why a large
number of epidemiological studies were not selected.
A.1.3. Results
Overall, 602 individual publications were included in the scientiﬁc review. These 602 publications
corresponded to 6,479 different analyses. The overwhelming majority of evidence comes from
retrospective or cross-sectional studies (38% and 32%, respectively) and only 30% of studies had a
prospective design. Exposure assessment varied widely between studies and overall 46% measured
biomarkers of pesticides exposure and another 46% used questionnaires to estimate exposure to
pesticides. Almost half of the studies (49%) were based in America. Most studies examined
associations between occupational exposure to pesticides and health effects. The entire spectrum of
diseases associated with pesticides has not been studies before. The report examined a wide variety of
outcomes (Figure A.1). The largest proportion of studies pertains to cancer outcomes (N = 164) and
outcomes related to child health (N = 84).
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 69 EFSA Journal 2017;15(10):5007
Despite the large volume of available data and the large number (> 6,000) of analyses available,
ﬁrm conclusions were not made for the majority of the outcomes studied. This was due to several
limitations of the data collected as well as to inherent limitations of the review itself. As mentioned
above, the review studied the whole range of outcomes examined in relation to pesticides during an
approximately 5 years’ period. Thus, only recent evidence was reviewed and the results of the meta-
analyses performed should be cautiously interpreted as they do not include all the available evidence.
It is therefore capable of highlighting outcomes which merit further in-depth analysis in relation to
pesticides by looking at the entire literature (beyond 5 years) and by focusing on appraising the
credibility of evidence selected. The limitations of the studies itself are in line with other ﬁeld of
environmental epidemiology and focus around the exposure assessment, the study design, the
statistical analysis and reporting. In particular:
a) Exposure assessment: The assessment of exposure is perhaps the most important
methodological limitation of the studies reviewed in the ESR. Studies used different methods for exposure
assessment and assignment. Most studies were based on self-reported exposure to pesticides, deﬁned as
‘ever versus never’ use or as ‘regular versus non-regular’ use. Such methods suffer from high
misclassiﬁcation rates and do not allow for dose–response analysis. This is especially the case for
retrospective studies where misclassiﬁcation would be differential with higher exposures reported in
participants with disease (recall bias) (Raphael, 1987). While questionnaires might be capable of
differentiating subjects with very high and very low exposure levels, they are not capable of valid exposure
classiﬁcation across an exposure gradient, thus not allowing the study of dose–response relationships.
Also, questionnaire for exposure assessment need to be validated for use in epidemiological studies.
Nonetheless, a vast proportion of studies use in house version of non-validated questionnaires which may
suffer from content (the questionnaire does not cover all sources of exposure to the hazard of interest) or
criterion validity (e.g. through inaccurate recall or misunderstanding of questions) (Coggon, 1995).
Although the range of categories of pesticide studied is wide, studies very often concentrate on a
broadly deﬁned pesticide category, so that it is difﬁcult to know what type of pesticide the population
is exposed to.
Figure A.1: Major outcome categories and corresponding percentage of studies examining those
outcomes among the publications reviewed by the EFSA external scientiﬁc report (Ntzani
et al., 2013)
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Exposure to pesticides was deﬁned as reported use of pesticides by the study participant or by
government registry data. These derive from self-administered questionnaires, interviewer administrated
questionnaires, job exposure matrices (JEM), by residential status (proximity to pesticide exposure), by
detecting biomarkers associated with pesticide exposure or by other means as deﬁned by each study.
Studies often examine pesticides that have already been banned in western populations and the
EU. The use of biomarkers as means of exposure assessment is infrequent, but still available in almost
half of the studies.
b) Study design: As mentioned above, the majority of evidence comes form case–control studies
and cross-sectional studies. Cross-sectional, and in part also case–control studies, cannot fully assess
the temporal relationships and thus are less able to provide support regarding the causality of
associations.
c) Outcomes examined: The deﬁnition of clinical outcomes displayed large variability in eligible
epidemiological studies, which can further cause the variability in results. Perhaps most important in
this setting is the use of a great number of surrogate outcomes examined. Surrogate outcomes are
biomarkers or physical measures that are generally accepted as substitutes for, or predictors of,
speciﬁc clinical outcomes. However, often these surrogate outcomes are not validated and do not meet
the strict deﬁnitions of surrogate outcomes. Such outcomes can be deﬁned as possible predictors of
clinical outcomes but do not fulﬁl the criteria for a surrogate outcome. It is essential to appraise the
evidence around non-validated surrogate outcomes by taking into account the implicit assumptions of
these outcomes.
A great variety of assessed outcomes covering a wide range of pathophysiologies was observed.
‘Hard’ clinical outcomes as well as many surrogate outcomes included in the database reﬂect the
different methodologies endorsed to approach the assessed clinical research questions. The different
outcomes were divided into 23 major disease categories, with the largest proportion of studies
addressing cancer and child health outcomes.
The adverse health effects assessed included:
a) major clinical outcomes, such as cancer, respiratory (allergy), reproductive (decreased fertility,
birth defects) and neurodegenerative (Parkinson’s disease);
b) clinical surrogate outcomes, e.g. neurodevelopmental impairment (assessed by neurocognitive
scales);
c) laboratory surrogate outcomes (e.g. liver enzyme changes).
For many adverse health effects attributed to pesticide exposure, there exist contradictory or
ambiguous studies. Whether this results from lack of consistency or real heterogeneity warrants
further clariﬁcation.
d) Statistical analysis:
Simultaneous exposure to multiple agents (heavy metals, solvents, suspended particulate matter
etc.) from different sources is common. It may introduce further bias in the results as all of them may
produce adverse health outcomes. Thus, it is essential to account for confounding from exposure to
multiple agents in order to delineate true associations but this has not been possible in the
overwhelming majority of evidence assessed in the EFSA external scientiﬁc report.
In addition, the evidence collected and appraised in the EFSA external scientiﬁc report (Ntzani et al.,
2013) is likely to suffer from selective reporting and multiple testing. The studies reported a very wide
range of analyses; 602 publications resulted in 6,000 analyses. The amount of multiple hypothesis testing is
enormous. These analyses need to be adjusted for multiple hypothesis testing else, otherwise the results
suffer from high false positive rate. Even when studies present only one analysis, selective reporting is
always a possibility as has been shown in other epidemiological ﬁelds as well. In addition, when interpreting
results one should also take into account that, especially for certain outcomes (e.g. cancers), the majority
of evidence comes from single study populations and the Agricultural Health Study in particular.
A.1.4. Conclusion of the EFSA External Scientiﬁc Report
Regardless of the limitations highlighted above, the External Scientiﬁc Report (Ntzani et al., 2013)
showed consistent evidence of a link between exposure to pesticides and Parkinson’s disease and
childhood leukaemia, which was also supported by previous meta-analyses. In addition, an increased
risk was also found for diverse health outcomes less well studied to date, such as liver cancer, breast
cancer and type II diabetes. Effects on other outcomes, such as endocrine disorders, asthma and
allergies, diabetes and obesity showed increased risks and should be explored further.
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 71 EFSA Journal 2017;15(10):5007
Childhood leukaemia and Parkinson’s disease are the two outcomes for which a meta-analysis after
2006 was found consistently showing an increased risk associated with pesticide exposure.
Nonetheless, the exposure needs to be better studied to disentangle the effect of speciﬁc pesticide
classes or even individual pesticides. Signiﬁcant summary estimates have also been reported for other
outcomes (summarised in Table A.2). However, as they represent studies from 2006 onwards results
should be regarded as suggestive of associations only and limitations especially regarding the
heterogeneity of exposure should always been taken into consideration. Data synthesis and statistical
tools should be applied to these data in relation to speciﬁc outcomes, after the update of the results to
include publications before 2006, in order to quantify the amount of bias that could exist and isolate
outcomes where the association with pesticides is well supported even when estimates of bias are
taken into account. Similarly, outcomes where further evidence is needed to draw ﬁrm conclusions
need to be highlighted.
Table A.2: Summary of meta-analyses performed in the report
Health outcome
N
studies
Meta-analysis
results
I2
Leukaemia 6 1.26 (0.93; 1.71) 59.4%
Hodgkin lymphoma 7 1.29 (0.81–2.06) 81.6%
Childhood leukaemia (exposure to pesticides during pregnancy) 6 1.67 (1.25–2.23) 81.2%
Childhood leukaemia (exposure to insecticides during pregnancy) 5 1.55 (1.14–2.11) 65%
Childhood leukaemia (exposure to insecticides during pregnancy –
update Turner, 2010)
9 1.69 (1.35–2.11) 49.8%
Childhood leukaemia (exposure to unspeciﬁed pesticides during
pregnancy)
5 2.00 (1.73–2.30) 39.6%
Childhood leukaemia (exposure to unspeciﬁed pesticides during
pregnancy – update Turner, 2010)
11 1.30 (1.06–1.26) 26.5%
Childhood leukaemia (exposure to pesticides during childhood) 7 1.27 (0.96–1.69) 61.1%
Childhood leukaemia (exposure to insecticides during childhood –
update Turner, 2010)
8 1.51 (1.28–1.78) 0%
Childhood leukaemia (exposure to unspeciﬁed pesticides during
childhood – update Turner, 2010)
11 1.36 (1.19–1.55) 0%
Breast cancer (DDE exposure) 5 1.13 (0.81–1.57) 0%
Breast cancer 11 1.24 (1.08–1.43) 0%
Testicular cancer (DDE exposure) 5 1.40 (0.82–2.39) 59.5%
Stomach cancer 6 1.79 (1.30–2.47) 0%
Liver cancer 5 2.50 (1.57–3.98) 25.4%
Cryptorchidism 8 1.19 (0.96–1.49) 23.9%
Cryptorchidism (DDT exposure) 4 1.47 (0.98–2.20) 51%
Hypospadias (general pesticide exposure) 6 1.01 (0.74–1.39) 71.5%
Hypospadias (exposure to speciﬁc pesticides) 9 1.00 (0.84–1.18) 65.9%
Abortion 6 1.52 (1.09–2.13) 63.1%
Parkinson’s disease 26 1.49 (1.28–1.73) 54.6%
Parkinson’s disease (DDT exposure) 5 1.01 (0.78–1.30) 0%
Parkinson’s disease (paraquat exposure) 9 1.32 (1.09–1.60) 34.1%
Amyotrophic lateral sclerosis 6 1.58 (1.31–1.90) 10%
Asthma (DDT exposure) 5 1.29 (1.14–1.45) 0%
Asthma (paraquat exposure) 6 1.40 (0.95–2.06) 53.3%
Asthma (chlorpyrifos exposure) 5 1.03 (0.82–1.28) 0%
Type 1 diabetes (DDE exposure) 8 1.89 (1.25–2.86) 49%
Type 1 diabetes (DDT exposure) 6 1.76 (1.20–2.59) 76.3%
Type 2 diabetes (DDE exposure) 4 1.29 (1.13–1.48) 0%
N = number of studies considered for the meta-analysis; in the column of meta-analysis results, the numbers represent the
statistical estimate for the size of effect (odds ratio (OR), or relative risk (RR)) with the corresponding 95% conﬁdence interval
(CI). I2 represents the percentage of total variation across studies that is due to heterogeneity.
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A.2. The INSERM report
In September 2013, the French National Institute of Health and Medical Research (INSERM)
released a literature review carried out with a group of experts on the human health effects of
exposure to pesticides.22 Epidemiological or experimental data published in the scientiﬁc literature up
to June 2012 were analysed. The report was accompanied by a summary outlining the literature
analysis and highlighting the main ﬁndings and policy lines, as well as the recommendations.
The INSERM report is composed of four parts: (1) exposure assessment, with a detailed description
of direct and indirect methods to assess exposure in epidemiological studies; (2) epidemiology, with an
inventory and analysis of epidemiological studies available in the literature up to 2012, and a scoring
system to assess the strength of presumed association; (3) toxicology, with a review of toxicological
data (metabolism, mode of action and molecular pathway) of some substances and assessment of
biological plausibility; (4) recommendations.
The vast majority of substances identiﬁed by the INSERM report as having a presumed moderate or
strong association with the occurrence of health effects are chemicals that are now prohibited. This is
mainly driven by the fact that the majority of the diseases examined are diseases of the elderly;
therefore, the studies performed to date are based on persons who were old at the time of the study
and exposed many years ago. By deﬁnition, it is not yet possible to investigate the potential long term
effects of many of the more recent products.
These substances belong to the group of organochlorine insecticides, such as DDT or toxaphene, or
insecticides with cholinesterase-inhibiting properties, such as terbufos or propoxur.
Of the seven approved active substances identiﬁed by the INSERM expert appraisal report (the
herbicides 2,4-D, MCPA, mecoprop, glyphosate, the insecticide chlorpyrifos, and the foliar fungicides
mancozeb and maneb), all had a presumed moderate or weak association with haematopoietic
cancers. Two of them (the foliar fungicides mancozeb and maneb) had a presumed weak association
with Parkinson’s disease and two (chlorpyrifos and glyphosate) had a presumed association with
developmental impairment identiﬁed as weak or moderate in the expert appraisal.
A.2.1. Description of methods to assess exposure in epidemiological
studies
Different methods (direct and indirect) have been developed to assess exposure, such as biological
or environmental monitoring data, ad hoc questionnaires, job- or crop-exposure matrices, analysis of
professional calendars, sales data, land use data, etc. According to the authors, these various tools can
be combined with each other but, to date none has been validated as a reference method for
estimating exposure in the context of occupational pesticide exposure assessment.
A.2.2. Epidemiology
The group of experts from INSERM carried out an inventory and analysis of epidemiological studies
available in the literature, examining the possible association between pesticide exposure and health
outcomes: eight cancer sites (non-Hodgkin lymphoma, leukaemia, lymphoma, multiple myeloma,
prostate, testis, brain, melanoma), three neurodegenerative diseases (Parkinson’s disease, Alzheimer’s
disease, amyotrophic lateral sclerosis), cognitive or depressive disorders, effects on reproductive
function (fertility, pregnancy and child development) and childhood cancers. These are health
outcomes that have been identiﬁed in previous studies as potentially related to pesticide exposure.
Epidemiological studies addressing primarily farmers, pesticide applicators and workers of the
pesticide manufacturing industries, as well as the general population when it was relevant, were
selected.
The INSERM group of experts established a hierarchy in the relevance of the studies, placing the
meta-analysis at the top, then the systematic review, then the cohort study, and ﬁnally, the case–
control study. Based on this hierarchy, a scoring system was deﬁned to assess the strength of
presumption of the association between exposure and the occurrence of health outcomes from the
analysis of the study results; for each disease or pathological condition investigated, this score may
vary depending on the quality, type and number of available studies, as, for example:
(++): strong presumption: based on the results of a meta-analysis, or several cohort studies or at
least one cohort study and two case–control studies, or more than two case–control studies;
22 INSERM. Pesticides. Effets sur la sante. Collection expertise collective, Inserm, Paris, 2013.
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(+): moderate presumption: based on the results of a cohort study or a nested case–control study
or two case–control studies;
(): weak presumption: based on the results of one case–control study. This synthesis takes the
work beyond the status of a simple mapping exercise.
A.2.3. Toxicological data
Toxicological data that were considered in the literature review were mainly those regarding
metabolism, mode of action and molecular pathways. None of the studies provided as part of the
procedures for placing products on the market were considered except if they were published in the
open literature.
When substances were clearly identiﬁed in the epidemiological studies, a scoring system was
deﬁned to assess the biological plausibility from the study results: coherence with pathophysiological
data and occurrence of health outcome.
(++): hypothesis supported by 3 mechanisms of toxicity;
(+): hypothesis supported by at least one mechanism of toxicity.
A.2.4. Findings
The major results of the INSERM report are summarised in Tables A.3–A.6.
Table A.3: Statistically signiﬁcant associations between occupational exposure to pesticides and
health outcomes in adults (health outcomes that were analysed in the review)
Health outcome Type of population with signiﬁcant risk excess
Strength of
presumption(a)
NHL Farmers, operators, manufacturing plant personnel ++
Prostate cancer Farmers, operators, manufacturing plant personnel ++
Multiple myeloma Farmers, operators ++
Parkinson’s disease Occupational and non-occupational exposure ++
Leukaemia Farmers, operators, manufacturing plant personnel +
Alzheimer’s disease Farmers +
Cognitive disorders(b) Farmers +
Fertility and fecundability disorders Occupational exposure +
Hodgkin lymphoma Agricultural workers 
Testicular cancer Agricultural workers 
Brain cancer (glioma, meningioma) Agricultural workers 
Melanoma Agricultural workers 
Amyotrophic lateral sclerosis Farmers 
Anxiety, depression(b) Farmers, farmers with a history of acute poisoning,
operators

(a): Scoring system: strong presumption (++), moderate presumption (+), weak presumption ().
(b): Almost all pesticides were organophosphates.
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Table A.4: Associations between occupational or home use exposure to pesticides and cancers or
developmental impairment in children (health outcomes that were analysed in the
review) (only statistically signiﬁcant associations are shown)
Health outcome
Type of exposure and population with signiﬁcant risk
excess
Strength of
presumption(a)
Leukaemia Occupational exposure during pregnancy, prenatal exposure
(residential)
++
Brain cancer Occupational exposure during pregnancy ++
Congenital malformation Occupational exposure during pregnancy;
Residential exposure during pregnancy (agricultural area, home
use)
++
+
Fetal death Occupational exposure during pregnancy +
Neurodevelopment Residential exposure during pregnancy (agricultural area, home
use, food)(b);
Occupational exposure during pregnancy
++

(a): Scoring system: strong presumption (++), moderate presumption (+), weak presumption ().
(b): Organophosphates.
Table A.5: Findings related to approved active substances: epidemiological assessment and
biological plausibility
Active substance Classiﬁcation Strength of presumption(a) Biological plausibility(b)
Organophosphates
Insecticide
Chlorpyrifos Acute Tox cat 3 Leukaemia (+)
Neurodevelopment (+)
NHL ()
Yes (++)
Yes (++)
Yes (++)
Dithiocarbamates
Fungicide
Mancozeb/Maneb Repro cat 2 Leukaemia (+)
Melanoma (+)
Parkinson’s disease
(in combination with paraquat) ()
?
?
Yes (+)
Phenoxy herbicides
Herbicide
2,4-D
MCPA
Mecoprop
Acute Tox cat 4
Acute Tox cat 4
Acute Tox cat 4
NHL (+)
NHL ()
NHL ()
?
?
?
Aminophosphonate glycine
Herbicide
Glyphosate NHL (+)
Fetal death ()
?
?
(a): Scoring system: strong presumption (++), moderate presumption (+), weak presumption ().
(b): Scoring system: (++): hypothesis supported by 3 different known mechanisms of toxicity, (+): hypothesis supported by at
least one mechanism of toxicity.
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Table A.6: Findings related to non-approved active substances: epidemiological assessment and
biological plausibility
Active substance Ban in the EU
IARC
classiﬁcation
Strength of
presumption(a)
Biological
plausibility(b)
Dieldrin 1978 3 or 2 (US-EPA) NHL(c) ()
Prostate cancer ()
Parkinson’s disease ()
Yes (+)
Yes (+)
?
DDT/DDE 1978 2B NHL (++)
Testicular cancer (+)
Child growth (++)
Neurodevelopment ()
Impaired sperm
parameters (+)
Yes (+)
?
?
?
?
Chlordane 1978 2B NHL ()
Leukaemia (+)
Prostate cancer ()
Testicular cancer (+)
Yes (+)
Yes (+)
Yes (+)
?
Lindane (c-HCH) 2002/2004/2006/2007 2B(d) NHL (++)
Leukaemia (+)
Yes (++)
Yes (++)
b-HCH 2002/2004/2006/2007 2B(d) Prostate cancer () ?
Toxaphene 2004 2B NHL(c) ()
Leukaemia (+)
Melanoma (+)
Yes (++)
Yes (++)
Yes (+)
Chlordecone 2004 2B Cancer prostate (++)
Impaired sperm
parameters (+)
Neurodevelopment (+)
Yes (+)
?
?
Heptachlor 1978 2B Leukaemia (+) Yes (+)
Endosulfan 2005 Not classiﬁed ? Yes (+)
Hexachlorobenzene
(HCB)
1978 2B Child growth (+) ?
Terbufos 2003/2007 NHL (+)
Leukaemia (+)
?
?
Diazinon 2008 NHL (+)
Leukaemia (+)
?
?
Malathion 2008 3 NHL (++)
Leukaemia (+)
Neurodevelopment (+)
Impaired sperm
parameters (+)
Yes (+)
Yes (+)
?
?
Fonofos 2003 NHL ()
Leukaemia (+)
Prostate cancer (+)
?
?
?
Parathion 2002 3 Melanoma (+) ?
Coumaphos Never notiﬁed and
authorised in the EU
Prostate cancer (+) ?
Carbaryl 2008 3 NHL ()
Melanoma (+)
Impaired sperm
parameters (+)
?
?
?
Propoxur 2002 Neurodevelopment (+)
Fetal growth (+)
?
?
Carbofuran 2008 NHL ()
Prostate cancer (+)
?
?
Butylate 2003 NHL (+)
Prostate cancer (+)
?
?
EPTC 2003 Leukaemia (+) ?
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A.2.5. Recommendations
The analysis of the available epidemiological and mechanistic data on some active substances
suggests several recommendations for developing further research:
a) Knowledge on population exposure to pesticides should be improved
1) Collect information about use of active substances by farmers
2) Conduct ﬁeld studies to measure actual levels of exposure
3) Monitor exposure during the full occupational life span
4) Measure exposure levels in air (outdoor and indoor), water, food, soil
5) Collect information on acute poisonings
6) Improve analytical methods for biomonitoring and external measurements
7) Allow researchers to have access to extensive formulation data (solvents, co-formulants, etc.).
b) Research potential links between exposure and health outcomes
1) Characterise substances or groups of substances causing health outcomes
2) Focus on susceptible individuals or groups of individuals (gene polymorphism of enzymes, etc.)
3) Focus on exposure windows and susceptibility (pregnancy, development)
4) Bridge the gap between epidemiology and toxicology (mode of action)
5) Improve knowledge on mixture toxicity
6) Foster new approaches of research (in vitro and in silico models, omics, etc.).
A.3. Similarities and differences between the EFSA External Scientiﬁc
Report and the INSERM report
The two reports discussed herein have used different methodologies. Yet, their results and
conclusions in many cases agree. The INSERM report is limited to predeﬁned outcomes and it
attempted to investigate the biological plausibility of epidemiological studies by reviewing toxicological
data as well, meanwhile the EFSA report is a comprehensive systematic review of all available
epidemiological studies that were published during an approximately 5 year window.
The differences between the reports are shown in Table A.7 and are related to the time period of
search (i.e. both reports did not assess the same body of published data), different criteria for
eligibility of studies and different approaches to summarising the evidence across and within outcomes.
Active substance Ban in the EU
IARC
classiﬁcation
Strength of
presumption(a)
Biological
plausibility(b)
Atrazine 2005 3 NHL ()
Fetal growth (+)
Yes (+)
?
Cyanizine 2002/2007 NHL(c) () ?
Permethrin 2002 3 Prostate cancer (+) Yes (+)
Fenvalerate 1998 Not classiﬁed Impaired sperm
parameters (+)
?
Methyl bromide 2010 3 Testicular cancer (+) ?
Dibromoethane Banned 2A Impaired sperm
parameters (+)
?
Dibromochloropropane
(DBCP)
Banned 2B Impaired sperm
parameters/impaired
fertility (+++) (causal
association)
Yes (+++) (mode
of action
elucidated)
Paraquat 2007 Parkinson’s disease (+) Yes (++)
Rotenone 2011 Parkinson’s disease (+) Yes (++)
Alachlor 2008 Leukaemia (+) Yes (++)
(a): Scoring system: strong presumption (++), moderate presumption (+), weak presumption ().
(b): Scoring system: (++): hypothesis supported by 3 mechanisms of toxicity, (+): hypothesis supported by at least one
mechanism of toxicity.
(c): Population with t(14,18) translocation, only.
(d): Technical mixture (a-, b-, and c-HCH).
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Overall, the INSERM report identiﬁed a greater number of associations with adverse health effects
than the EFSA report. However, a well-documented association with pesticide exposure was claimed by
both reports for the same health outcomes (childhood leukaemia, Parkinson’s disease).
A.4. The Ontario College of Family Physicians Literature review
(OCFPLR)
In 2004, the Ontario College of Family Physicians (Ontario, Canada) reviewed the literature
published between 1992 and 2003 on major health effects associated with pesticide exposure. The
authors concluded that positive associations exist between solid tumours and pesticide exposures as
shown in Table A.8. They noted that in large well-designed cohort studies these associations were
consistently statistically signiﬁcant, and the relationships were most consistent for high exposure levels.
They also noted that dose–response relationships were often observed, and they considered the
quality of studies to be generally good.
Table A.7: Comparison between methods used in the EFSA External Scientiﬁc Report and the
INSERM Report
EFSA External report INSERM report
Articles reviewed 602/43,000 NR
Language Yes NR
Search strategy (key words, MeSH) Yes NR
Search database Yes (4) NR
Years of publication 2006–2012 (Sep) ? to 2012 (Jun)
Type of epi studies assessed Cross-sectional Cross-sectional
Case–control Case–control
Cohort Cohort
Inclusion criteria Yes NR
Exclusion criteria Yes NR
Methodological quality assessment Yes (12 criteria) NR
Exposure groups(a) Yes Yes
Exposure assessment Yes Yes
Quantitative synthesis (meta-analysis) Yes No
Qualitative synthesis(c) Yes Yes
Supporting Toxicological data NI Yes
Associations with individual pesticides Yes Yes
Health outcomes studied
Haematological cancer Yes Yes
Solid tumours Yes Yes
Childhood cancer Yes Yes
Neurodegenerative disorders Yes Yes
Neurodevelopmental outcomes Yes Yes
Neuropsychiatric disturbances(b) No Yes
Reproductive and developmental Yes Yes
Endocrine Yes NI
Metabolism Yes Yes
Immunological Yes NI
Respiratory Yes NI
NR: not reported; NI: not investigated.
(a): Exposure type (environmental, occupational, etc.) and period (general population, children, etc.).
(b): E.g. depressive disorders.
(c): Add explanation.
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The report concluded that there was compelling evidence of a link between pesticide exposure and
the development of non-Hodgkin’s lymphoma (NHL), and also clear evidence of a positive association
between pesticide exposure and leukaemia. The authors also claimed to have found consistent ﬁndings
of a number of nervous system effects, arising from a range of exposure time courses.
Table A.8: Health Effects considered in the Ontario College of Family Physicians review, 2004
Endpoint
Associations identiﬁed by the Ontario College, pesticide (if
differentiated), study type, (no. of studies/total no. of studies)
A) Cancer
1. Lung ve cohort (1/1)
+ve case–control (1/1)
+ve carbamate, phenoxy acid, case–control (1/1)
2. Breast +ve case–control (2/4)
+ve ecological (1/1)
+ve triazine, ecological (1/1)
ve atrazine, ecological (1/1)
3. Colorectal
4. Pancreas +ve cohort (1/1)
+ve case–control (2/2)
5. Non-Hodgkin’s lymphoma +ve cohort (9/11)
+ve case–control (12/14)
+ve ecological (2/2)
6. Leukaemia +ve cohort (5/6)
+ve case–control (8/8)
ve ecological (1/1)
+ve lab study (1/1)
7. Brain +ve cohort (5), similar case–control (5)
8. Prostate +ve cohort (5/5) case–control (2/2) ecological (1/1)
9. Stomach
10. Ovary
11. Kidney +ve pentachlorophenol cohort (1/1)
+ve cohort (1/1)
+ve case–control (4/4)
12. Testicular
B) Non-Cancer
1) Reproductive effects +ve glyphosate
Congenital malformations +ve pyridyl derivatives
Fecundity/time to pregnancy Suggest impaired
Fertility
Altered growth Possible +ve association, but further study required
Fetal death Suggested association
Mixed outcomes
2) Genotoxic/immunotoxic
Chromosome aberrations
+ve Synthetic pyrethroids (1)
+ve organophosphates (1)
+ve fumigant and insecticide applicators
NHL rearrangements +ve fumigant and herbicide applicators
3) Dermatologic
4) Neurotoxic Mental & emotional
impact
+ve
Functional nervous system impact + ve organophosphate/carbamate poisoning
Neurodegenerative impacts (PD) +ve cohort (4/4)
+ve case–control (2/2)
+ve ecological (1/1)
+ve: positive; ve: negative.
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Such strong conclusions found favour with Non-Governmental organisations (NGOs) and raised
questions among some Regulatory Authorities. The Advisory Committee on Pesticides (ACP), at that
time an UK government independent advisory committee, was asked to provide an evaluation of the
outcome of the Ontario College review. The committee membership included one epidemiologist and
the committee consulted ﬁve other epidemiologists involved in providing independent advice to other
government committees. They all agreed that the review had major shortcomings (e.g. exact search
strategy and selection criteria not speciﬁed, selective reporting of results, inadequate understanding
and consideration of relevant toxicology, insufﬁcient attention to routes and levels of exposure, not
justiﬁed conclusions, etc.). Overall, the conclusions of the Ontario College review were considered not
to be supported by the analysis presented. In 2012, the Ontario review authors published an update of
their evaluation; in their second report they used a very similar approach but offered more detail
concerning the inclusion criteria used. This example is a reminder of the risk of over interpretation of
epidemiological studies. In particular, a causal inference between exposure and the occurrence of
adverse health effects is often made, but this represents an association that should be further
assessed.
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Annex B – Human biomonitoring project outsourced by EFSA23
In 2015, EFSA outsourced a project to further investigate the role of HBM in occupational health
and safety strategies as a tool for reﬁned exposure assessment in epidemiological studies and to
contribute to the evaluation of potential health risks from occupational exposure to pesticides. It was
in fact recognised that exposure assessment is a key part of all epidemiological studies and
misclassiﬁcation of exposure and use of simple categorical methods are known to weaken the ability of
a study to determine whether an association between contact and ill-health outcome exists; at
present, this limits integration of epidemiological ﬁndings into regulatory risk assessment.
The consortium formed by Risk & Policy Analysts Limited (RPA), IEH Consulting Limited (IEH) and
the Health&Safety Laboratory (HSL) carried out a systematic literature review for the period 1990–2015
with the aim to provide an overview on the use of HBM as a tool for occupational exposure assessment
reﬁnement, identifying advantages, disadvantages and needs for further development (ﬁrst objective).
The search identiﬁed 2096 publications relating to the use of HBM to assess occupational exposure to
pesticides (or metabolites). The outcome of the search (Bevan et al., 2017) indicated that over the past
10–20 years there has been an expansion in the use of HBM, especially into the ﬁeld of environmental
and consumer exposure analysis. However, further improvement of the use of HBM for pesticide
exposure assessment is needed, in particular with regards to: development of strategies to improve or
standardise analytical quality, improvement of the availability of reference material for metabolites,
integration of HBM data into mathematical modelling, exposure reconstruction, improvements in
analytical instrumentation and increased availability of human toxicology data.
The contractors performed a review of available HBM studies/surveillance programmes conducted in
EU/US occupational settings to identify pesticides (or metabolites) both persistent and not persistent,
for which biomarkers of exposure (and possibly effect) were available and validated (second
objective). A two-tiered screening process that included quality scoring for HBM, epidemiological and
toxicological aspects, was utilised to identify the most relevant studies, resulting in 178 studies for
critical review. In parallel with the screening of identiﬁed studies, a Master Spreadsheet was designed
to collate data from these papers, which contained information relating to: study type; study
participants; chemicals under investigation; biomarker quality check; analytical methodology; exposure
assessment; health outcome/toxicological endpoint; period of follow-up; narrative of results; risk of
bias and other comments.
HBM has been extensively used for monitoring worker exposure to a variety of pesticides.
Epidemiological studies of occupational pesticide use were seen to be limited by inadequate or
retrospective exposure information, typically obtained through self-reported questionnaires, which can
potentially lead to exposure misclassiﬁcation. Some examples of the use of job exposure or crop
exposure matrices were reported. However, little validation of these matrix studies against actual
exposure data had been carried out. Very limited data was identiﬁed that examined seasonal exposures
and the impact of PPE, and many of the studies used HBM to only assess one or two speciﬁc
compounds. A wide variety of exposure models are currently employed for health risk assessments and
biomarkers have also often been used to evaluate exposure estimates predicted by a model.
From the 178 publications identiﬁed to be of relevance, 41 individual studies included herbicides, and
of these, 34 separate herbicides were identiﬁed, 15 of which currently have approved for use in the EU.
Similarly, of the 90 individual studies that included insecticides, 79 separate insecticides were identiﬁed,
of which 18 currently have approved for use in the EU. Twenty individual studies included fungicides,
with 34 separate fungicides being identiﬁed and of these 22 currently have approved for use in the EU.
The most studied herbicides (in order) were shown to be: 2,4-D > atrazine > metolachlor = MCPA >
alachlor = glyphosate. Similarly, the most studied insecticides (in order) were: chlorpyrifos > permethrin
> cypermethrin = deltamethrin > malathion, and the most studied fungicides were: captan > mancozeb >
folpet.
Current limitations comprised the limited number of kinetic data from humans, particularly with
respect to the ADME of individual pesticides in human subjects, which would allow more accurate HBM
sampling for all routes of exposure. A wider impact of this is on the development of PBPK models for
the risk assessment of pesticides, which rely on toxicokinetic data, and on validation of currently used
exposure assessment models. Further limitations currently impacting on the use of HBM in this ﬁeld
are a lack of large prospective cohort studies to assess long term exposure to currently used
pesticides.
23 Bevan et al. (2017).
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The evidence identiﬁed has been used to help formulate recommendations on the implementation
of HBM as part of the occupational health surveillance for pesticides in Europe. Some key issues were
considered that would need to be overcome to enable implementation. These included the setting of
priorities for the development of new speciﬁc and sensitive biomarkers, the derivation and adoption of
health-based guidance values, development of QA schemes to validate inter-laboratory measurements,
good practice in ﬁeld work and questionnaire design, extension of the use of biobanking and the use
of HBM for post-approval monitoring of pesticide safety.
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Annex C – Experience of international regulatory agencies in regards to
the integration of epidemiological studies for hazard identiﬁcation
C.1. WHO-International Agency for Research on Cancer (IARC)
The IARC Monographs on the Evaluation of Carcinogenic Risks to Humans of the International
Agency for Research on Cancer (IARC) is a programme established four decades ago to assess
environmental exposures that can increase the risk of human cancer. These include individual
chemicals and chemical mixtures, occupational exposures, physical agents, biological agents and
lifestyle factors.
IARC assembles international interdisciplinary Working Groups of scientists to review and assess the
quality and strength of evidence from scientiﬁc publications and perform a hazard evaluation to assess
the likelihood that the agents of concern pose a cancer risk to humans. In particular, the tasks of IARC
Working Group Members include the evaluation of the results of epidemiological and other
experimental studies on cancer, to evaluate data on the mechanisms of carcinogenesis and to make an
overall evaluation of the carcinogenicity of the exposure to humans.
The Monographs are widely used and referenced by governments, organisations, and the public
around the world to set preventive and control public health measures.
The Preamble24 to the IARC Monographs explains the scope of the programme, the scientiﬁc
principles and procedures used in developing a Monograph, the types of evidence considered and the
scientiﬁc criteria that guide the evaluations. The scope of the monographs broadened to include not
only single chemicals but also groups of related chemicals, complex mixtures, occupational exposures,
physical and biological agents and lifestyle factors. Thus, the title of the monographs reads ‘Evaluation
of carcinogenic risks to humans’.
Relevant epidemiological studies, cancer bioassays in experimental animals, mechanistic data, as
well as exposure data are critically reviewed. Only reports that have been published or accepted for
publication in the openly available scientiﬁc literature are included. However, the inclusion of a study
does not imply acceptance of the adequacy of the study design or of the analysis and interpretation of
the results. Qualitative aspects of the available studies are carefully scrutinised.
Although the Monographs have emphasised hazard identiﬁcation, the same epidemiological and
experimental studies used to evaluate a cancer hazard can also be used to estimate a dose–response
relationship. A Monograph may undertake to estimate dose–response relationships within the range of
the available epidemiological data, or it may compare the dose–response information from
experimental and epidemiological studies.
The structure of a Monograph includes the following sections:
1) Exposure data
2) Studies of cancer in humans
3) Studies of cancer in experimental animals
4) Mechanistic and other relevant data
5) Summary
6) Evaluation and rationale.
Human epidemiological data are addressed in point 2, where all pertinent epidemiological studies
are assessed. Studies of biomarkers are included when they are relevant to an evaluation of
carcinogenicity to humans.
The IARC evaluation of epidemiological studies includes an assessment of the following criteria:
types of studies considered (e.g. cohort studies, case–control studies, correlation (or ecological)
studies and intervention studies, case reports), quality of the study (e.g. bias, confounding, biological
variability and the inﬂuence of sample size on the precision of estimates of effect), meta analysis and
pooled analyses, temporal effects (e.g. temporal variables, such as age at ﬁrst exposure, time since
ﬁrst exposure, duration of exposure, cumulative exposure, peak exposure), use of biomarkers in
epidemiological studies (e.g. evidence of exposure, of early effects, of cellular, tissue or organism
responses), and criteria for causality.
With speciﬁc reference to causality, a judgement is made concerning the strength of evidence that
the agent in question is carcinogenic to humans. In making its judgement, the Working Group
24 http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf
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considers several criteria for causality (Hill, 1965). A strong association (e.g. a large relative risk) is
more likely to indicate causality. However, it is recognised that weak associations may be important
when the disease or exposure is common. Associations that are replicated in several studies of
different design under different exposure conditions are more likely to represent a causal relationship
than isolated observations from single studies. In case of inconsistent results among different
investigations, possible reasons (e.g. differences in exposure) are sought, and high quality studies are
given more weight compared to less methodologically sound ones. Risk increasing with the exposure is
considered to be a strong indication of causality, although the absence of a clear dose–response effect
is not necessarily evidence against a causal relationship. The demonstration of a decline in risk after
cessation of or reduction in exposure also supports a causal interpretation of the ﬁndings. Temporality,
precision of estimates of effect, biological plausibility and coherence of the overall data are considered.
Biomarkers information may be used in an assessment of the biological plausibility of epidemiological
observations. Randomised trials showing different rates of cancer among exposed and unexposed
individuals provide particularly strong evidence for causality.
When epidemiological studies show little or no indication of an association between an exposure
and cancer, a judgement of lack of carcinogenicity can be made. In those cases, studies are
scrutinised to assess the standards of design and analysis described above, including the possibility of
bias, confounding or misclassiﬁcation of exposure. In addition, methodologically sound studies should
be consistent with an estimate of effect of unity for any observed level of exposure, provide a pooled
estimate of relative risk near to unity, and have a narrow conﬁdence interval. Moreover, no individual
study nor the pooled results of all the studies should show any increasing risk with increasing level of
exposure. Evidence of lack of carcinogenicity can apply only to the type(s) of cancer studied, to the
dose levels reported, and to the intervals between ﬁrst exposure and disease onset observed in these
studies. Experience with human cancer indicates that the period from ﬁrst exposure to the
development of clinical cancer is sometimes longer than 20 years, and latent periods substantially
shorter than 30 years cannot provide evidence for lack of carcinogenicity.
Finally, the body of evidence is considered as a whole, in order to reach an overall evaluation which
summarises the results of epidemiological studies, the target organs or tissues, dose–response
associations, evaluations of the strength of the evidence for human and animal data, and the strength
of the mechanistic evidence.
At the end of the overall evaluation, the agent is assigned to one of the following groups: Group 1,
the agent is carcinogenic to humans; Group 2A, the agent is probably carcinogenic to humans; Group
2B, the agent is possibly carcinogenic to humans; Group 3, the agent is not classiﬁable as to its
carcinogenicity to humans; Group 4, the agent is probably not carcinogenic to humans.
The categorisation of an agent is a matter of scientiﬁc judgement that reﬂects the strength of the
evidence derived from studies in humans and in experimental animals and from mechanistic and other
relevant data. These categories refer only to the strength of the evidence that an exposure is
carcinogenic and not to the extent of its carcinogenic activity (potency).
For example, Group 1: The agent is carcinogenic to humans. This category is used when there is
sufﬁcient evidence of carcinogenicity in humans. Exceptionally, an agent may be placed in this
category when evidence of carcinogenicity in humans is less than sufﬁcient but there is sufﬁcient
evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the
agent acts through a relevant mechanism of carcinogenicity.
Although widely accepted internationally, there have been criticisms of the classiﬁcation of
particular agents in the past, and more recent criticisms have been directed at the general approach
adopted by IARC for such evaluations possibly motivating publication of a rebuttal (Pearce et al.,
2015).
C.2. The experience of US-EPA in regards to the integration of
epidemiological studies in risk assessment
The US Environmental Protection Agency’s Ofﬁce of Pesticide Programs (OPP) is the governmental
organisation in the US responsible for registering and regulating pesticide products.25 As part of this
activity and prior to any permitted use of a pesticide, OPP evaluates the effects of pesticides on human
health and the environment. EPA receives extensive hazard and exposure information to characterise
25 See https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks for general information on pesticide science and
assessing pesticide risks.
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the risks of pesticide products through the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)
and the Federal Food, Drug, and Cosmetic Act (FFDCA). Information on the toxic effects of pesticides
is generally derived from studies with laboratory animals conducted by pesticide registrants and
submitted to EPA.
In the past, information from well-designed epidemiology studies on pesticides has not been
typically available to inform EPA’s evaluations of potential risks that might be associated with exposure
to pesticides. With an increasing number of epidemiology studies entering the literature which explore
the putative associations between pesticides exposure and health outcomes, EPA is putting additional
emphases on this source of information. This is especially true for the wealth of studies deriving from
the Agricultural Health Study26 (AHS), a large, well-conducted prospective cohort study following close
to 90,000 individuals over more than 20 years and from the Children’s Environmental Health and
Disease Prevention Research Centers.27 EPA intends to make increasing use of these epidemiology
studies in its human health risk assessment with the goal of using such epidemiological information in
the most scientiﬁcally robust and transparent way.
C.2.1. OPP Epidemiological Framework Document
As an early ﬁrst step in this process, EPA-OPP developed a proposed epidemiological framework
document released as a draft in 2010, ‘Framework for Incorporating Human Epidemiologic and
Incident Data in Health Risk Assessment’ (US-EPA, 2010a). The 2010 draft framework was reviewed
favourably by the FIFRA Scientiﬁc Advisory Panel (SAP) in February, 2010 (US-EPA, 2010b). This
document was recently updated in 2016 to the ‘Ofﬁce of Pesticide Programs’ Framework Document for
Incorporating Human Epidemiology and Incident Data in Risk Assessments for Pesticides’ (US-EPA,
2016). The revised and updated 2016 Framework document proposes that human information like that
found in epidemiology studies (in addition to human incident databases, and biomonitoring studies)
along with experimental toxicological information play a signiﬁcant role in this new approach by
providing insight into the effects caused by actual chemical exposures. In addition, epidemiological/
molecular epidemiological data can guide additional analyses, identify potentially susceptible
populations and new health effects and potentially conﬁrming existing toxicological observations. The
concepts in the 2016 Framework are based on peer-reviewed robust principles and tools and rely on
many existing guidance documents and frameworks (Table C.1) for reviewing and evaluating
epidemiology data. It is also consistent with updates to the World Health Organization/International
Programme on Chemical Safety mode of action (MoA)/human relevance framework which highlight the
importance of problem formulation and the need to integrate information at different levels of
biological organisation (Meek et al., 2014). Furthermore, it is consistent with recommendations by the
National Academy of Sciences’ National Research Council (NAS/NRC) in its 2009 report Science and
Decisions (NRC, 2009) in that the framework describes the importance of using problem formulation at
the beginning of a complex scientiﬁc analysis. The problem formulation stage is envisioned as starting
with a planning dialogue with risk managers to identify goals for the analysis and possible risk
management strategies. This initial dialogue provides the regulatory context for the scientiﬁc analysis
and helps deﬁne the scope of such an analysis. The problem formulation stage also involves
consideration of the available information regarding the pesticide use/usage, toxicological effects of
concern, exposure pathways, and duration along with key gaps in data or scientiﬁc information.
26 See https://aghealth.nih.gov/
27 See https://www.epa.gov/research-grants/niehsepa-childrens-environmental-health-and-disease-prevention-research-centers
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Brieﬂy, this EPA Framework document describes the scientiﬁc considerations that the Agency will
weigh in evaluating how such epidemiological studies and scientiﬁc information can be integrated into
risk assessments of pesticide chemicals and also in providing the foundation for evaluating multiple
lines of scientiﬁc evidence in the context of the understanding of the adverse outcome pathway (or
MoA). The framework relies on and espouses standard practices in epidemiology, toxicology and risk
assessment, but allows for the ﬂexibility to incorporate information from new or additional sources.
One of the key components of the Agency’s framework is the use the MoA framework/adverse
outcome pathway concept as a tool for organising and integrating information from different sources
to inform the causal nature of links observed in both experimental and observational studies. MoA
(Boobis et al., 2008; Simon et al., 2014; Meek et al., 2014) and adverse outcome pathway (Ankley
et al., 2010) provide important concepts in the integrative analysis discussed in the Framework
document. Both a MoA and an adverse outcome pathway are based on the premise that an adverse
effect caused by exposure to a compound can be described by a series of causally linked biological key
events that result in an adverse human health outcome, and have as their goal a determination of
how exposure to environmental agents can perturb these pathways, thereby causing a cascade of
subsequent key events leading to adverse health effects.
A number of concepts in the Framework are taken from two reports from the National Academies,
Science and Decisions: Advancing Risk Assessment (NAS 2009) and Toxicity Testing on the 21st
Century (NAS 2007). These two NRC reports advocate substantial changes in how toxicity testing is
performed, how such data are interpreted, and ultimately how regulatory decisions are made. In
particular, the 2007 report on 21st century toxicity testing advocates a decided shift away from the
current focus of using apical toxicity endpoints to using toxicity pathways to better inform toxicity
testing, risk assessment, and decision-making.
The MoA framework begins with the identiﬁcation of the series of key events that are along the
causal path and established on weight of evidence using criteria based on those described by Bradford
Hill taking into account factors such as dose–response, temporal concordance, biological plausibility,
coherence and consistency. Speciﬁcally, the modiﬁed Bradford Hill Criteria (Hill, 1965) are used to
evaluate the experimental support that establishes key events within a MoA or an adverse outcome
pathway, and explicitly considers such concepts as strength, consistency, dose response, temporal
Table C.1: Key guidance documents and frameworks used by OPP (from US-EPA, 2016)
1983 Risk Assessment in the Federal Government. Managing the Process
NAS 1994 Science and Judgement
2007 Toxicity testing in the 21st Century
2009 Science and Decisions: Advancing Risk Assessment
WHO/
IPCS
2001–2007 Mode of Action/Human Relevance Framework
2005 Chemical Speciﬁc Adjustment Factors (CSAF)
2014 New Development in the evolution and application of the WHO/IPCS framework
on mode of action/species concordance analysis
EPA 1991–2005 Risk Assessment Forum Guidance for Risk Assessment (e.g. guidelines for
carcinogen, reproductive, developmental, neurotoxicity, ecological, and exposure
assessment, guidance for benchmark dose modelling, review of reference dose
and reference concentration processes)
http://www.epa.gov/risk_assessment/guidance.htm
2000 Science Policy Handbook on Risk Characterisation
http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=40000006.txt
2006 Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK)
Models and Supporting Data for Risk Assessment
2014 Framework for Human Health Risk Assessment to Inform Decision-making
2014 Guidance for Applying Quantitative Data to Develop Data-Derived Extrapolation
Factors for Inter-species and Intra-species Extrapolation
2001 Aggregate Risk Assessment
https://www.epa.gov/sites/production/files/2015-07/documents/aggregate.pdf
OPP 2001 and 2002 Cumulative Risk Assessment
http://www.epa.gov/ncer/cra/
OECD 2013 Organisation for Economic Co-operation and Development Guidance Document
on Developing and Assessing Adverse Outcome Pathways
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concordance, and biological plausibility in a weight of evidence analysis. Using this analytic approach,
epidemiological ﬁndings can be evaluated in the context of other human information and experimental
studies to evaluate consistency, reproducibility, and biological plausibility of reported outcomes and to
identify areas of uncertainty and future research. Figure C.1 below (adapted from NRC, 2007)
suggests how different types of information relate to each other across multiple levels of biological
organisation (ranging from the molecular level up to population-based surveillance) and is based on
the rapidly evolving scientiﬁc understanding of how genes, proteins, and small molecules interact to
form molecular pathways that maintain cell function in humans.
C.2.2. Systematic reviews: Fit for purpose
The National Academies’ National Research Council (NRC) in its review of EPA’s IRIS program
deﬁnes systematic review as ‘a scientiﬁc investigation that focuses on a speciﬁc question and uses
explicit, prespeciﬁed scientiﬁc methods to identify, select, assess, and summarise the ﬁndings of similar
but separate studies’.28 In recent years, the NRC has encouraged the agency to move towards
systematic review processes to enhance the transparency of scientiﬁc literature reviews that support
chemical-speciﬁc risk assessments to inform regulatory decision-making.29
Consistent with NRC’s recommendations, EPA-OPP employs ﬁt-for-purpose systematic reviews that
rely on transparent methods for collecting, evaluating and integrating the scientiﬁc data supporting its
decisions. As such, the complexity and scope of each systematic review will vary among risk
assessments. EPA-OPP starts with scoping/problem formulation followed by data collection, data
evaluation, data integration and summary ﬁndings with critical data gaps identiﬁed.
Systematic reviews often use statistical (e.g. meta-analysis) and other quantitative techniques to
combine results of the eligible studies, and can use a semi-quantitative scoring system to evaluate the
levels of evidence available or the degree of bias that might be present. For EPA’s Ofﬁce of Pesticide
Programs, such a Tier III (systematic review) assessment conducted as part of its regulatory review
process would involve review of the pesticide chemical undergoing review and a speciﬁc associated
suspected health outcome (as suggested by the initial Tier II assessment).
A number of federal and other organisations in the US are evaluating or have issued guidance
documents for methods to conduct such systematic reviews and a number of frameworks have been
Greater toxicological Greater risk
relevance
understanding
Figure C.1: Source to Outcome Pathway: Chemical effects across levels of biological organisation
(adapted from NRC, 2007)
28 http://dels.nas.edu/Report/Review-Integrated-Risk/18764
29 NRC, 2011. ‘Review of the Environmental Protection Agency’s Draft IRIS Assessment of Formaldehyde’ available for download
at https://www.nap.edu/catalog/13142/review-of-the-environmental-protection-agencys-draft-iris-assessment-of-formaldehyde;
See also NRC, 2014. ‘Review of EPA’s Integrated Risk Information System (IRIS) Process’ available for download at https://
www.nap.edu/catalog/18764/review-of-epas-integrated-risk-information-system-iris-process
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developed. These include the EPA IRIS programs’ approach,30 the National Toxicology Programs’ Ofﬁce
of Health Assessment and Translation (NTP/OHAT) approach31 the Cochran Collaboration’s approach,32
the Campbell Collaboration and the Navigation Guide,33 with this latter described in a series of articles in
the journal Environmental Health Perspectives. Each broadly shares four deﬁned steps: data collection,
data evaluation, data integration, and summary/update. For example, The Cochrane Collaboration in its
Cochrane Handbook for Systematic Reviews of Interventions for evidence-based medicine lists a number
of the important key characteristics of a systematic review to be (from US-EPA, 2016):
• a clearly stated set of objectives with predeﬁned eligibility criteria for studies;
• an explicit, reproducible methodology;
• a systematic search that attempts to identify all studies that would meet the eligibility criteria;
• an assessment of the validity of the ﬁndings from the identiﬁed studies;
• a systematic presentation and synthesis of the characteristics and ﬁndings of the included
studies.
As described and elaborated in the following sections of this Annex, OPP’s approach to review and
integration of epidemiological data into pesticide risk assessments takes a tiered approach which each
tier appropriately ﬁt-for-purpose in the sense that is considers ‘the usefulness of the assessment for its
intended purpose, to ensure that the assessment produced is suitable and useful for informing the
needed decisions (US-EPA, 2012) and that required resources are matched or balanced against any
projected or anticipated information gain from further more in-depth research. A Tier 1 assessment is
either a scoping exercise or an update to a scoping exercise in which a research and evaluation is
limited to studies derived from the AHS. A Tier II assessment involves a broader search of the
epidemiological literature, comprehensive data collection, and a deeper, more involved data evaluation
and is more extensive but is generally limited in scope to epidemiology and stops short of
multidisciplinary integration across epidemiology, human poisoning events, animal toxicology and
adverse outcome pathways. A Tier III assessment is a complete systematic review with data
integration and more extensive data evaluation and extraction and may involve more sophisticated
epidemiological methods such as meta-analysis and meta-regression, causal inference/causal diagrams,
and quantitative bias and sensitivity analyses, among others.
C.2.3. Current and Anticipated Future EPA Epidemiology Review
Practices
C.2.3.1. Tier I (Scoping & Problem Formulation) and Tier II (more extensive
literature search)
Currently at EPA, epidemiology review of pesticides is conducted in a tiered process as the risk
assessment develops, as brieﬂy described above. The purpose of this early Tier I/scoping epidemiology
report is to ensure that highly relevant epidemiology studies are considered in the problem
formulation/scoping phase of the process and, if appropriate, fully reviewed in the (later) risk
assessment phase of the process. In Tier I, EPA-OPP focuses on well-known high quality cohort studies
which focus on pesticide issues, particularly the Agricultural Health Study (AHS). The AHS is a federally
funded study that evaluates associations between pesticide exposures and cancer and other health
outcomes and represents a collaborative effort between the US National Cancer Institute (NCI), the
National Institute of Environmental Health Sciences (NIEHS), CDC’s National Institute of Occupational
Safety and Health (NIOSH) and the US EPA. The AHS participant cohort includes more than 89,000
licensed commercial and private pesticide applicators and their spouses from Iowa and North Carolina.
Enrolment occurred from 1993 to 1997, and data collection is ongoing. The AHS maintains on its
website a list of publications associated with and using the AHS cohort (see https://aghealth.nih.gov/
news/publications.html).
If the pesticide of interest has been investigated as part of the AHS (www.aghealth.org), a
preliminary (Tier I/scoping) review of these studies is performed early on in the evaluation as the
30 See https://www.epa.gov/iris/advancing-systematic-review-workshop-December-2015
31 See http://ntp.niehs.nih.gov/pubhealth/hat/noms/index-2.html and NTP’s ‘Handbook for Conducting a Literature-based
Assessment Using OHAT Approach for Systematic Review and Evidence Integration’ at https://ntp.niehs.nih.gov/ntp/ohat/pub
s/handbookjan2015_508.pdf
32 See http://handbook.cochrane.org/
33 See http://ehp.niehs.nih.gov/1307175/
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docket (or ‘dossier’) is opened as part of EPA’s ‘Scoping’ analysis. In this early Tier I/scoping phase,
basic epidemiological ﬁndings and conclusions from the Agricultural Health Study are described in a
Tier I/scoping document which is designed to simply summarise in brief form the pertinent conclusions
of various AHS study authors if there are AHS ﬁndings relevant to a the pesticide undergoing review;
this Tier I scoping review is not designed to offer detailed content, critical evaluation, or evidence
synthesis, and may only touch on summarised highlights of the relevant AHS -related journal articles.
If other high-quality non-AHS studies are available like those from the Children’s Environmental Health
and Disease Prevention Research Centres, these may be similarly summarised in this Tier I/scoping
epidemiological review as well. Again, no critique or synthesis of the literature is offered. In some
cases, the Tier I/scoping review may conclude that no additional epidemiological review of available
evidence is further required. Alternatively, it may recommend that further review is necessary as part
of a more involved Tier I/update or Tier II assessment.
A Tier I/update assessment is generally completed 1" to 3 years following the completion of the
Tier I/scoping assessment and is issued, like the Tier II discussed below, along with and as part of
the Draft Human Health Risk Assessment. Tier I/update assessments perform a thorough review of the
available literature in the AHS. A Tier I/update assessment reviews, summarises and evaluates in a
qualitative, narrative summary (including reported measures of association), the applicable studies that
are listed on the AHS website.34 Reviews are generally in the form of a narrative, focusing on the key
aspects of studies and their conclusions and include EPA OPP commentary along with summary EPA
OPP conclusions and recommendations for further study, if necessary.
C.2.3.2. Tier II (more extensive literature search)
A Tier II assessment is a more complete review of the available epidemiological evidence and is
generally done only if the earlier Tier I/scoping document suggests a potential for a speciﬁc concern (e.g.
a speciﬁc and credible exposure–disease hypothesis has been advanced and needs to be further
evaluated as part of a more detailed assessment). A Tier II epidemiology assessment, similar to the Tier
I/update, is generally completed 1" to 3 years following the completion of the Tier I assessment and is
issued along with and as part of OPP’s Draft Human Health Risk Assessment; the Tier II evaluation is
considered to be a qualitative narrative review that incorporates certain elements of a systematic review.
For example, a Tier II assessment will include a thorough and complete literature search that is broader
than that of the Tier I/update, including not only the AHS database, but also such databases as PubMed,
Web of Science, Google Scholar and Science Direct, and sometimes others using standardised,
transparent and reproducible query language for which specialised professional library and information
science support is obtained.35 Evidence synthesis by EPA – albeit generally in a qualitative and narrative
form – also occurs in a Tier II assessment, and overall conclusions regarding the body of epidemiological
literature are made. In addition, the Tier II assessment may indicate areas in which further
epidemiological data and studies with respect to speciﬁc hypothesised exposure–health outcome is of
interest for future work. The Tier II assessment document will not generally attempt to integrate the
epidemiological ﬁndings with other lines of evidence such as that from animal toxicology studies or
information from MoAs/AOPs which may be done (separately) to some degree as part of the risk
assessment. To the extent that the Tier II assessment identiﬁes speciﬁc health outcomes putatively
associated with a given pesticide, further investigation and integration across disciplines can
subsequently be done as part of a more comprehensive Tier III assessment (see below).
C.2.3.3. Tier III (Full Systematic Review with Data Integration)
While a Tier II assessment examines a wide range of health outcomes appearing in the
epidemiological literature that are hypothesised to be associated with a given pesticide chemical, a Tier III
assessment might encompass a broader (multidisciplinary) and sometimes more quantitative/statistical
evaluation of at the epidemiological evidence for the association of interest, and it attempts to more
34 https://aghealth.nih.gov/news/publications.html
35 Additional searches conducted under the rubric of epidemiology and biomonitoring/exposure could be done using the NHANES
Exposure Reports (http://www.cdc.gov/exposurereport/); TOXNET (http://toxnet.nlm.nih.gov/); CDC NBP Biomonitoring
Summaries (http://www.cdc.gov/biomonitoring/biomonitoring_summaries.html); ICICADS (http://www.inchem.org/pages/cicad
s.html); ATSDR Toxicological Proﬁles (http://www.atsdr.cdc.gov/toxprofiles/index.asp); IARC Monographs (http://monographs.
iarc.fr/ENG/Monographs/PDFs/; EFSA’s Draft Assessment Report Database (http://dar.efsa.europa.eu/dar-web/provision); and
Biomonitoring Equivalents (https://blog.americanchemistry.com/2014/07/biomonitoring-equivalents-a-valuable-scientific-tool-
for-making-better-chemical-safety-decisions/
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formally integrate this with animal toxicology and MoA/AOP information. Such a Tier III assessment could
take the form of a systematic review of the epidemiological literature which would be performed together
with evaluation of toxicity and adverse outcome pathways. For pesticide chemicals from AHS, a Tier III
analysis would also ideally incorporate the results of evaluations from other high-quality epidemiological
investigations and incorporate ‘Weight of the Evidence’ to a greater degree to reﬂect a more diverse set of
information sources. Results from these investigations would be used to evaluate replication and
consistency with results from the AHS. Early AHS ﬁndings in a number of cases were based on only a small
number of participants that had developed speciﬁc outcomes or a relatively few number of years over
which the participants have been followed. As the AHS cohort ages, the release of second evaluations of
some chemicals from AHS will be based on additional years of follow-up and a greater number of cases
that are expected to provide a more robust basis for interpreting positive and negative associations
between exposure and outcome. In addition, the AHS is increasingly generating a substantial amount of
biochemical, genetic marker, and molecular data to help interpret results from the epidemiological
studies. Such results may further clarify AHS ﬁndings, provide evidence for a biological basis linking
exposures to outcomes, or suggest additional laboratory and observational research that might
strengthen evidence for mechanisms underlying causal pathways. In addition, Tier III analyses also may
take advantage of efforts to bring together information and results from international cohort studies in
the International Agricultural Cohort Consortium (AgriCOH) in which AHS is a member. AgriCOH is actively
working to identify opportunities and approaches for pooling data across studies, and the availability of
these other cohort data should aid in assessing reproducibility and replication of exposure–outcome
relationships as EPA considers, evaluates and weighs the epidemiological data.
C.2.4. OPP’s open literature searching strategies and evaluation of study
quality
An important aspect of the systematic review approach is the thorough, systematic, and
reproducible searching of the open epidemiological literature such that much of the literature that
meets the established eligibility criteria can be located.36 OPP uses speciﬁc databases as part of their
literature search and has speciﬁc guidance on their conduct (for example, OPP’s open literature search
guidance for human health risk assessments37). Evaluation of all relevant literature, application of a
standardised approach for grading the strength of evidence, and clear and consistent summative
language will typically be important components (NRC, 2011). In addition, a high quality exposure
assessment is particularly important for environmental and occupational epidemiology studies.
A second important component of the above systematic review approach is the assessment of the
validity of the ﬁndings from the identiﬁed studies. Generally speaking, the quality of epidemiological
research, sufﬁciency of documentation of the study (study design and results), and relevance to risk
assessment will be considered when evaluating epidemiology studies from the open literature for use
in agency risk assessments. When considering individual study quality, various aspects of the design,
conduct, analysis and interpretation of the epidemiology studies are important. These include (from
US-EPA, 2016):
1) clear articulation of the hypothesis, or a clear articulation of the research objectives if the
study is hypothesis-generating in nature;
2) adequate assessment of exposure for the relevant critical windows of the health effects, the
range of exposure of interest for the risk assessment target population, and the availability of a
dose/exposure–response trend from the study, among other qualities of exposure assessment;
3) reasonably valid and reliable outcome ascertainment (the correct identiﬁcation of those with
and without the health effect in the study population);
4) appropriate inclusion and exclusion criteria that result in a sample population representative
of the target population, and absent systematic bias;
5) adequate measurement and analysis of potentially confounding variables, including
measurement or discussion of the role of multiple pesticide exposure, or mixtures exposure
in the risk estimates observed.
36 Some advocate looking at the grey or unpublished literature to lessen potential issues associated with publication bias.
37 See https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/guidance-identifying-selecting-and-evaluating-open
and speciﬁcally p. 10 of the document ‘Guidance for Considering and Using Open Literature Toxicity Studies to Support Human
Health Risk Assessment’ dated 28.8.2012 at https://www.epa.gov/sites/production/files/2015-07/documents/lit-studies.pdf for
Special Notes on Epidemiologic Data.
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6) overall characterisation of potential systematic biases in the study including errors in the
selection of participation and in the collection of information, including performance of
sensitivity analysis to determine the potential inﬂuence of systematic error on the risk
estimates presented;
7) adequate statistical power for the exposure–outcome assessment, or evaluation of the
impact of statistical power of the study if under-powered to observed effects, and
appropriate discussion and/or presentation of power estimates; and
8) use of appropriate statistical modelling techniques, given the study design and the nature of
the outcomes under study.
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Annex D – Effect size magniﬁcation/inﬂation
As described in the main text of this document, a potential source of bias may result if a study has
low power. This lesser known type of bias is known ‘effect size magniﬁcation’. While it is as widely
known that, generally small, low-powered studies can result in false negatives since the study power is
inadequate to reliably detect a meaningful effect size, it is less well known that these studies can result
in inﬂation of effect sizes if those estimated effects are required to pass a statistical threshold (e.g. the
common p < 0.05 threshold used for statistical signiﬁcance) to be judged important, relevant, or
‘discovered’. This effect – variously known as effect size magniﬁcation, the ‘winners curse’, truth
inﬂation, or effect size inﬂation – is a phenomenon by which a ‘discovered’ association (i.e. one that
has passed a given threshold of statistical signiﬁcance to be judged meaningful) from a study with
suboptimal power to make that discovery will produce an observed effect size that is artiﬁcially and
systematically inﬂated.
Such truth inﬂation manifests itself as (systematic) bias away from the null in studies that achieve
statistical signiﬁcance in instances where studies are underpowered (Reinhart, 2015). This is because
low-powered (and thus generally smaller) studies are more likely to have widely varying results and
thus be more likely to be affected by random variation among individuals than larger ones. More
speciﬁcally, the degree of effect size magniﬁcation that may be observed in any study depends, in
part, on how widely varying the results of a study is expected to be and this depends on the power of
the study; low powered studies tend to produce greater degrees of effect size magniﬁcation in results
that are found to be statistically signiﬁcant (or pass other threshold criteria) than higher powered
studies.
As an example of this ‘effect size magniﬁcation’ concept and why it may come about, it is useful to
imagine a trial run thousands of times with variable sample sizes. In this case, there will be a broad
distribution of observed effect sizes. While the observed medians of these estimated effect sizes are
expected to be close to the true effect size, the smaller trials will necessarily systematically produce a
wider variation in observed effect sizes than larger trials. However, in low powered studies, only a
small proportion of observed effects will pass any given (high) statistical threshold of signiﬁcance and
these will be only the ones with the greatest of effect sizes. Thus, when these generally smaller, low
powered studies with greater random variation do indeed ﬁnd a signiﬁcance-triggered association as a
result of passing a given statistical threshold, they are more likely to overestimate the size of that
effect. What this means is that research ﬁndings of low-powered and statistically signiﬁcant studies are
biased in favour of ﬁnding inﬂated effects. As summarised by Gelman and Carlin (2014): ‘when
researchers use small [underpowered]38 samples and noisy measurements to study small effects. . ., a
signiﬁcant result is often surprisingly likely to be in the wrong direction and to greatly overestimate an
effect’. In general, it can be shown that low background (or control or natural) rates, low effect sizes
of interest, and smaller sample sizes in the study end to produce lower power in the study and this
leads to a greater tendency towards and magnitude of (any) inﬂated effect sizes.
It is important to note that the effect size inﬂation phenomenon is a general principle applicable to
discovery science in general and is not a speciﬁc afﬂiction or malady of epidemiology (Ioannidis, 2005;
Lehrer, 2010; Button, 2013; Button et al., 2013; Gelman and Carlin, 2014; Reinhart, 2015). It is often
seen in studies in pharmacology, in gene studies, in psychological studies, and in much of the most-
often cited medical literature. When researchers have limited ability to increase the sample size such
as in most epidemiological studies, effect size magniﬁcation is not a function or fault of the research or
research design, but rather a function of how that the results of that research are interpreted by the
user community. Thus, unlike other possible biases such as selection or information bias in
epidemiology studies, the bias is not intrinsic to the study or its design, but rather characteristic of
how that study is interpreted.
In order to determine (and quantify) the potential degree of effect size magniﬁcation for any given
study that produces a statistically signiﬁcant result, the reviewer must perform various power
calculations. More speciﬁcally, when the association between a chemical exposure and a disease is
found to be statistically signiﬁcant, a power analysis can be done to determine the degree to which
the statistically signiﬁcant effect size estimate (e.g. odds ratio, relative risk or rate ratio) may be
artiﬁcially inﬂated.
38 [italics added]
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In order to perform the requisite power calculation, the reviewer must know or obtain four values:
1) the number of subjects in non-exposed group;
2) the number of subjects in the exposed group;
3) the number of individuals with the disease of interest (or cases) in the non-exposed group;
and
4) a target value of interest to detect a difference of a given (predetermined) size in a
comparison of two groups (e.g. exposed vs. not exposed)
The ﬁrst three listed values are provided in or must be obtained from the publication while the
target value of interest (typically an OR or RR in epidemiology studies) is selected by the risk
managers (and is ultimately a policy decision).39 This Annex examines this effect size inﬂation
phenomenon in a quantitative way using simulations. The annex uses two example published studies
and simulations of hundreds of trials to evaluate the degree to which effect size magniﬁcation may
play a role in producing biased effect sizes (such as odds ratios, rate ratios or relative risks) due to low
power.
The ﬁrst example uses data from Agricultural Health Study prospective cohort publication
examining diazinon exposure and lung cancer and illustrates the effect size magniﬁcation issue for a
calculated RR. The second example uses ever-never data from a case–control study studying
malathion exposure and NHL and illustrates the effect size magniﬁcation concept from the point of
view of an estimated OR.
An Example Illustrating Effect Size Magniﬁcation and Relative Risk (Jones et al. (2015))
The power associated with a comparison between those that are not exposed to diazinon to those
that are exposed at the highest tertile (T) can be computed from the information provided in the AHS
study publication ‘Incidence of solid tumours among pesticide applicators exposed to the
organophosphate insecticide diazinon in the Agricultural Health Study - an updated analysis’ by Jones
et al. (2015) for lung cancer. The number of subjects at each exposure level was provided in the
article (non-exposed group: N = 17710, and T(ertile)1, T2 and T3 were categorised based on
exposure distribution; speciﬁcally: N of each tertile = (2,350 + 2,770)/3 = 1,710 from the publication’s
Table 1 where: (a) the value of 2,350 represents the number in the lowest exposed level and (b) the
value of 2,770 represents the number of the two highest exposed levels when the exposed subjects
were dichotomously categorised. Since we have (i) the number of subjects in the reference non-
exposed group = 17,710; (ii) the number of subjects in each of the exposed groups (tertiles) = 1710;
and (iii) the number of diseased individuals (lung cancer) in the reference non-exposed group = 199
(from Table 3 of the cited publication), we can calculate the power of the comparisons between T1 vs
non-exposed, T2 vs non-exposed and T3 vs non-exposed that were presented in the article, given the
assumption that any true Rate Ratio = 1.2, 1.5, or 2.0, etc.
Here, we are interested in evaluating the power associated with the estimated background rate
of 199/17710 (= 0.011237), and, as a form of sensitivity analysis, one half of this background rate
(or 0.005617), and twice this rate (0.022473) for detecting (admittedly arbitrary) relative rates of
(possible regulatory interest of) 1.2, 1.5, 2.0 and 3.0 among the subjects in each tertile of the
diazinon exposed individuals. This analysis was performed using Stata statistical software and is
shown below in both tabular and graphical format for true Rate Ratios of 1.2, 1.5, 2.0 and 3.0 for
39 This target value is an effect size of interest, often expressed as either a relative risk (for cohort studies) or an odds rate (for
case control studies). That is, the target value is generally an OR or RR of a given magnitude that the risk manager desires to
detect with a given degree of conﬁdence. The higher the OR or RR, the greater the magnitude of the estimated association
between exposure and the health outcome. While there are not strict guidelines about what constitutes a ‘weak’ association
vs a ‘strong’ one – and it undoubtedly can be very context-dependent – values less than or equal to about 1 (or sometimes
≤ 1.2) are considered to be ‘null’ or ‘essentially null’ (this ignores the possibility of a protective effect which in some contexts –
for example, vaccination efﬁcacy – may be appropriate to consider). Values less than 2 or 3 are often considered by some as
‘weak’. Values greater than 2 (or 3) and up to about 5 might be considered ‘moderate’, and values greater than 5 are
considered by some to be ‘large’. Monson (1990) describes as a guide to the strength of association a rate ratio of 1.0–1.2 as
‘None’, of from 1.2 to 1.5 as ‘Weak’, of from 1.5 to 3.0 as ‘Moderate’, and of 3.0–10.0 as ‘Strong’. Other authors use Cohen’s
criteria to describe ORs of 1.5 as ‘small’ and 5 as ‘large’, with 3.5 as ‘medium’ in epidemiology (Cohen and Chen, 2010).
Others describe 1.5 as ‘small’, 2.5 as ‘medium’ or ‘moderate’, 4 as ‘large’ or ‘strong’ and 10 as ‘very large’ or ‘very strong’
(Rosenthal, 1996) Taube (1995) discusses some of the limitations of environmental epidemiology in detecting weak
associations (also see invited commentary illustrating counter-arguments in Wynder (1997). It should be recognized that none
of the demarcation lines are ‘hard’ and there can be legitimate disagreements about where these are drawn and how these
are considered and interpreted. Regardless, these can be very much context-dependent and the above demarcations should
not be regarded as in any way ofﬁcial or deﬁnitive.
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1/2x-, 1x- (shown below in bold/shaded) and 2x- the (observed) background rate of 199 diseased
individuals/17,710 persons40:
Results of power analysis for a one-sided, two-sample proportions test (a = 0.05)(a)
Ncontrol Nexposed
Proportion
control(b)
Proportion
exposed
Relative
risk
Power
17,710 1,710 0.00562 0.00674 1.2 0.1634
17,710 1,710 0.00562 0.00843 1.5 0.4353
17,710 1,710 0.00562 0.01124 2.0 0.8182
17,710 1,710 0.00562 0.01685 3.0 0.9935
17,710 1,710 0.01124 0.01348 1.2 0.2259
17,710 1,710 0.01124 0.01685 1.5 0.6379
17,710 1,710 0.01124 0.02247 2.0 0.9652
17,710 1,710 0.01124 0.03371 3.0 1
17,710 1,710 0.02247 0.02697 1.2 0.3353
17,710 1,710 0.02247 0.03371 1.5 0.8632
17,710 1,710 0.02247 0.04495 2.0 0.9991
17,710 1,710 0.02247 0.06742 3.0 1
Stata code used to generate the above power calculation results: power two proportions (‘= 0.5 * 199/
17710‘= 199/17710‘= 2 * 199/17710), test(chi2) RR (1.2 1.5 2.0 3.0) n1(17710) n2
(1710) one-sided table(N1:‘‘N control‘‘ N2:‘‘N exposed‘‘ p1:‘‘proportion
control‘‘ p2:‘‘proportion exposed‘‘ RR:‘‘relative risk‘‘ power:‘‘power‘‘).
(a): One-sided test a = 0.05 Ho: p2 = p1 vs Ha: p2 > p1; Ncontrols = 17,710, Nexposed = 1,710; Number of Iterations = 1,000 (data sets).
(b): Representing 1/2x-, 1x- and 2x- the observed background rate of lung cancer of 199/17710 in Jones et al. (2015).
Highlighted/bolded region in table above represents power associated with this 1x observed background rate of lung cancer
in cited study.
These values can be graphed as shown below41:
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Estimated power for a two-sample proportions test
Graph showing estimated power for a (one-sided) two-sample proportions test evaluating power as a function of control-group
proportion at true RRs of 1.2-, 1.5-, 2.0- and 3.0. Dashed red vertical lines represent control group proportions at 1/2x of that
observed, 1x of that observed and 2x of that observed and illustrate sensitivity of the power to these background rate assumptions.
40 The RRs of 1.2, 1.5, 2.0 and 3.0 were selected somewhat arbitrarily to illustrate the power associated with a series of relative
risks that might be of interest to the risk manager/decision-maker. The values of RR or OR = 2.0 and 3.0 are considered by
some to be a demarcation between weaker effect sizes and stronger effect sizes. The RR value of 1.2 is what some consider
‘near to or essentially null’, and the RR of 1.5 is an intermediate value between these. In determining whether the
epidemiological evidence suggests a relationship between an exposure and a health outcome, a risk manager might consider
the ‘essentially null’ RR of 1.2 from a robust study with acceptable statistical power (generally considered 80–90%) as
sufﬁcient evidence for failing to ﬁnd an association and, in effect, may provide supporting evidence for a conclusion of no
observable association between the exposure and the outcome.
41 Stata code for generating the above graph: power twoproportions (‘ = 0.5 * 199/17710‘(0.0001)
‘= 2 * 199/17710‘), test(chi2) rrisk(1.2 1.5 2.0 3.0) n1(17710) n2(1710)graph
(recast(line) xline(‘= 0.5 * 199/17710‘ ‘=199/17710‘ ‘= 2 * 199/17710‘, lpattern
(dash)) legend(rows(1)size(small)) ylabel(0.2(0.2)1.0)) one sided.
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As can be seen in the above table and graph, this study had a power of about 23% at 1x the
background rate (control-group proportion, equal to 199 diseased individuals/17,710 subjects = 0.011237)
to detect a RR of 1.2. To detect an RR of 1.5, there is about 64% power. If the true background rate were in
reality twice the observed background rate (2 9 0.011237 = 0.022473), we would have about 86% power
to be able to detect a RR of 1.5 and essentially 100% power to detect an RR of 2.0.42
Given the above, SAS was used to simulate the degree to which there may be effect size
magniﬁcation (aka effect size inﬂation) given true relative risks of 1.2, 1.5, 2.0 and 3.0. The table
below illustrates the power analysis for diazinon and lung cancer which shows the extent of the effect
size magniﬁcation from the simulation results. The analysis presented in the table below parallels that
done by Ioannidis (2008) and presented in his Table 2 for a set of hypothetical results passing the
threshold of formal statistical signiﬁcance to illustrate the effect size magniﬁcation concept.
SAS simulation results illustrating effect size magniﬁcation given true odds ratios of 1.2, 1.5, 2.0
and 3.0(a)
True values
N analysed
data sets
Power(b)
Distribution of observed signiﬁcant RRs
Proportion of
diseased
individuals
in control
RR N
10th
percentile
Median
(% inﬂation)
90th
percentile
0.005617
(1/2 9 background)
1.2 1,000 0.16 157 1.6 1.7 (42) 2.0
1.5 1,000 0.40 401 1.6 1.8 (20) 2.3
2 1,000 0.82 823 1.7 2.1 (5) 2.8
3 1,000 1 997 2.3 3.0 (0) 3.9
0.011237
(1 9 background)
1.2 1,000 0.22 224 1.4 1.6 (33) 1.8
1.5 1,000 0.63 627 1.4 1.6 (7) 2.0
2 1,000 0.98 977 1.6 2.0 (0) 2.5
3 1,000 1 1,000 2.5 3.0 (0) 3.6
0.022473
(2 9 background)
1.2 1,000 0.33 331 1.3 1.4 (17) 1.6
1.5 1,000 0.87 871 1.3 1.5 (0) 1.8
2 1,000 1 1,000 1.7 2.0 (0) 2.3
3 1,000 1 1,000 2.6 3.0 (0) 3.4
Poisson regression model was used to compare the rate of (relative risks) between the groups. The EXACT Test was used in the
analysis of some data sets when the generalised Hessian matrix is not positive deﬁnite (due to a zero cases in one of the groups).
(a): One-sided test, a = 0.05, N Controls = 17,710, N diazinon Exposed = 1,710, Number of iterations = 1,000 (data sets).
(b): The power resulting from this simulation may be close but not precisely match the power calculated from built-in procedures
in statistical software such as SAS (PROC POWER) or Stata (power two-proportion). This may be due to the number of data
sets simulated being of insufﬁcient size. However, 1,000 iterations is sufﬁcient to adequately estimate the power and to
illustrate the degree of effect size magniﬁcation given a statistically signiﬁcant result (here, a ≤ 0.05).
Note that – given a statistically signiﬁcant result at p < 0.05 – the percent effect size inﬂation at the
median of the statistically signiﬁcant results varies from 0% to 42% depending on both the rate of
lung cancer among individuals not exposed to diazinon (i.e. proportion of diseased individuals in the
non-exposed group) and the true relative risk (ranging from 1.2 to 3.0). For example, if the true RR
of a tertile of exposed vs non-exposed were 1.2, where the non-exposed group has a rate of lung
cancer of 0.011237 (bolded row in the above table), half of the observed statistically signiﬁcant RRs
would be above the median of 1.6 and half would be below 1.6; this represents a median inﬂation of
33% over the true RR of 1.2 used in the simulation.
For the background rate found in the Jones et al. (2015) study (0.011237), a true RR of 1.2 that
was found to be statistically signiﬁcant would instead were the study to be repeated be observed to
vary from 1.4 (at the 10th percentile) to 1.8 (at the 90th percentile) with the aforementioned median
of 1.6. When the true RR is 2 or 3, the power is greater than 80% (as seen in the above table) and
the median of observed RR is close to the true RR and the range of observed RRs are narrow. As the
true RR increases to 3, the study’s power increases such that the effect size inﬂation disappears and
the median from the simulations indeed reﬂects the true RR.
42 Said another way, if the true (but unknown) background rate were actually twice the observed background rate, we could
reasonably conclude (with 86% conﬁdence) if no statistically signiﬁcant relationship was found that the true OR did not
exceed 1.5.
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An Example Illustrating Effect Size Magniﬁcation and Odds Ratios in an Ever/Never Analysis (Waddell,
et al. 2001)
Sometimes comparisons between exposed group vs non-exposed group are presented in an
‘ever/never’ comparison as opposed to a comparison based on some other categorisation or grouping
such as terciles or quartiles. This exposure category-based analysis might be done because there are an
insufﬁcient number of cases to break the exposure categories into small (more homogenous) exposure
classiﬁcations or groupings or because the measurements of exposure are not available or are less
reliable (such as in case–control studies). In these situations, we similarly need (i) the total number of
subjects in non-exposed group; (ii) the number of subjects in exposed group; (iii) the number of
diseased individuals in the non-exposed group in order to calculate the power of the comparison
between exposed group vs non-exposed group at some; (iv) given or preselected odds ratios.
To illustrate how a power and effect size magniﬁcation analysis might be done for a case–control
study using ever-never exposure categorisations, a study investigating the association between
malathion and NHL (Waddell et al., 2001) was selected. Here, we have (i) the number of subjects in the
reference non-exposed group = 1,018 (from Table 1: non-farmers = 243 diseased individuals + 775
non-diseased individuals); (ii) the number of subjects in the exposed group = 238 (from Table 4:
malathion exposed individuals = 91 exposed cases + 147 non-exposed controls); (iii) the number of
diseased individuals in the reference non-exposed group = 243 (from Table 1: 243 diseased individuals
in the non-farmer or non-exposed group), we can similarly calculate the power of the comparisons
between the ever vs never exposed, given the assumption that any true OR = 1.2, 1.5, 2.0, etc.
As was described above for lung cancer and diazinon, we estimated a power of 30.5% to detect an
OR of 1.2 at the study-estimated NHL proportion of 0.2387 among non-farmers (non-exposed), as
illustrated in the table below:
Results of power analysis for a one-sided, two-sample proportions test (a = 0.05)(a)
Ncontrol Nexposed
Proportion
control(b)
Proportion
exposed
Odds
Ratio
Power
1,018 238 0.1194 0.1399 1.2 0.2279
1,018 238 0.1194 0.1689 1.5 0.647
1,018 238 0.1194 0.2133 2.0 0.9693
1,018 238 0.1194 0.2891 3.0 1
1,018 238 0.2387 0.2734 1.2 0.3047
1,018 238 0.2387 0.3199 1.5 0.8149
1,018 238 0.2387 0.3854 2.0 0.9971
1,018 238 0.2387 0.4847 3.0 1
1,018 238 0.4774 0.523 1.2 0.3522
1,018 238 0.4774 0.5781 1.5 0.8779
1,018 238 0.4774 0.6463 2.0 0.9992
1,018 238 0.4774 0.7327 3.0 1
Stata code used to generate the above results: power two-proportions (‘= 0.5 * 243/1018‘ ‘= 243/
1018‘ ‘= 2 * 243/1018‘), test(chi2) OR (1.2 1.5 2.0 3.0) n1(1,018) n2(238) one-side
table(N1:‘‘N control‘‘ N2:‘‘N exposed‘‘ p1:‘‘proportion control‘‘ p2‘‘proportion
exposed‘‘ OR:‘‘odds ratio‘‘ power:‘‘power‘‘).
(a): One-sided test a = 0.05 Ho: p2 = p1 vs Ha: p2 > p1; Ncontrols = 1,018, Nexposed = 238, Number of iterations = 1,000 (data sets).
(b): Representing 1/2x-, 1x- and 2x- the observed background rate of lung cancer of 243/1018 in Waddell et al. (2001). Highlighted,
bolded region in table above represents power associated with this 1x observed background rate of NHL in cited study.
Such power relations for malathion and NHL are graphed below43 – as was done in the above AHS
prospective cohort study for diazinon and lung cancer – with the middle vertical dotted line in the
graph showing power at the NHL proportion of 0.2387 among non-farmers/non-exposed and the left-
hand and right-hand vertical dashed lines representing a form of sensitivity analysis at one-half and
twice the NHL proportion among non-farmers/non-exposed, respectively.
43 Stata code for generating the graph: power two proportions (‘= 0.5 * 243/1018‘(0.01)
‘= 2 * 243/1018‘), test(chi2) OR (1.2 1.5 2.0 3.0) n1(1018) n2(238)graph(recast
(line) x-line(‘= 0.5 * 243/1018‘ ‘= 243/1018‘ ‘= 2 * 243/1018‘, lpattern(dash))
legend(rows(1)size(small)) y-label(0.2(0.2)1.0)) one sided.
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At the study-estimated NHL proportion of 0.2387 among non-farmers/non-exposed, the power
(one-sided) to detect ORs of 1.2, 1.5, 2.0 and 3.0 is shown to be 30.5%, 81.5%, 99.7% and > 99.9%,
respectively. Note that Waddell et al. (2001) reported an OR of 1.6 with a 95% CI of 1.2–2.2, based
on 91 NHL cases who used malathion and 243 cases that were among non-farmers who did not.
Given the above, SAS was used to simulate the degree to which effect size magniﬁcation may exist
given true odds ratios of 1.2, 1.5, 2.0 and 3.0. Below is a SAS-generated table for the power analysis
for malathion and NHL showing the magnitude of the effect size magniﬁcation from the SAS-based
simulation results.
SAS simulation results illustrating effect size magniﬁcation given true odds ratios of 1.2, 1.5, 2.0,
and 3.0(a)
True values
N analysed
data sets
Power(b)
Distribution of observed signiﬁcant ORs
Proportion of
diseased individuals
in non-exposed
group
OR N
10th
percentile
Median
(% inﬂation)
90th
percentile
0.1194 (1/2 background) 1.2 1,000 0.22 220 1.4 1.5 (25) 1.8
1.5 1,000 0.66 661 1.5 1.7 (13) 2.0
2 1,000 0.97 972 1.6 2.0 (0) 2.5
3 1,000 1.0 1,000 2.4 3.0 (0) 3.7
0.2387 (19 background) 1.2 1,000 0.32 323 1.3 1.4 (17) 1.6
1.5 1,000 0.81 812 1.4 1.6 (7) 1.8
2 1,000 1.0 997 1.6 2.0 (0) 2.4
3 1,000 1.0 1,000 2.5 3.0 (0) 3.6
0.4774 (29 background) 1.2 1,000 0.34 337 1.3 1.4 (17) 1.6
1.5 1,000 0.87 872 1.3 1.5 (0) 1.8
2 1,000 1.0 1,000 1.6 2.0 (0) 2.5
3 1,000 1.0 1,000 2.4 3.0 (0) 3.7
The logistic regression model was used to compute the odds ratios for the two groups. The EXACT Test was used in the analysis
of some data sets when the maximum likelihood estimate did not exist (perhaps due to a zero cases in one of the groups).
(a): One-sided test, a = 0.05, N non-exposed = 1,018, N malathion exposed = 238, N iterations = 1,000 (data sets).
(b): The power resulting from this simulation may be close but not match exactly with the power calculated from built-in
procedures in statistical software such as SAS (PROC POWER) or Stata (power two-proportion). This may be due to number
of data sets simulated being of insufﬁcient size. However, 1,000 iterations are sufﬁcient to adequately estimate the power
and to illustrate the degree of effect size magniﬁcation given a statistically signiﬁcant result (here, a ≤ 0.05).
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Graph showing estimated power for a (one-sided) two-sample proportions test evaluating power as a function of control-group
proportion at true RRs of 1.2-, 1.5-, 2.0- and 3.0. Dashed red vertical lines represent control group proportions at 1/2x of that
observed, 1x of that observed and 2x of that observed and illustrates the sensitivity of the power to these background rate
assumptions.
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Note that – given a statistically signiﬁcant result at p < 0.05 – the median effect size varies from
1.4 to 3, depending on the NHL proportion in the non-exposed group, and the true odds ratio (ranging
from 1.2 to 3.0). For example, if the true OR for a NHL proportion among non-farmers of 0.2387 was
1.2 (bolded row in the table), half of the observed statistically signiﬁcant ORs would be above the
median of 1.4 and half would be below. Further, most (90%) of the statistically signiﬁcant ORs would
be observed to be above 1.3, and a few (10%) would be observed even to be above 1.6.
In sum, then, the power of an epidemiological study is an important factor that should considered
by regulators and others evaluating such studies. A study that is sufﬁciently powered will not only be
more likely to detect a true effect of a given size if it is indeed present (the classic deﬁnition of power
which relates to the issue of a Type II error or a false negative) but will also be less likely to magnify
or exaggerate the effect if it is not there but (by chance) crosses a preselected threshold (such as the
0.05 level for statistical signiﬁcance). If a study is suitably powered (say, 80% or more), the observed
effect size is more likely to be a reﬂect a true effect size and any observed chance variation in this
effect size will reﬂect a distribution symmetrically centred around the unknown true value. The take
home message from these simulations and the original work by Ioannidis and extensions by Gelman
and Carlin (2014) is that a study should be not only suitably powered to avoid a false negative (Type
II error) but also suitably powered to avoid a magniﬁcation of the effect size for those effect sizes that
are statistically signiﬁcant (or pass some other threshold). Gelman and Carlin (2014) go further, stating
that such ‘retrospective design calculations may be more relevant for statistically signiﬁcant ﬁndings
than for nonsigniﬁcant ﬁndings. The interpretation of a statistically signiﬁcant result can change
drastically depending on the plausible size of the underlying effect’. Note that if a study is suitably
powered, there is NO systematic risk inﬂation, but the effect estimates for underpowered studies that
produce statistically signiﬁcant effects are prone to what might be substantial risk inﬂation, the
interpretation of which depends on realistic estimates of the true (underlying) effect.
Ideally, then, published literature studies should conduct and document power analyses. Short of
that, published literature should provide adequate information for the reader to perform such power
calculations (or, as Gelman and Carlin (2014) term them: (retrospective) design calculations). In the
two examples provided above, the authors did provide sufﬁcient information for the reader to calculate
power and the potential for effect size magniﬁcation. This is not always the case. Sometimes
information used for power calculations are only partially provided in the publications or provided
information was structured in a way that does not permit such calculations.44,45 For example, if
authors use number of cases instead of level of exposure to determine tertiles or quartiles (which
would be evidenced by a constant number of cases between groups) or if authors group multiple
cancer outcomes together and use that number to determine tertiles, then the power (or design)
calculations illustrated here are not possible since the required inputs are not able to be derived. Since
the counts and data which are tabulated and reported are not necessarily standardised among authors
and publications, one strong recommendation would be for publications to require reporting (even if in
supplementary or online data) the necessary information to estimate power such that such evaluations
can be done by both peer reviewers and interested readers.
44 For example, in the review of the association between malathion exposure vs aggressive prostate cancer presented in the
publication ‘Risk of Total and Aggressive Prostate Cancer and Pesticide Use in the Agricultural Health Study’ by Stella Koutros
et al. (2012), the Panel was not able to calculate the power of the comparison between the malathion-exposed groups vs
non-exposed group because critical information was not provided in the published article. From the publication and the
supplemental document of the publication, we were able to easily ﬁnd the number of cases in the non-exposed group
(Table 2 in the main article), but the number of subjects in the non-exposed group or at each exposed level (i.e., quartile)
appeared not to be available. We attempted to derive the number of subjects in the non-exposed group and number of
subjects in each quartile from the information in Table 1 of the supplemental document of the article but were not able to do
so since the information in Table 1 was presented in a way that was not consistent with many other AHS publications in that
the exposed subjects were categorized into groups based on the quartiles of number of cases.
45 Sometimes, information used for power calculations may have only been partially provided in the publications. For example,
we calculated the powers associated with various thyroid cancer comparisons from the information provided in the AHS study
publication ‘Atrazine and Cancer Incidence Among Pesticide Applicators in the Agricultural Health Study (1994–2007)’, by Laura
Beane-Freeman et al. (2011). In this publication, the authors did not categorize the subjects into quartiles based on exposure
but instead categorized or grouped the subjects based on the total number of all cancer cases combined. In this way, the
number of cases of all types of cancer was the same between categorized groups and thus both the number of cases of any
speciﬁc cancer of interest (e.g. thyroid, here) was not the same between groups and the number of subjects was not the
same between groups. In this example, the publication provided (i) the reference Q1: N = 9,523, (ii) total subjects in Q2, Q3
and Q4: N = 26,834 (Table 1) and (iii) the number of thyroid cancer cases in the reference Q1 = 3 (Table 2). The exact
number of subjects in each of the compared groups (Q2, Q3 or Q4) was, however, not available.
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While the above analysis suggests that potential implications of the effect size inﬂation
phenomenon are important considerations in evaluating epidemiological studies, it is important to
remember a number of caveats regarding the phenomenon and how its consideration should enter
into any interpretation of epidemiological studies.
• First, while this phenomenon would tend to inﬂate effect sizes for underpowered studies for
which the effect of interest passes a statistical (or other) threshold, there are other biases that
may be present that bias estimates in the other direction, towards the null. This bias might be
referred to as effect size suppression. Perhaps, the most well-known of these is non-differential
misclassiﬁcation bias discussed in the main body of the text. This can commonly (but not
always) produce predictable biases towards the null, thereby systematically under-predicting
the effect size. Recognising that this is not always true and there are potentially countervailing
or counteracting factors like effect size magniﬁcation (at least for small underpowered studies)
is an important step forward. Speciﬁcally, underpowered studies can result in biased estimates
in a direction away from the null to a degree that that can potentially offset (and possibly
more than offset) any biases towards the null that may result, for example, from non-
differential misclassiﬁcation bias. Regardless, what is of critical importance is to recognise that
adequately powered studies are necessary to be able to have at least some minimal degree of
conﬁdence in the estimate of the effect size for a statistically signiﬁcant result.
• Secondly – and as stated in the main body of the text – effect size magniﬁcation is linked to a
focused effort on the part of the researcher (or regulators interpreting such a study) on
identifying effects that pass a given threshold of signiﬁcance (e.g. p < 0.05) or achieve a
certain size (e.g. OR > 3) when that study is underpowered. This phenomenon, then, is of
most concern when a ‘pre-screening’ for statistical signiﬁcance (or effect size). To the extent
that regulators, decision-makers and others avoid acting by focusing on only those associations
that ‘pass’ some predetermined statistical threshold and then use that effect size to evaluate
and judge the magnitude of the effect without acknowledging that it might be inﬂated if the
study is underpowered, the phenomenon is of lesser concern. Note that effect size
magniﬁcation is not a function or fault of the research or research design, but rather a
function of how that research is interpreted by the user community.
Unfortunately, there is sometimes a tendency for attention to focus on effect sizes that are
greater than a given size or that pass a certain statistical threshold and are as such
‘discovered’. As recommended by Ioannidis with respect to how these ‘discoveries’ should be
considered (Ioannidis, 2008):
‘At the time of the ﬁrst postulated discovery, we usually cannot tell whether an association exists at
all, let alone judge its effect size. As a starting principle, one should be cautious about effect sizes.
Uncertainty is not conveyed simply by CIs (no matter if these are 95%, 99% or 99.9%).
For a new proposed association, credibility and accuracy of the proposed effect varies depending on
the case. One may ask the following questions: does the research community in the ﬁeld adopt
widely statistical signiﬁcance or similar selection thresholds for claiming research ﬁndings? Did the
discovery arise from a small study? Is there room for large ﬂexibility in the analyses? Are we
unprotected from selective reporting (e.g. was the protocol not fully available upfront?). Are there
people or organisations interested in ﬁnding and promoting speciﬁc “positive” results? Finally, are
the counteracting forces that would deﬂate effects minimal?’
• Thirdly, it should be remembered that the effect size inﬂation phenomenon is a general principle
applicable to discovery science in general and is not a speciﬁc afﬂiction or malady of epidemiology
(Ioannidis, 2005; Lehrer, 2010; Button, 2013; Button et al., 2013; Reinhart, 2015). As indicated
earlier, it is often seen in studies in pharmacology, in gene studies, in psychological studies, and in
much of the most-often cited medical literature. Such truth inﬂation occurs in instances where
studies are small and underpowered because such studies have widely varying results. It can be
particularly problematic in instances where many researchers are performing similar studies and
compete to publish ‘new’ or ‘exciting’ results (Reinhart, 2015).
Summary and Conclusions
Effect size magniﬁcation or ‘truth inﬂation’ is a phenomenon that can result in exaggerated
estimates of odds ratios, relative risks or rate ratios in those instances in which these effect measures
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are derived from underpowered studies in which statistical or other thresholds need to be met in order
for effects to be ‘discovered’. The phenomenon is not speciﬁc to epidemiology or epidemiological
studies, but rather to any science in which studies tend to be small and predetermined thresholds such
as those relating to effect sizes or statistical signiﬁcance are used to determine whether an effect
exists. As such, it is important that users of epidemiological studies recognise this issue and its
potential interpretational consequences. Speciﬁcally, any discovered associations from an
underpowered study that are highlighted or focused upon on the basis of passing a statistical or other
similar threshold are systematically biased away from the null. While we cannot know if any speciﬁc
observed effect size from a speciﬁc study is biased away from the null as a result of being a
‘discovered’ association that passes a statistical threshold (just as we can’t say that a speciﬁc study
showing non-differential misclassiﬁcation will necessarily be biased towards the null), we do know that
that chance favours such a bias to some degree as illustrated by the explications presented and
simulations performed here. Said another way: by choosing to focus on, report, or act upon effect
sizes on the basis of those effect sizes passing a statistical or other threshold, a bias is introduced
since it is inevitably more likely to select those associations that are helped by chance rather than hurt
by it (Yarkoni, 2009). Again, this is an issue related to how studies are interpreted by users, not one
that is intrinsic to the study design nor one that is related to good scientiﬁc principles or practices.
One (partial) solution to the above issue is for the reader to cautiously interpret effect sizes in
epidemiological studies that pass a prestated threshold or are statistically signiﬁcant if they arise from
an underpowered study, recognising that the observed effect sizes can be systematically biased away
from the null. Such an approach would require that either the authors report the power of the study or
that the authors provide sufﬁcient information for the reader to do so. Effects sizes from studies with
powers substantially less than 80% should be interpreted with an appropriate degree of scepticism,
recognising that these may be inﬂated – perhaps substantially so (particularly if the power is less than
50%). The potential degree of this inﬂation will depend on a number of issues including background
rate of the health outcome of interest, the sample size of the study and the effect size of interest.
More speciﬁcally, when (a) the smaller the background rate of the health outcome of interest is low,
(b) the sample size of the study is small and (c) the effect size of interest is weak, then the power of
the study (to detect that effect size) will be low and the tendency towards inﬂated effect sizes in
statistically signiﬁcant results will be high. Low power studies investigating small or weak effects in
populations that have a low background rate of the health outcome of interest will tend towards the
greatest degree of effect size inﬂation. As a result, the PPR Panel recommends that epidemiological
publications either incorporate such calculations or include key information such that those calculations
can be performed by the reader. Speciﬁcally:
When the association between a given pesticide exposure and a disease is found to be statistically
signiﬁcant, particularly in (presumed) low powered studies, data user should perform various power
calculations (or a power analysis) to determine the degree to which the statistically signiﬁcant effect
size estimate (OR or RR) may be artiﬁcially inﬂated or magniﬁed. This requires three values to be
clearly reported by epidemiological studies: (i) the number of subjects in the non-exposed group
(including diseased and non-diseased individuals); (ii) the number of subjects in the exposed group
(including diseased and non-diseased individuals); and (iii) the number of diseased subjects in the
non-exposed group. Risk managers can then select the target value of interest (typically an OR or
RR) to detect a difference of a given (predetermined) effect size between the exposed and
non-exposed subjects, and evaluate the degree to which effect size magniﬁcation could potentially
explain the effect size that was estimated in the study of interest.
Since it appears that (i) many epidemiological studies are frequently underpowered; (ii) it is not
common for authors to provide either power calculations or (sometimes) the information in
publications required to do them, and (iii) the phenomenon of effect size magniﬁcation generally
appears to be little recognised in the epidemiological ﬁeld, the above PPR Panel recommendation will
require effort on the part of researchers/grantees, publishers, and study sponsors to implement. While
the above suggests that the current state of practice in this area may leave one pessimistic, an opinion
piece on this topic by researcher Kate Button (Button, 2013) describing her work in Nature Reviews
Neuroscience (Button et al., 2013) offered guarded reasons for optimism:
‘Awareness of these issues is growing and acknowledging the problem is the ﬁrst step to improving
current practices and identifying solutions. Although issues of publication bias are difﬁcult to solve
overnight, researchers can improve the reliability of their research by adopting well-established (but
Epidemiological studies and pesticides
www.efsa.europa.eu/efsajournal 100 EFSA Journal 2017;15(10):5007
often ignored) scientiﬁc principles: Also, researchers can improve the usefulness/reliability of their
research by adopting well-established (but often ignored) scientiﬁc principles:
1) Consider statistical power in the design of our studies, and in the interpretation of our
results;
2) Increase the honesty with which we disclose our methods and results.
3) Make our study protocols, and analysis plans, and even our data, publically available; and
4) Work collaboratively to pool resources and increase our sample sizes and power to replicate
ﬁndings.’
Although the above set of recommendations and thoughts were set in the context of sample size
and neurotoxicology, they have broad applicability to any discovery science, including epidemiology. In
sum, while there is much room for improvement in the conduct and reporting of epidemiological
studies for them to be useful to regulatory bodies in making public health-based choices, the issues
are beginning to be better deﬁned and recognised and – going forward – there is reason for optimism.
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